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Abstract
Background
Acute illness results in millions of hospital admissions per year. Assessment of 
illness severity can guide the intensity and location of care provided but although 
multiple clinical decision aids exist for large numbers of conditions no well-validated 
clinical decision aid exists for the assessment of patients with unselected medical 
emergencies. It cannot be assumed that tools which predict death will accurately 
identify those patients with the most potential to benefit from urgent care.
Methods
A prospective cohort was analysed using logistic regression to develop bedside 
scores to identify patients at high risk of death, and those where emergency care 
has the potential to affect survival. Consensus methodology was used to develop 
threshold responses for the Emergency Department.
Results
7 variables and one interaction (age, respiratory rate, diastolic blood pressure, 
oxygen saturation, temperature, GCS, pre-existing respiratory disease, respiratory 
disease by temperature interaction) predicted death in 7 days with AUROC 0.753 
(derivation set: n=2437) and 0.719 (validation set: n=2322). Other scores showed 
AUROC 0.658 – 0.762.
3 variables (pulse, systolic blood pressure, GCS) predicted potentially preventable or 
potentially prevented death with AUROC 0.737 (derivation set: n=398) and 0.686 
(validation set: n=227). Other scores showed AUROC 0.559 – 0.684.
Consensus was reached on four thresholds of clinical response on the 0-27 point 
score for potentially preventable or potentially prevented death. 
Conclusions
No published tool exists to identify the patient most likely to benefit from 
emergency department care. Variables predicting death do not necessarily predict 
potential to benefit from care, and existing scores have only moderate 
discrimination for this. The tool developed here shows potential but ongoing 
research should address which patients will benefit from time-critical interventions 
and the complexities of ED prioritisation.
[10]
Chapter 1
Background
1.1 Introduction
“Patients die not of their disease, they die of the physiological abnormalities of their  
disease.”
Sir William Osler (1849-1919)
As Osler described, the deleterious effects of a disease process on a patient are 
usually mediated by a disruption in homeostasis.  Recognition of this underpins the 
traditional “TPR” (temperature, pulse and respiration) nursing observations.  This 
thesis will explore the extent to which easily-identifiable markers of homeostatic 
disruption, such as those obtained in a standard set of nursing observations, can be 
used to identify patients at risk of further physiological decompensation.  It will 
attempt to construct a tool which can be used at the bedside to help medical and 
nursing staff recognise patients who are likely to benefit from high-acuity care as 
provided in intensive care and high dependency areas.
1.2 Acute illness
1.2.1 Prevalence of acute illness
There were 18.3 million attendances at Emergency Departments in England in 2012-
3, 3.8 million of which resulted in a hospital admission (1). 
1.2.2 Prevalence of severe acute illness
Of 5 million emergency hospital admissions in 2008-9, 203,790 resulted in inpatient 
death (2).  Similarly, in 2010-1, only 71,801 (45%) of 160,460 critical care admissions 
were planned (3).  Thus it is clear that acute severe illness has significant human 
and resource implications for the NHS.
1.2.3 Acuity assessment: the context of triage
Triage (from the French trier, to sort) has been a part of battlefield medicine since 
the early 19th century, when Napoleon’s surgeon Baron Dominique-Jean Larrey 
[11]
recognised that “those who are dangerously wounded should receive the first 
attention, without regard to rank or distinction” (4).
Triage in civilian emergency medicine in the developed world is usually a matter of 
ranking the severity of patient illness or injury to determine the order in which 
patients are seen, rather than limiting care, as for the most part resources and 
demand are roughly matched in toto (although there may be a temporal mismatch). 
In a typical Emergency Department, therefore, triage aims to identify levels of 
patient acuity (severity of illness/injury) and match the patient to an appropriately 
resourced and staffed area of the department (or for some low-acuity patients, to 
an alternative healthcare provider).  A number of triage scales exist for triage within 
the ED; these are more fully explored in section 1.2.5b below.  
The importance of casualty sorting in civilian disasters was suggested following the 
Harrow and Wealdstone railway disaster in which 85 died and 170 were 
hospitalised (5).  More recently the Millian utilitarian philosophy of the “greatest 
happiness for the greatest number”(6) has been integrated into civilian practice 
(usually misquoted as “the greatest good for the greatest number”); system 
requirements for “maximal casualty survival” (ie the greatest possible number of 
survivors in the best possible functional condition) were identified two decades ago 
(7).  To illustrate, the 5 patients in figure 1 might present in quick succession. 
If resources (in blue) are allocated purely on a first-come, first-served basis, the first 
patient, who has suffered an unsurvivable burn, receives intubation, intravenous 
fluids and rapid transport to an intensive care bed despite his poor prognosis; he 
dies anyway.  The patient with an uncomplicated lower limb fracture who would 
survive without intervention is cannulated, given intravenous fluids and transported 
to theatre for non-life-saving surgery.  No resources are left for the last three 
patients, who despite being potentially salvageable all die (black lines), resulting in 
80% mortality (fig 2).
[12]
Figures 1-4: the value of triage
Figure 1: initial presentations
90% burns Lower limb 
fracture
Intra-
abdominal 
bleeding
Allergic 
reaction with 
airway 
compromise
Acute ST-
elevation 
myocardial 
infarction
Figure 2: first-come, first-served resource allocation (80% mortality)
Figure 3: triaged resource allocation
Figure 4: effects of triage (20% mortality)
If patients are triaged resources are triaged, the burn patient, who is irretrievably 
injured, receives less resource-intensive palliative care.  The patient with a limb 
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fracture receives immobilisation, the patient with abdominal bleeding is treated for 
shock and transferred to an operating theatre early, the patient with the allergic 
reaction has her airway secured, and the patient with an acute ST elevation 
myocardial infarction has thrombolysis or primary percutaneous coronary 
intervention.  This consumes the same resources as previously (fig 3).  However, the 
targeting of treatment using triage results in a reduction in mortality to 20% (fig 4) 
(8).
Accurate assessment of illness severity has implications both for the individual 
patient and the health care system.  Patients admitted to critical care areas via non-
critical care areas (such as standard wards) have higher rates of mortality than 
those admitted directly from the ED (9-11), with significant numbers of patients 
(23/122 (9) and 144/343 (11)) admitted to critical care more than 24 hours after 
their ED attendance.  The observational studies supporting this are of course 
subject to many confounders; the clinician who thinks of critical care for a patient 
may also be the clinician who understands the implications of delays in antibiotic 
therapy; thus early admission to critical care may be a proxy for higher quality care 
globally.  Conversely, unnecessary admission, whether simply to hospital, or to a 
critical care area, is likely to expose a patient and family to extra stress and the 
health care system to excessive expenditure.  There is also the potential for 
morbidity or even mortality caused by unnecessary interventions and healthcare 
associated infection.
If one assumes that a gold standard for defining patient acuity exists (this is 
discussed further in sections 1.2.4 and 1.4 below), undertriage occurs when a 
critically ill patient is not triaged to immediate or urgent care.  Conversely, 
overtriage involves the allocation of a non-critical patient to high intensity care 
(table 1).  The overtriage rate is calculated as true positive/(true positive plus false 
positive), analogous to one minus the positive predictive value of a test. The 
undertriage rate is calculated as false negative/true positive plus false negative, 
analogous to one minus the specificity. Although undertriage may intuitively seem 
much worse (a sick patient is sent to an area with inadequate resources), it has 
[14]
been demonstrated in the major incident literature that the critical mortality of any 
incident (the proportion of patients surviving to hospital who then die as a result of 
the incident) is directly related to the rate of overtriage to that facility during that 
incident (12).  The same is likely to be true outside the major incident arena; even if 
overtriaged patients (false positives) may come to no individual harm from 
unnecessary interventions, there is a system-wide opportunity and financial cost in 
using resources where they are not required.  This has been recently highlighted in 
the context of the US debate over affordable care, with arguments advanced that 
“waste avoidance” in healthcare provision is a professional obligation (13).  It is also 
possible that there is a “grey” group not included in this conceptualisation; those 
who will survive in a lower acuity area but whose morbidity would be reduced by 
higher acuity care.
 
Table 1: Under- and over-triage
Critically ill patient Non-critical patient
High acuity area Correct high priority triage
(True positive)
Incorrect high priority 
triage = OVERTRIAGE
(False positive)
Low acuity area Incorrect low priority 
triage = UNDERTRIAGE
(False negative)
Correct low priority triage
(True negative)
This represents a huge challenge in terms of patient assessment, with many EDs still 
staffed by relatively junior doctors and struggling to provide 24 hour senior shop-
floor cover.  ED staff are required to make decisions in a limited time and often with 
incomplete information in order to maintain patient flow through the ED.  The 
National Confidential Enquiry into Patient Outcomes (NCEPOD) has documented 
widespread failings in the identification of sick patients and their escalation to 
appropriately senior staff (14), and the National Early Warning Score has been 
launched by the Royal College of Physicians in response to the problem (15).
1.2.4 Acuity assessment: what is patient acuity?
Severity of illness could be defined in a number of ways – risk of death in either the 
short or long term, magnitude of symptoms such as pain or nausea, effect on 
functional status and deviation from either clinical or laboratory “norms”.  I will 
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argue that patient acuity is not necessarily concurrent with illness severity.  I 
suggest that the point of an emergency care system is to provide prompt care to 
those patients likely to benefit in a time-sensitive manner from interventions.  
These are not inherently the same patients who are at highest risk of death – some 
of these patients will progress to death irrespective of interventions. Nor are they 
the patients with the highest overall benefit from healthcare interventions – the 
young man with a testicular teratoma has massive potential for benefiting from 
treatment, but this will not be affected by whether he is seen within one hour or six 
hours in the Emergency Department.  A measure of patient acuity should therefore 
reflect patients whose outcome will be improved with prompt care and/or those 
whose outcome will worsen without this care.
Unfortunately within emergency care little evidence exists as to the time-sensitive 
nature of many interventions (16).  Although, as has been argued in the context of 
critical care outreach, it is intuitively appealing to define a deteriorating patient and 
respond rapidly (17), meta-analysis of tools to do this in an in-patient setting has 
failed to identify a benefit in terms of patient outcome (18-19). The introduction of 
a medical emergency team in one hospital was associated with a decrease in 
mortality amongst surgical patients but a sustained increase in mortality in medical 
patients, highlighting the non-congruence of risk of death with the potential to 
benefit from early medical intervention (20).  Recent commentary on clinical 
decision rules has drawn attention to the disconnect between the identification of 
patients at risk of a particular outcome and the potential of those patients to 
benefit from available interventions (21).  The evidence available for specific time-
sensitive interventions will be discussed in section 1.4 below.
1.2.5 Acuity assessment: application in the clinical setting
One potential role of formalised severity assessment tools is to identify patients 
who need higher levels of care, in an attempt to prevent the pattern where a 
patient’s physiological decompensation is carefully documented but no action taken 
in the hours before the patient’s cardiac arrest (22).  Of 383 hospitals surveyed by 
NCEPOD in 2009, 376 reported some kind of “early warning system” to identify the 
[16]
deteriorating patient; 365 of these formally linked the early warning score to an 
escalation policy with a mandated medical and nursing response (14). Some 
hospitals have even adopted the paradigm to the extent that an automatic bleep to 
the critical care team is generated by the electronic patient record system when 
deranged observations are recorded.
However, it is possible that a similar philosophy could be adopted at the opposite 
end of the severity spectrum.  The Pneumonia Severity Index was originally 
developed to identify patients with low risk of complications to support clinicians in 
discharging these patients home (23).  There is particular potential value to this 
approach in situations where a significant proportion of patients presenting are the 
“worried well”, who have symptoms that cause them concern but usually represent 
benign disease, such as headache or chest pain in the young.  A tool to identify the 
low-risk patient would help to standardise care provided purely due to clinical risk 
aversion and potentially liberate resources to treat other patients who might 
benefit more.
In some cases severity of illness can provide guidance on the extent to which 
aggressive care is appropriate.  If an inevitable death can reliably be identified, 
ceilings can be placed on care and a dignified death with adequate palliation 
achieved.  Equally, some treatments are only justifiable in terms of risk-benefit ratio 
within particular severity parameters; notably stroke thrombolysis may have a 
window of benefit in moderate severity stroke in which the benefits justify the risks; 
this benefit is not seen in severe stroke (24).
1.2.5 Current severity assessment in acute illness
1.2.5a Ambulance dispatch assessment
Emergency ambulances in the UK are dispatched at three levels of urgency: 
categories A (patients who are or may be immediately life threatened), B (patients 
who require urgent face to face clinical attention) and C (patients who do not 
require an immediate or urgent response by blue light).  Expectations for speed of 
response vary depending on the category to which the call is assigned, and in fact 
[17]
ambulance dispatch is not required for all category C calls, which can be reassigned 
to an alternative care provider.
The allocation of dispatch category depends on a severity assessment obtained by 
asking the caller a standardised set of questions about the patient’s condition.  For 
example a patient with chest pain would be allocated to category A if clammy or 
vomiting, but category C if breathing normally and aged under 35; a patient who 
has apparently fainted is allocated category C if fully recovered and aged under 35, 
category B if female of reproductive age with abdominal pain and category A if still 
unconscious or having had multiple episodes.
These dispatch categories require only minimal assessment by the caller, as no 
medical training can be assumed on the part of the caller, and are therefore biased 
towards overtriage, the assumption that a patient is more ill and requires higher 
acuity care than is actually the case. The evidence for accuracy of dispatch priority 
systems is, however, mixed (25-26) and there is little data to assess whether patient 
outcomes are influenced by the use of such systems (27).
1.2.5b Emergency Department triage
Almost all UK EDs use some form of nurse-led triage system.  This involves patients 
being seen within a short time-frame, as close to arrival as possible, to undergo a 
brief assessment.  This triage assessment is then used to allocate patients to a 
specific area of the ED (resuscitation, majors, minors, minor injuries, primary care 
etc) and, if the patient is found to be in need of emergency treatment, to alert 
appropriate senior nursing and medical staff.  A number of standardised triage 
systems exist.
The Manchester Triage System (MTS) (28) was developed and revised by a 
consensus group in the UK.  It uses a set of presentational flowcharts (eg 
“abdominal pain – adult” or “unwell adult”) with various discriminators (eg airway 
compromise, severe pain, abnormal pulse, recent onset) to allocate patients to five 
categories (red, orange, yellow, green and blue) which correlate to the urgency with 
[18]
which they should be seen by a clinical decision-maker (immediately, under 10 
minutes, under 2 hours, under 4 hours, non-urgent). Figure 5 shows an example 
MTS flowchart.
Figure 5: Manchester Triage flowchart for Shortness of Breath in Children
The Emergency Severity Index (ESI) (29), widely used in the US, combines the triage 
nurse’s assessment of severity of illness (for categories 1 and 2), defined 
physiological variables (for categories 2 and 3) and the triage nurse’s estimate of 
resource requirement (categories 3 to 5).  The ESI flowchart is shown in figure 6.
[19]
Figure 6: Emergency Severity Index flowchart (from Agency for Healthcare Research 
and Quality)
The Canadian Triage and Acuity Scale (CTAS) (30) initially stratifies patients 
according to their presenting complaint, which allocates a minimum triage category 
(from 1 to 5) defined by the presenting complaint.  This is then modified by vital 
signs (haemodynamic compromise, temperature and consciousness) and pain level, 
followed by modifiers specific to the condition (such as mechanism of injury for 
trauma or blood glucose in diabetics).
These various triage systems have been assessed in terms of inter-rater reliability 
(31) and their ability to identify high-risk patients (32-34), but analysis of the effect 
of their implementation on patient-oriented outcomes is minimal (35-36).
[20]
Some institutions have adopted RATS (Rapid Assessment and Treatment System) 
whereby a senior clinician is allocated to “eyeball” patients on or soon after arrival 
to initiate investigations and immediate treatment.  This has been demonstrated to 
reduce the number of patients waiting (37) and time spent waiting at various stages 
of the process (38-39) but has not been shown to influence non-time-related 
outcomes.
1.2.5c Admission and in-patient severity of illness scoring
As stated above, almost all UK hospitals now have some form of physiological Early 
Warning Score in use in in-patient areas (14).  This was originally based on the work 
of McQuillan et al, in a confidential inquiry into care preceding intensive care 
admission (10), and Goldhill et al, in analysing physiological data in the 24 hours 
preceding intensive care admission (22).  Both these groups identified a pattern of 
clearly documented worsening physiological derangement which was either not 
recognised, not communicated appropriately, or not acted upon.  It is now a 
national recommendation that all acutely ill patients should have an early warning 
score recorded at the point of the decision to admit to hospital, and that such a 
score should form part of routine observations, the frequency of which should be 
stipulated in the care plan (40). Despite this the NCEPOD investigation into cardiac 
arrest management found widespread failure to recognise acutely ill patients and to 
involve appropriately senior personnel in their care (14); it appears that simply the 
existence of a scoring system is insufficient to have an impact on patient outcomes.
1.3Clinical decision aids 
Clinical decision aids exist in a number of contexts; they can be used to guide 
diagnosis and inform on prognosis, they can take the form of cumulative scores or 
absolute decision rules and they can be applicable to broad populations or 
restricted to specific disease sets.
1.3.1 The role of clinical decision aids in the clinical environment
It might be argued that clinical decision aids would be unnecessary were clinicians 
appropriately trained and competent.  Indeed, it has been demonstrated that in 
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identifying patients at low risk of pulmonary embolism, the gestalt of a senior 
clinician is as good as any validated decision aid (41).  However, care is not provided 
universally by senior clinicians, and the value of safety checklists in high-stakes 
situations has been demonstrated following the adoption of the WHO surgical 
safety checklist (42). A recent CEPOD analysis identified recurrent failures of clinical 
staff, particularly those with less experience, to recognise and act on severe illness 
(14), and similar patterns have been identified in the Emergency Department triage 
process (43).  There is also an argument that in terms of fairness and medicolegally 
it is beneficial to objectify the decision-making process as this may have potential to 
standardise both the process and its recording.  
1.3.2 Diagnostic and prognostic decision aids
The difference between diagnostic and prognostic decision aids is probably best 
illustrated in the context of pulmonary embolism.  The Wells and Geneva diagnostic 
scores use a variety of features of the patient’s history and examination to calculate 
a probability that the patient is suffering from a pulmonary embolism, and 
therefore to guide the investigative strategy.  They provide no information, 
however, about the severity of the embolism if that is the final diagnosis.  
Conversely, the Pulmonary Embolism Severity Index (44) calculates a risk of poor 
outcome in patients known to have pulmonary embolism, but is of no value in 
making the initial diagnosis.
1.3.3 Clinical scores and decision rules
Clinical decision aids can supplement risk assessment in two different ways: a 
decision rule will provide an (almost) absolute rule-in or rule-out based on a 
number of criteria; once ruled-in or ruled-out no further conclusions can be drawn 
about the relative risks of two different patients fulfilling the criteria.  A clinical 
score will provide ranking information on the relative risk between two patients, 
and can be repeated over time to establish trends in improvement or deterioration, 
but tends to involve more variables (often weighted) and be more cumbersome.  
This difference is well illustrated by the two stages of calculating the Pneumonia 
Severity Index (23).  Stage 1 is a clinical decision rule: if the patient is negative for 3 
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criteria (1. age over 50; 2. history of neoplasm, congestive heart failure, 
cerebrovascular disease, renal disease and liver disease; 3. abnormalities on 
examination: mental status, pulse, respiratory rate, blood pressure and 
temperature) he is considered to be class I (very low risk).  A patient not fitting into 
class I is then assessed using a score, with weighted values for various demographic 
and historical factors and examination and laboratory findings.
1.3.4 General and disease-specific decision aids
Clinical decision aids can be applicable across a wide unselected population, or 
specific to patients with a particular diagnosis.  Specific decision aids may be more 
accurate within their patient population, but all require an accurate diagnosis to be 
made; their role may therefore be limited in the ED where specific diagnosis is often 
not possible given time constraints and incomplete information, and are vulnerable 
to misdiagnosis.  A patient who is low-risk according to the CURB-65 pneumonia 
severity score is likely to be at high risk if his pneumonia is in fact a misdiagnosed 
dissecting thoracic aneurysm, while a generic score such as APACHE II might have 
identified his severity-of-illness without providing specific information as to the 
source of that illness.  Generic scores also allow (to some extent) the prioritisation 
of patients with a variety of conditions; this is likely to be of particular relevance in 
resource-limited situations such as pandemics, and the application of scores to that 
purpose has been discussed in the pandemic planning literature (45-46).
1.3.5 The ideal decision aid
I suggest that an ideal clinical decision aid has three major characteristics – ease of 
use, accuracy and reproducibility.  These are reflected in Stiell and Wells’ processes 
for the development of a decision aid discussed below. In order to be adopted and 
useful in the clinical environment, it needs to be easily and readily recalled and 
applied, using variables that are readily accessible in that particular environment. 
Thus an aid requiring knowledge of the pulmonary artery wedge pressure is unlikely 
to be useful in an Emergency Department but may be of great value in a 
cardiothoracic critical care area.  The aid should be as accurate as possible; failures 
to predict poor outcomes (false negatives) will not only risk compromising patient 
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care but may also reduce staff confidence in the tool, while large numbers of false 
alarms (false positives) are likely to result in the tool being ignored.  Finally, an ideal 
aid will produce the same prediction whether applied at 10am by the senior sister 
or 3am by the FY2 doctor; this is particularly important in emergency care with its 
high level of both patient and staff turnover.
It has been suggested that in order to be useful, medical information should be 
relevant, valid and easy to access (47). Decision rules that relate to diagnosis or 
prognosis are related to the concept of test and treatment thresholds; ideally the 
rule is defined in the clinical context and provides cut points that coincide with risk 
levels where the risk-benefit balance is clearly in favour of treatment or not (see 
figure 11 from Ebell (48)). Thus a rule with a cut-point based on maximising the sum 
of sensitivity and specificity may not be clinically helpful as it may not coincide with 
the clinical treatment threshold (see further discussion in 1.9.2 below).
Figure 7: test and treatment thresholds
Data from implementation studies of computerised clinical decision support 
systems suggests that they can positively influence practitioner behaviour, but 
evidence for benefit in terms of patient outcome is more limited (49), and calls have 
been made for further investigation of their integration into real-world practice 
situations (50).  It appears that decision support systems that are integrated into 
existing data management practices (whether paper or computerised) are more 
likely to influence patient outcomes, as are those that require a clinician to provide 
a justification for deviation from system recommendations (51). 
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1.3.6 Development of a decision aid
The processes for the development of clinical decision rule have been elucidated by 
Stiell and Wells, both authors of rules which are widely used in emergency medicine 
(52).  They describe six steps (table 2).
Table 2: Stiell and Wells processes for development of a clinical decision rule
1. Identifying a 
need
a. Prevalence of relevant condition – common enough for a 
rule to have a reasonable impact.
b. Current use of the related diagnostic test – the currently 
used test has low enough specificity for a rule to improve on 
this.
c. Variation in practice – similar institutions and practitioners 
vary in their use of the diagnostic test.
d. Attitudes of physicians – adoption of a rule is more likely if 
physicians suspect that their current practice involves 
unnecessary testing.
e. Clinical accuracy – potential for clinical examination to 
make or exclude a diagnosis.
2. Deriving the rule 
with appropriate 
standards
a. Defining outcome – clinically important and clearly 
defined; assessed by a blinded observer.
b. Defining predictor variables – clearly defined and ideally 
collected in a prospective standardised manner.
c. Reliability of predictor variables – good intra- and inter-
rater reliability.
d. Selection of subjects – subjects well-defined; subjects and 
setting clearly described so that generalisability of the rule 
can be assessed.
e. Sample size 
f. Mathematical techniques
g. Sensibility of the decision rule – rules are more likely to be 
adopted if clinicians consider them to have content validity, 
ie if they include plausible variables and have not excluded 
any variables widely felt to be important.
h. Accuracy – presented in terms of sensitivity and specificity.
3. Prospective 
validation
a. Prospective validation – new patient population, ideally 
with different clinicians in a different setting.
b. Selection of subjects – ideally an unselected set of patients 
with the condition in question.
c. Application of the rule – including adequate training of 
clinicians in its use.
d. Outcomes – ideally all patients would undergo the gold 
standard test as used in the derivation study, but proxies can 
be substituted.
e. Accuracy of the rule
f. Reliability of the rule – its intra- and inter-rater reliability in 
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the validation population.
g. Physicians’ interpretation – accuracy of clinicians’ 
interpretation, and ease of use.
h. Refinement – this phase may result in a modified or 
streamlined version of the rule.
i. Potential effect
4. Successful 
implementation 
into clinical 
practice
a. Clinical trial – ideally a randomised controlled trial, but 
before-and-after studies may also be used.
b. Effect on use
c. Rule accuracy
d. Acceptability
5. Cost-
effectiveness of 
using the rule
6. Dissemination 
and 
implementation 
of the rule
McGinn further quantified the process of validation and the clinical confidence that 
could be placed in a decision aid (53) (table 3).
Table 3: McGinn levels of clinical confidence in a decision aid
Level 1: Rule can be used in a wide 
variety of settings with confidence it can 
change clinician behaviour and improve 
patient outcomes.
At least 1 prospective validation in a 
different population and 1 impact 
analysis demonstrating change in 
clinician behaviour with beneficial 
consequences.
Level 2: Rule can be used in various 
settings with confidence in its accuracy.
Demonstrated accuracy in either 1 large 
prospective study including a broad 
spectrum of patients and clinicians or 
validated in several smaller settings that 
differ from one another.
Level 3: Rule that clinician may consider 
using with caution and only if patients in 
the study are similar to those in the 
clinician’s clinical setting.
Validated in only one narrow 
prospective sample.
Level 4: Rule that needs further 
evaluation before it can be applied 
clinically.
Derived but not validated or validated 
only in split samples, large retrospective 
databases or by statistical techniques.
The issues of identifying a need (Stiell stage 1) are addressed in section 1.2 above.  
Topics underlying rule derivation and validation (stages 2 and 3) are in sections 1.4 
to 1.9 and 1.10 respectively. Stages 4 and 6, of implementation and dissemination, 
[26]
are outwith the scope of this thesis, but issues around operationalisation are 
explored in chapter 10.
1.4 Outcome measures
Prognostic clinical decision aids can predict a variety of outcomes; the most 
frequently used is patient death, but non-death events and composite outcomes 
are also used.  This section will explore the different properties of outcome 
measures and their relevance in emergency care.
1.4.1 Death
Death is arguably the outcome that matters most to patients and their families.  
However, there are a number of issues in using only death as an outcome measure.  
In some patients, death may reflect the end stage of a chronic disease process, 
rather than an acute event or derangement.  There are some occasions where 
clinician, patient and family have agreed that interventions aiming to extend life are 
futile and/or not in the best interests of the patient; there may be many benefits to 
identifying these occasions early in order to facilitate good palliative care. Apart 
from these cases, discrimination between “inevitable” and “preventable” death is 
notoriously observer-dependent (54) and clinicians have not yet demonstrated the 
ability to prognosticate reliably even in restricted specialist fields such as intensive 
care (55).  
In health care systems with well developed critical care, the use of death as an 
outcome measure for early warning systems may become a self-denying prophesy; 
a patient initially at high risk of death is identified by the early warning system, 
treated adequately and promptly and therefore becomes a patient with a low risk 
of death.  As addressed in 1.2.4 above, patient acuity does not necessarily equate to 
longer-term probability of death. This has been further explored in the trauma 
literature; patients with low probabilities of death overall may still require 
emergent care. Trauma scoring can include the use of an Abbreviated Injury Score 
(AIS), which rates the injuries in each anatomical area on a scale from 1 (minor) to 5 
(critical) and 6 (unsurviveable) (56). A chest wall injury causing tension 
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pneumothorax may well kill a patient rapidly but would only be coded with an 
Abbreviated Injury Score of 2 (57).
1.4.2 Non-death adverse events
Non-death adverse events may reflect either process or outcome.  
It has previously been assumed by some authors that immediate acuity can be 
retrospectively identified using long-term mortality (this is the premise of injury 
severity scoring).  However, a relatively low mortality condition, (eg facial 
angioedema) may cause a patient to be of high acuity, requiring an emergent 
intervention (airway management) to prevent death.  It has therefore been more 
recently suggested that acuity could be better quantified using process outcomes of 
various urgency, such as emergency airway interventions or surgery (58-59).
Process events might include admission to critical care areas or procedures such as 
emergency surgery or cardioversion that eventually result in a good outcome for 
the patient.  The use of these events as outcome measures has been criticised on 
the grounds that they are harder to define than death, and may be subject to 
individual clinician variation (for example if using intensive care admission as an 
outcome, one clinician may be unduly pessimistic about the benefits of ventilation 
for patients with COPD, so will admit very few, whereas a different clinician has a 
particular interest in long-term ventilatory weaning so will admit significantly more). 
They may also be subject to variation in external resources; a process measure of 
emergency surgery within six hours may vary between a hospital with on-site 
vascular surgery where the emergency theatre is occupied by a patient undergoing 
an aneurysm repair and another hospital with no vascular surgery where the 
theatre is immediately available for a patient with the same severity of illness.  A 
major flaw in the use of process measures is their potential circularity; if, for 
example, patients with a low blood pressure receive aggressive fluid resuscitation, 
low blood pressure will become a predictor of aggressive intervention without there 
necessarily being any evidence of benefit from that intervention.  This is difficult to 
illustrate from the literature as many emergency interventions have been inferred 
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from basic principles to be effective without rigorous supporting evidence (this is 
discussed further in section 3.7.2 below). Intuitively it seems that requiring 
evidence for the efficacy of identifying patients with airway obstruction is as 
perverse as requiring evidence for the efficacy of parachutes when jumping out of 
planes (60). However amongst mid-range acuity conditions this does not hold; it is 
not clear that identification of small bowel obstruction in four hours rather than 
two changes outcome, and it is unlikely that primary research will ever address this 
point.  Some examples exist, however, including a Scottish series which argued that 
although depressed consciousness is taught to be an indication for endotracheal 
intubation, some patients with severely reduced consciousness can be managed 
safely without (61). 
Non-death outcome measures include measures of global outcome (the Glasgow 
Outcome Score), functional status (the Barthel index), psychological health (Hospital 
Anxiety and Depression Scale) and measures of health-related quality of life (EQ5D). 
It is arguable that these may reflect quality of health care with more subtlety than 
crude death rates, but they are more complex to administer, require patient (or 
relative) co-operation and are more vulnerable to criticisms of response and 
expectation bias than hard outcomes such as death.  The usual process of collecting 
quality of life data using patient self-reporting further potentiates bias as certain 
patient sets (for example the unconscious or acutely critically ill) may be less likely 
or able to respond. 
1.4.3 Patients with the potential to benefit
Overlapping with both death and non-death groups as above are patients with the 
potential to benefit from health interventions.  Within this thesis the potential to 
benefit will be framed in terms of avoidable premature mortality.  Although it must 
be recognised that many health interventions also aim to improve quality as well as 
quantity of life, assessment of quality of life outcomes is outwith the scope of this 
study.
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Patients with the potential to benefit are those in whom mortality could have been 
prevented had an intervention been provided, or those in whom mortality has been 
prevented by the provision of said intervention. Thus not all patients who die had 
potential to benefit, as for some death may have represented an inevitable end 
point of an unalterable disease process.  This “preventability” concept is explored 
by Hillman, whose structure for identifying preventable adverse events amongst in-
patients excludes those patients in whom death is felt to be inevitable (those 
deemed “not for resuscitation”) (62) (table 4).
Table 4: Hillman structure for preventable adverse events
Potential 
preventability
Deaths Minus all ‘not for 
resuscitation’ 
patients
Potentially unexpected 
deaths
All events 
preceded by pre-
defined criteria 
which have not 
been 
appropriately 
acted on
Cardiorespiratory 
arrests
Minus all ‘not for 
resuscitation’ 
patients
Potentially unexpected 
cardiorespiratory 
arrests
Intensive care 
admissions
Minus all elective 
or expected 
admissions from 
operating rooms, 
recovery area, ED
Unanticipated 
admissions to ICU
It is possible, even likely, that the overlap between risk of death and potential to 
benefit from life-saving treatment varies between subgroups of patients. Some 
patients with a high risk of death (many previously young fit patients with major 
trauma) have a high likelihood of benefiting from timely care (left in figure 8); a 
different patient with high risk of death (the elderly patient with metastatic cancer 
and little cardiopulmonary reserve) has minimal chance of his or her life being 
saved, however prompt the treatment (right in figure 8).
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Figure 8: Overlap between risk of death and potential to benefit
1.4.4 Composite outcome measures
Probably the most widely known composite outcome measure is MACE – major 
adverse cardiac events – comprised of death, acute myocardial infarction or urgent 
coronary revascularisation, and sometimes including life-threatening arrhythmia 
and new onset heart failure, within a given timeframe.  Composite outcome 
measures may seem attractive, in that they include all outcomes that patients are 
likely to wish to avoid, and may aggregate individually rare outcomes to a point 
where they are more statistically manageable.  However, they risk all the flaws of 
their individual components, and assume that all component measures are equally 
unattractive (ie that it would be as unwelcome for a patient to undergo 
percutaneous angioplasty as to die).  Use of a composite outcome measure to 
develop a prognostic rule also implies an assumption that the risk factors for each 
of the components are the same.
1.4.5 Timescale for outcome measures
The most widely used timeframe for analysis of outcome is 30 days, or the length of 
the inpatient stay; over half of the literature analysed in chapter 2 used these 
timeframes.  It is unclear whether this is the most appropriate timeframe to use 
when analysing events and care in the emergency department as it is so open to 
confounding by the quality of ongoing care, the patient’s underlying chronic state 
and unrelated chance occurrences. It may be that longer timescales are required for 
some patient subsets where issues of quality take longer to manifest.
1.5 Potential predictor variables
1.5.1 Demographic variables
Age is included as a variable in a number of well-known prognostic scoring systems; 
ABCD2, which predicts risk of stroke after transient ischaemic attack, gives a point 
for age ≥60 (63), APACHE II, predicting intensive care mortality, uses a cut-off of 45 
(64), and CURB-65, adopted by the British Thoracic Society for mortality prediction 
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in pneumonia (65) and TIMI, for predicting major adverse cardiac events (66) both 
include age 65 or over.  It is not clear whether increasing age is associated with 
increasing disease acuity or simply with a globally increased risk of all-cause 
mortality, and this will be explored in the thesis.
Sex is not widely included in prognostic scores, although it has been found that 
females have a higher risk of mortality after acute myocardial infarction (67) and of 
cardiogenic shock after cardiac thrombolysis (68), and that males have a higher risk 
of ICU admission with pneumonia (69).  The prognostic effect of gender may be 
confounded by a higher proportion of females presenting with “atypical” 
symptomatology or by a preponderance of women amongst the oldest old, and this 
will be further explored.
1.5.2 Chronic health and functional state
Chronic illness is included as a variable in many prognostic aids including APACHE II 
(hepatic, cardiovascular, renal, respiratory and immunosuppressive (64)), the 
Blatchford score for upper gastrointestinal bleeding (hepatic and cardiac (70)), the 
Pulmonary Embolism Severity Index (cardiopulmonary (71)) and the Pneumonia 
Severity Index (neoplasia (23)).  However, an apparently standardised diagnosis may 
not represent the same additional risk in all populations – a patient newly 
diagnosed with diabetes in a deprived resource-poor area with low health literacy is 
likely to have suffered more pathophysiological damage before diagnosis than a 
patient who is newly diagnosed in an affluent area – the “constant risk fallacy”  (72). 
The use of a global functional state to predict prognosis is well-recognised in other 
medical specialities, particularly oncology, where the Karnofsky (73) and other 
scores are used to assess fitness for chemotherapy and other interventions.  This is 
less prevalent in emergency care, although the MEDS (Mortality in ED sepsis) 
allocates points for nursing home residence (74), and the PMEWS score includes 
points for limitation to any activity other than strenuous work (75). 
1.5.3 Acute physiology
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If one assumes that physiological derangement in response to illness represents the 
same risk across all populations, a measure of acute physiological derangement 
would provide a more robust tool for prognostication.  This assumption is likely to 
be defensible as biologically-based physiological measurements can be expected to 
have a relatively constant association with risk, unlike diagnostic labels which are 
more likely to be setting-specific.  This does not guarantee that physiological 
measures are constant predictors of risk across all populations; it is clear from 
paediatrics that the association varies with patient age and it may well be that this 
variability continues across adulthood.  However, physiological predictors will 
hopefully be more robust across healthcare settings. 
There are, however, potential problems with the use of physiological data to 
prognosticate.  The DaVROS study showed that even physiology is subject to a 
constant risk fallacy – ie that the same physiological derangement does not confer 
the same risk across different settings; this may reflect variations in underlying 
population “normality”, different practices in the measurement and documentation 
of physiological variables, or the effect of varying caregiver responses to physiology 
(76).  
It has generally been assumed in the medical literature that most physiological 
variables are distributed in a Gaussian (normal) distribution, with a mean in the 
healthy population from which deviation is correlated with severity of illness. There 
are potential flaws in this assumption; firstly that the ranges quoted in the medical 
literature as “healthy” accurately represent the population.  This has been 
questioned in the paediatric field, where meta-analysis of observational studies 
produced centile ranges that differed substantially from reference ranges quoted in 
life support courses (77). Tarassenko et al, in analysing a large adult vital signs 
database, found mean values amongst acute inpatients of 84.2 for pulse rate, 18.6 
for respiratory rate, 96% for SaO2 and 128.5 for systolic blood pressure (78).  
Secondly, it is unclear whether the “normal” range in the well population is the 
same as that associated with the best prognosis in the acutely ill population; it may 
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be, for example, that some degree of tachycardia during acute illness represents an 
appropriate physiological response and the lack of this is in fact a marker of poor 
prognosis. The published literature includes cut-offs for pulse rates that carry a 
higher risk of adverse outcome at 80, 90, 100, 110, 113, 115, 120, 125 and 130 
beats per minute, neatly dissecting both the “normal” and “abnormal” ranges.  It 
has often been assumed in the existing literature that a linear relationship exists 
between physiological variables and adverse outcome (ie, the faster the pulse, the 
greater the risk of death).  This is not supported where the assumption has been 
explored and relationships exist in the form of U-shaped curves (for pulse in acute 
coronary syndrome and blood pressure in stroke), J-shaped curves (blood pressure 
in stroke), inverse exponentials (blood pressure in acute coronary syndrome) and 
interactions between two variables (pulse and blood pressure in sepsis).
1.6 Selection of subjects 
Prognosis researchers must define a priori subjects to be included in the data set.  
This involves a decision about whether the inclusion and exclusion criteria should be 
narrow or pragmatic.  For example, almost all prognostic studies of community-
acquired pneumonia exclude patients who are immunosuppressed, and require 
identification of infiltrates on chest Xray by a radiologist.  This limits generalisability 
to routine practice, where many patients are unknowingly HIV positive or taking 
steroids, and where radiologists rarely review all ED chest Xray films.  It would 
appear therefore that for the development of tools to use in the ED setting, broad 
pragmatic inclusion criteria are to be preferred.  This risks, however, confusion 
where a particular variable has different effects in different subgroups; a study of all 
patients seen in the resuscitation area might conclude that a systolic blood pressure 
of 180 has prognostic benefit, based on patients with acute coronary syndrome or 
pulmonary oedema, when for the subgroup with stroke it is a marker of poor 
prognosis.
1.6.1 Prospective versus retrospective data collection
Prospective data collection has the benefits of specific standardised measurement 
of both variables and outcomes, and overcomes the requirement for blinding during 
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the extraction of retrospective data.  However, data collection may be a confounder 
in itself, where the data collection tool may trigger measurement of variables which 
would otherwise not have been carried out and which then alter treatment 
decisions.
In some rare conditions it may not be practically feasible to collect purely 
prospective data, and retrospective disease registries may be of value.  This is 
unlikely to be applicable to this study.
1.6.2 Source of data set
It is generally accepted that the optimal data set from which to derive a clinical 
decision aid is a cohort study or the placebo arm of a randomised controlled trial 
(both arms can be combined if the treatment had no significant effect).  Use of data 
from a randomised controlled trial may offer longer follow-up times (if these are 
relevant) for fewer resources, but there are likely to be more problems with 
generalisability given the usually tighter recruitment restrictions for randomised 
controlled trials.  It is also conceivable that willingness (or not) to participate in a 
randomised controlled trial could be a prognostic feature in itself.  Although a case-
control model can be used this is limited by lack of knowledge of the size of the 
source population (79).
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1.7 Sample size
Statistical simulation studies have suggested that for use of logistic regression 
analysis, a cohort including ten outcomes events for interest per variable assessed 
provides an acceptable precision of regression coefficients (80).  This rule has been 
challenged more recently (81), but this thesis will adopt the more conservative 
estimate. This will be discussed in more detail in section 3.10 below.
1.8 Mathematical techniques
Clinical decision aids can be developed using a variety of statistical methods, the 
two most common being logistic regression analysis and recursive partitioning.  
Logistic regression generates β-coefficients that simultaneously weight the value of 
variables in predicting a dichotomous outcome.  These coefficients can then be 
rounded to create a clinically-useable score.  Logistic regression models can provide 
good overall accuracy but may lack the ability to generate very high sensitivity or 
specificity if this is what is required.  Recursive partitioning sequentially identifies 
dichotomous predictor variables that divide a population into subgroups with only a 
particular binary outcome of interest.  This is particularly effective for generating 
decision rules with very high sensitivity, and generates a rule that does not require 
the user to make calculations, but requires arbitrary dichotomisation of continuous 
and categorical data. This thesis will therefore use regression techniques.
1.9 Assessment of accuracy
1.9.1 Discrimination and calibration
Decision aids providing a probability of an adverse outcome can be assessed in two 
main ways: discrimination and calibration.  
Discrimination is the ability of a decision aid accurately to identify that a patient 
who suffers the outcome is at higher risk of the designated outcome than a patient 
who does not suffer the outcome (ie the probability that a randomly selected 
patient with the designated outcome will have a higher score than a randomly 
selected patient without the designated outcome).  This is usually presented in 
terms of the area under ROC (receiver operator characteristic) curve, also known as 
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the c-statistic.  The ROC curve plots sensitivity at various threshold values against 1-
specificity in order to quantify the trade-off between increasing sensitivity and 
falling specificity (or vice versa).  An ideal decision aid would have a c-statistic of 1.0. 
A c-statistic of 0.5 is no better than chance, while realistically a good model 
achieves a c-statistic of 0.8 or above.
Calibration is a measurement of the agreement between the predicted risk of death 
in subgroups of the population (usually demarcated by deciles of the risk score or 
deciles of risk of death) and observed rates of death in the same subgroups.  The 
most frequently presented measure of this is the Hosmer-Lemeshow test, a 
modification of the chi-squared test.  Figure 9 below is a graphical presentation of a 
calibration test from Altman (82), where the observed and predicted proportions of 
an outcome are plotted – in this example calibration (shown by the red line) is poor.
Figure 9: graphical representation of calibration
1.9.2 Trade-off of sensitivity and specificity
In order to be clinically relevant and useful, a decision aid must make an acceptable 
trade-off between sensitivity (ensuring that all patients with the condition have a 
positive test result) and specificity (ensuring that patients without the condition 
have a negative test result).  The ideal test would be 100% sensitive and 100% 
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specific (the definition of a gold standard or reference test) but such tests remain 
elusive in the near-patient environment.
An acceptable trade-off between sensitivity and specificity will depend on the 
potential benefit of identifying true positive outcomes (a function of the severity of 
the outcome and its amenability to treatment), the potential harm (in health and 
economic terms) of treating false positive outcomes, and the individual patient’s 
preferences.  For example a decision rule to dictate CT brain scanning in patients 
with head injury would need to have high sensitivity if the outcome measure was 
immediate neurosurgical intervention (as a false negative rule result could be 
disastrous), whilst lower sensitivity would be tolerated in an attempt to avoid 
radiation exposure if the outcome measure was radiologic findings not requiring 
any intervention.  Conversely a decision rule for the diagnosis of appendicitis would 
need to have high specificity (to minimise unnecessary surgical procedures) but 
might tolerate lower sensitivity as it could be reapplied to patients with an evolving 
presentation. 
1.10 Validation
The validation of clinical decision aids addresses two potential problems.  Firstly, 
clinical decision aids tend to perform better in the data set from which they are 
derived – known as “over-fitting”.  In figure 10, the black line represents the true 
relationship between two variables.  The red dots represent a sample from which 
the relationship is estimated, generating the green line.
Figure 10: a well fitted model
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In an overfitted model, shown in figure 11, the green line fits the sampled data 
more closely (obscuring the red dots) but is a less accurate estimate of the true 
relationship.  
Figure 11: an overfitted model
Internal validation addresses this by providing an alternate set of sampled data.  
Secondly, decision aids perform better in populations similar to those from which 
they were derived (the similarity may be explicit in terms of the variables included 
in the decision aid or occult in terms of unmeasured variables).  External validation 
addresses the problem of generalisability to other institutions and health care 
settings.
1.10.1 Selection of data set
Internal validation involves the splitting of a single data set into two subsets before 
derivation of the decision aid from one subset, with subsequent validation on the 
second subset.  This can be combined with “bootstrapping”, where resampling is 
randomly undertaken from the full data set.  This has a number of practical benefits 
in that the data collection infrastructure only has to be established once and 
piloting issues are minimised.  However, it risks overestimating the performance of 
the decision aid in other settings, as the validation population should be very similar 
to the derivation population.  A partial response to this is temporal validation, 
where a temporally separate dataset is collected at the same institution(s) as the 
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derivation dataset.  This does not, however, address the issue of similarities in the 
patient population likely to present to the same setting.
External validation involves testing the rule against a dataset from a different 
institution.  This dataset can reflect closely the inclusion and exclusion criteria from 
the derivation study, or can be much broader.  Broader datasets, however, tend to 
demonstrate poorer performance of the decision aid; a model derived to predict 
complications in young ambulatory patients with pneumonia is likely to suffer if 
applied to a population where a significant number of patients are bedbound in 
nursing homes.
1.11 Summary
 Acute illness and acute severe illness present a significant logistical challenge to 
the NHS.
 Severity assessment of acute illness has a role in guiding immediate care and in 
case-mix adjustment for research and audit.
 Clinical decision aids exist in a number of forms and have been used to predict a 
number of outcomes.
 Multiple issues of quality exist in the development and testing of clinical 
decision aids.
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Chapter 2
Literature review
2.1 Introduction
The literature review was undertaken to inform the empirical work in terms of 
identifying structures of decision aids suitable for emergency care, potential 
variables which are both feasibly collected in the emergency situation and may 
predict relevant outcomes, and gaps in the current evidence base around decision 
aids in emergency care.  Specifically, it aimed to identify existing tools to identify 
critical illness in the acutely ill, ideally in an undifferentiated population. 
During the conduct of this research, the Royal College of Physicians launched a 
National Early Warning Score developed by a multidisciplinary consensus panel.  
This was in response to “the multiplicity of early warning systems used in different 
hospitals in the UK …causing a lack of consistency in detecting deterioration of 
patients’ conditions and calling for urgent medical help”. The NEWS is advocated, 
for the purposes of standardisation “during the initial prehospital and/or hospital 
assessment of a patient and throughout the patient’s hospital stay”, although the 
development group did not include emergency physicians or nurses as stakeholders 
and the group was unable to identify any relevant literature relating to Emergency 
Department patients (15).
2.1.1 Background
The literature review aimed to address three broad points:
1. Format and scope of existing clinical decision aids, with particular attention to an 
undifferentiated patient group.
2. The role of physiological variables in existing clinical decision aids;
3. Evidence to support the predictive value of individual physiological variables.
2.1.2 Format of clinical decision aids
As discussed previously, clinical decision aids can take a number of forms.  There is 
no widely accepted standard format and it may be that a variety of formats are 
required for different situations; it may be reasonable to trade off some reduction 
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in performance for simplicity of application where a decision aid is to be applied to 
a large number of patients, while in a patient set with low numbers but high-stakes 
decision-making a more complex model is appropriate.  The most appropriate 
format of aid may also be influenced by the availability of technology; the increasing 
availability of near-patient and smartphone apps will enable the real-time use of 
more complex modelling.
 
The first aim was therefore to summarise the various formats of clinical decision aid 
reported.
2.1.3 Scope of existing clinical decision aids
Attempts to implement risk-prediction methods for both clinical decision-making 
and audit and research are hampered by the substantial range and number of risk 
scores available. There are so many potential scores for non-trauma patients that 
deciding which score should be used and which outcome is most relevant presents 
a challenge in itself. 
The aim was to summarise the scope of clinical decision aids which related to short-
term outcomes and were applicable at the point of patient presentation to 
unscheduled healthcare services (excluding trauma, paediatrics and purely obstetric 
or psychiatric presentations).  This would support the underlying aim of the thesis, 
to identify prognostic factors in emergency patients and construct a bedside tool to 
support their care.
2.1.4 Existing clinical decision aids for general medical emergencies
As discussed in chapter 1, the applicability of disease-specific decision aids is limited 
by the impracticality of always reaching a definitive diagnosis in the Emergency 
Department.  They can also be misleading if misdiagnosis has occurred, and do not 
allow for comparison of severity of illness between patients with different 
diagnoses.  The aim was therefore to identify the extent to which any decision aids 
relating to general unselected medical emergencies had been developed and 
validated.
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2.1.5 Physiological variables in existing clinical decision aids
It appears that inclusion of physiological variables in existing scoring systems is 
inconsistent, both in the variables included and in their weighting and cut-off values 
for “abnormality”.  For example, if a patient with sepsis secondary to pneumonia is 
assessed using a sepsis score (MEDS), a respiratory rate over 20 is a marker of 
severity, while if the same patient is assessed using a pneumonia score (CURB-65), 
his respiratory rate needs to be over 30 before it is considered a marker of severity.
The aim was therefore to summarise the inclusion of physiological variables in 
existing clinical decision aids, and the various cut-points at which physiological 
derangement was considered significant.
2.1.6 Evidence for the use of individual physiological variables
Although it appears self-evident that deviation from physiological norms is likely to 
be associated with adverse outcome, there is in fact little evidence to support 
widely-used definitions of “normal”, particularly in the acutely unwell patient.  For 
example, although various life support courses may teach that the “normal range” 
of pulse rate in adults is 60 – 100 beats per minute, a pulse of over 90 is one of the 
criteria for systemic inflammatory response syndrome (SIRS), while one pneumonia 
score (PSI) does not include tachycardia as a marker of severity until the rate 
reaches 125 beats per minute. 
Non-physiological markers such as pre-existing diagnoses and treatment have been 
identified as predictors of outcome in a number of situations.  These may be 
problematic in the emergency situation, where the patient may be too unwell to 
communicate, may have forgotten information previously conveyed to them or may 
not have had all relevant investigations (not all patients with clinically diagnosed 
heart failure have undergone echocardiographic quantification of ejection fraction, 
for example).  Pre-existing diagnoses are also subject to the “constant risk fallacy” 
(72) whereby the same diagnosis does not confer the same risk in different 
populations; a diagnosis of diabetes in a population which generally does not 
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engage with health care is likely to be worse prognostically than the “same” 
diagnosis in a population with well established early screening programmes and 
widespread community engagement.  There is little evidence as to whether 
physiological variables are equally applicable across all patient populations, as has 
previously been assumed, although the DAVROS study indicated that they too 
exhibited non-constant risk (76).
The aim was therefore to summarise the evidence supporting the value of 
individual physiological variables as predictors of various adverse outcomes.
2.2 Methods
2.2.1 Search strategy 
The literature review used a deliberately inclusive strategy, which aimed to identify 
literature relating specifically to severity scores and also that relating to prognostic 
indicators, whether or not incorporated into a score.  
The first strategy was to search generically for scores or aids applicable to 
undifferentiated patients in emergency or acute care. This involved searching 
Medline 1946 – 2013 using the strategy as below:
1  clinical prediction aid.mp. (0)
2  clinical prediction rule.mp. or Decision Support Techniques/ (10582)
3  clinical decision aid.mp. (17)
4  clinical decision rule.mp. (211)
5  score.mp. (238805)
6  risk.mp. or Risk/ (1317067)
7  prognosis.mp. or Prognosis/ (437345)
8  outcome.mp. (1029477)
9  acute.mp. (821130)
10 emergency.mp. or Emergencies/ (185645)
11 1 or 2 or 3 or 4 or 5 (248848)
12 6 or 7 or 8 (2397572)
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13 9 or 10 (973362)
14 11 and 12 and 13 (18135)
15 limit 14 to (english language and humans and "all adult (19 plus years)") (13242)
 
The second strategy was to search for previously identified severity scores by name 
and commonly-used abbreviation.  The scores were identified from personal 
knowledge, informal discussion with colleagues, and snowballing as the literature 
review developed.  The final search covered Medline 1950 to October 2009 (in title, 
keywords, abstract or text): Altona (peritonitis), Alvarado (appendicitis), APACHE, 
Balthazar (pancreatitis), Blatchford (GI bleed), Canadian Triage and Acuity (CTAS), 
Emergency Severity Index (ESI), Essen, Early Warning Score (EWS), Geneva 
(pulmonary embolism) Glasgow Coma Scale/Score (GCS), Glasgow (pancreatitis), 
Goldman (acute coronary syndromes/ACS), GRACE (ACS), Hardman (abdominal 
aortic aneurysm/AAA), Manchester Triage (MTS), Mannheim (peritonitis), MEDS 
(sepsis), Mainz (unselected), MELD (cirrhosis), Mortality Probability Model (MPM), 
Norris (ACS), peritonitis severity score, POSSUM (emergency surgery), PURSUIT 
(ACS), Ranson (peritonitis), Rapid Acute Physiology Score (RAPS), Rapid Emergency 
Medicine Score (REMS), RISC (cerebrovascular event), Rockall (GI bleed), ROSE 
(syncope), San Francisco (syncope), Simplified Acute Physiology Score (SAPS), 
Scorten (toxic epidermal necrolysis), Sequential Organ Failure Assessment (SOFA), 
TIMI (ACS), Therapeutic Intervention Severity Score (TISS) and Wells (pulmonary 
embolism).
The third strategy was to search for prognostic indicators by condition.  This 
involved searching Medline 1950 to October 2009 for: Prognosis/ OR “Severity of 
illness index”/ OR severity.mp OR risk/.  This was then cross-referenced to the 
MeSH terms of: acute coronary syndrome, aneurysm (including dissecting, false, 
iliac, infected, ruptured), aortic aneurysm, arachnoiditis, arsenic poisoning, arterial 
occlusive disease, asthma (exp), bacteremia, brain abscess, brain infarction, chronic 
bronchitis, bronchopneumonia, cardiomyopathy (alcoholic, chagas, dilated, 
hypertrophic, takotsubo), chronic obstructive pulmonary disease, cirrhosis, CNS 
infections (bacterial, fungal, parasitic, viral), confusion, coronary aneurysm, 
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delirium, dermatitis (including herpetiformis), dermatomyositis, diabetic coma, 
diabetic ketoacidosis, encephalitis, encephalomyelitis, endocarditis (including 
bacterial and subacute), epidural abscess,  fungaemia, gastrointestinal haemorrhage 
(exp), heart aneurysm, heart failure, heat exhaustion (exp), heat stroke (exp), 
hematemesis (exp), hepatic encephalopathy, hepatic insufficiency, hepatitis, 
hyperglycaemic hyperosmolar nonketotic coma, hypothermia (exp), intracranial 
aneurysm, intracranial embolism, intracranial thrombosis, liver failure (including 
acute), melaena (exp), meningitis (including aseptic, bacterial, fungal, viral), 
meningoencephalitis, mesenteric vascular occlusion, myocardial infarction, 
myocarditis, necrotising fasciitis, pancreatitis (including acute necrotising, 
alcoholic), peptic ulcer haemorrhage (exp), peritonitis (including tuberculous), 
pleuropneumonia, pneumonia (including aspiration, bacterial, pneumocystis, viral), 
poisoning (arsenic, cadmium, carbon monoxide, carbon tetrachloride, ciguatera, 
fluoride, food, gas, heavy metal, lead, manganese, mercury, MPTP, mushroom, 
plant, salmonella, staphylococcal), pulmonary embolism, pulmonary infarction, 
renal artery obstruction, sepsis, septic shock, skin diseases (including eczematous, 
infectious, metabolic), soft tissue infection, status asthmaticus, stroke, 
subarachnoid haemorrhage, subdural empyema, subphrenic abscess, suppuration, 
syncope (including vasovagal), toxaemia, transient ischaemic attack, urinary tract 
infaction and ventricular dysfunction (including left and right).  The MeSH terms 
were selected by manual scanning of the MeSH subject headings to include all 
conditions that could reasonably present in the acute setting.  All searches were 
limited to English language, humans and adults.  
2.2.2 Article selection
The initial searches identified 13242 (strategy 1), 14659 (strategy 2) and 46605 
(strategy 3) titles.  A significant number of titles were identified by more than one 
search.  Titles and abstracts were screened initially and where they appeared 
relevant or where relevance could not be established from the title and/or abstract 
the full paper was obtained. 47 (method 1), 682 (method 2) and 1661 (method 3) 
abstracts were screened.
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To assess formalised scores or decision aids, search output was limited by title, 
abstract or full paper review to those papers including a wholly or predominantly 
clinical assessment (ie not biomarkers or specialist tests not available in the 
majority of EDs such as myocardial scintigraphy), to those which assessed an adult 
population and to those who assessed an outcome measure within 30 days of 
presentation.  Also excluded were assessment tools requiring a specialist algorithm 
not freely available, or those which were applied only to patients in a critical care 
setting. 225 papers were deemed to fit the inclusion criteria.
To assess specific potential predictor variables, search output was limited to those 
papers assessing physiological variables at presentation and describing outcome 
measures up to 30 days after presentation.  Data sets consisting purely or 
predominantly (over 50%) of trauma, paediatric, obstetric and psychiatric patients 
were excluded.  542 papers were deemed to fit the inclusion criteria.
Figure 12: Flow diagram of literature review
2.2.3 Data extraction
In the assessment of formalised scores or decision aids, the following data were 
extracted from each article selected for inclusion: the name and/or acronym of the 
score, the target condition or conditions, the patient groups included in the target 
condition(s), the main outcomes measured and the discriminant value of the score, 
expressed as the area under the receiver-operator characteristic curve (AUROC) or 
sensitivity and specificity.
In the assessment of potential predictor variables, scores identified as above were 
examined for the cut-off points of the variables deemed significant.  From the 
search specifically for these variables, data were extracted from each article 
selected for inclusion was: the physiological variable(s) under analysis, the target 
condition or conditions, the patient groups included in the target condition(s), the 
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main outcomes measured and the relationship between the variable and outcome 
(difference in means, odds or risk ratios, non-linear relationship).
2.3 Results
2.3.1 Format of existing clinical decision aids
Clinical decision aids published to date appear to adopt one of five formats: the “all 
or nothing” rule, the unweighted simple summative score, the weighted summative 
score, the decision tree and the nomogram. Table 5 shows the number of decision 
aids identified in each format and the broad patient categories to which they have 
been applied.
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Table 5: Format of existing clinical decision aids
Format Number of tools Patient categories
All or nothing 7 Acute coronary syndrome
GI bleed
Influenza
Pneumonia
Poisoning
Syncope
Unweighted summative score 33 Aortic aneurysm
Acute coronary syndrome
Asthma/COPD
GI bleed
Heart failure
Influenza
Pancreatitis
Pneumonia
Pulmonary embolism
Sepsis
Surgical
Syncope
TIA
Unselected
Weighted summative score 78 Aortic aneurysm
Acute coronary syndrome
Asthma/COPD
GI bleed
Heart failure
Hypothermia
Influenza
Pancreatitis
Pneumonia
Pulmonary embolism
Sepsis
Stroke
Surgical
Syncope
Unselected
Decision tree 5 Acute coronary syndrome
Asthma/COPD
Heart failure
Sepsis
Unselected
Nomogram 0
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2.3.1a The “all or nothing” rule
These rules are generally to be found as “rule-out” systems in common conditions 
that occasionally indicate sinister underlying disease processes, and require a 
consistent answer (usually “no”) to a set of questions.  For example, the San 
Francisco Syncope rule requires the patient to have none of: a. congestive heart 
failure history, b. haematocrit under 30%, c. abnormal ECG, d. history of shortness 
of breath and e. systolic blood pressure under 90mmHg in order to be deemed low 
risk (83).
2.3.1b Unweighted summative scores
These scores include a number of variables, scoring one point for each variable.  The 
number of points is then summed and risk of adverse outcome related to the total 
score.  For example, the CURB-65 pneumonia score allocates a point each for: a. 
confusion, b. urea over 7.0, c. respiratory rate over 30 breaths per minute, d. blood 
pressure of under 90mmHg (systolic) or 60mmHg (diastolic) and e. age over 65.  A 
score of 0 or 1 is deemed low risk, 2 intermediate risk and 3 high risk (65). 
2.3.1c Weighted summative scores
These scores also sum points from individual variables to create a score which 
relates to risk.  The weighting can be inter-variable (such as the PSI, where a 
respiratory rate of over 29 breaths per minute scores 20 points, but a pulse of over 
124 beats per minute scores only 10 points), or intra-variable (in APACHE II a pulse 
of 120 beats per minute scores 2 points but one of 165 beats per minute scores 3 
points).
2.3.1d Decision trees
Decision trees subdivide the population at risk according to various nodal points; 
the next nodal point is dependent on the response to the previous one.  For 
example, in the decision tree shown below, which predicts probability of death or 
survival in patients with AIDS-related pneumocystis pneumonia, the two possible 
values at the initial node (alveolar-arterial oxygen gradient) lead to different 
secondary decision nodes (age or prior diagnosis of AIDS).
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Figure 13: Example of decision tree
Reproduced from Yarnold et al (84).
2.3.1e Nomograms
Nomograms diagrammatically represent the effect of a particular variable 
conditional on the values existing for other variables.  For example, in the 
nomogram reproduced in figure 14, which predicts 1-year mortality based on the 
results of a Bruce protocol exercise ECG, the ischaemia reading is conditional on the 
results of ST-segment deviation and angina, while the prognosis is conditional on 
the results of the ischaemia reading and the duration of exercise.  No nomograms 
were identified applicable to the patient group of interest to this thesis.
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Figure 14: Example of nomogram
Reproduced from Mark et al (85).
2.3.2 Decision aids for undifferentiated patient populations
Full details are given in appendix 1.  Briefly, 23 manuscripts related to decision aids 
or risk stratification in undifferentiated patient populations. 2 manuscripts could 
not be obtained despite interlibrary loan requests and attempts to contact the 
authors. A further study described a decision aid for use in the prehospital 
environment (86).  The structure of the identified decision aids is summarised in 
table 6.
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Table 6: Structure and variables of decision aids for undifferentiated patient 
populations
Structure Variables included
Bispebjerg (87) Weighted summative 
score
Consciousness (AVPU)
Heart rate
Respiratory rate
Systolic blood pressure
Temperature
Hillerød (88) Multiple level all-or-
nothing
Airway problem
Chest pain
Comorbidity
Consciousness (GCS)
Dyspnoea
ECG changes
Heart rate
Oxygen saturation
Respiratory rate
Systolic blood pressure
Temperature
HOTEL (89) Unweighted summative 
score
ECG changes
Mobility
Oxygen saturation
Systolic blood pressure
Temperature
PREEMPT-2 (90) Weighted summative 
score
Age
Consciousness (AVPU)
H+
Oxygen saturation
PaCO2
Respiratory rate
Systolic blood pressure
Rapid Emergency 
Medicine Score 
(91)
Weighted summative 
score
Consciousness (GCS)
Heart rate
Mean arterial pressure
Oxygen saturation
Respiratory rate
Temperature
Simple Clinical 
Score (92)
Weighted summative 
score
Age
Breathlessness
Consciousness
Diabetes
ECG changes
Functional status
Heart rate
Mobility
Oxygen saturation
Stroke
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Systolic blood pressure
Temperature
South African 
Triage Score (93) 
and Cape Triage 
Score (94)
Weighted summative 
score plus all-or-nothing 
discriminators
Consciousness (AVPU)
Heart rate
Mobility
Pain
Respiratory rate
Systolic blood pressure
Target time to treatment
Temperature
Trauma as presenting complaint
Multiple features of clinical 
history
Sun score (95) Weighted summative 
score
Age
Arrival by ambulance
Comorbidity
Racial group
Recent hospitalisation or ED visit
Unstructured triage nurse 
assessment
Vital Signs Score 
(96)
Unweighted summative 
score
Airway problems
Consciousness (GCS)
Heart rate
Oxygen saturation
Respiratory rate
Seizures
Systolic blood pressure
VitalPACTM EWS 
(ViEWS) (97)
Weighted summative 
score
Consciousness (AVPU)
Heart rate
Inspired oxygen
Oxygen saturation
Respiratory rate
Systolic blood pressure
Temperature
The various scores have been evaluated as in table 7 below.  Notable is the general 
lack of external validation.
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Table 7: Evaluation of decision aids for undifferentiated patient populations
Title and 
year
Design of study P
a
ti
e
n
ts 
a
n
d 
s
e
tt
in
g
Outcome measures Main results
Acute illness severity score
Mikulich 
2011 (98)
Database analysis 2
5
8
8
3 
p
a
ti
e
n
ts
; 
4
9
30-day in-hospital mortality OR (vs group 1) for group 2: 1.72, group 3: 
4.66, group 4: 6.51, group 5: 10.00, group 
6: 19.92.
3
3
7 
a
d
m
is
si
o
n
s. 
A
d
m
is
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o
n 
u
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t, 
H
D
U 
o
r 
I
C
U
Canadian Triage and Acuity Scale (30)
Lee 2011 
(99)
Retrospective chart review 1
9
0
3 
p
a
ti
e
n
ts 
a
g
e
d 
≥
6
5 
y
e
a
rs 
p
r
e
s
e
n
ti
n
g 
Life-saving intervention in ED 49% CTAS 1 and 2
2% CTAS 3
0 CTAS 4 and 5
ICU admission 75% CTAS 1
40% CTAS 2
3% CTAS 3
0 CTAS 4 and 5
Death 4% CTAS 1
1% CTAS 2
0 CTAS 3, 4 and 5
t
o 
E
D
.
Prah Ruger 
2007 (100)
Retrospective chart review 7
7
7
0
9 
a
d
ul
t 
p
a
ti
e
n
ts 
u
n
d
e
r
g
oi
n
g 
E
Hospital admission or ED death 70% CTAS 1
43% CTAS 2
10% CTAS 3
Admitted to ICU or theatre 24% CTAS 1
3% CTAS 2
0.4% CTAS 3
D 
tr
ia
g
e.
Cape Triage Score
Bruijns 
2008 (94)
Prospective database with post hoc 
simulation.
7
9
8 
p
a
ti
e
n
ts 
(i
n
cl
u
di
n
g 
tr
a
u
m
a 
& 
o
b
Admission or ED death Undertriage (green) 24%, overtriage 
(orange/red) 25%.
st
e
tr
ic
) 
p
r
e
s
e
n
ti
n
g 
t
o 
E
D 
in 
o
ff
ic
e 
h
o
u
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.  
Early Warning Score
Armagan Prospective cohort study 3 Hospital admission 57% admitted score >4 vs 37% score <5.
2008 (101) 0
9 
p
a
ti
e
n
ts 
p
r
e
s
e
n
ti
n
g 
t
o 
E
D
ICU admission OR for score >4 1.95
Death OR for score >4 14
Groarke 
2008 (102)
Retrospective chart review 2
2
5 
p
a
ti
e
n
ts 
ICU admission OR for each rise in score category 3.35.
Death OR for each rise in score category 2.19.
a
d
m
it
t
e
d 
t
o 
m
e
di
c
al 
w
a
r
d 
vi
a 
M
A
U
Burch 
2008 (103)
Retrospective chart review 7
9
0 
m
e
di
c
Hospital admission Score 0-2 45%, score 3-4 59%, score >4 
79%.
Inhospital death Score 0-2 5%, score 3-4 16%, score >4 
26%.
al 
p
a
ti
e
n
ts 
p
r
e
s
e
n
ti
n
g 
t
o 
E
D
Heitz 2010 
(104)
Retrospective chart review 2
8
0 
a
d
ul
t 
p
a
ti
Higher level care in 24h AUROC of maximum EWS in ED 0.73.
AUROC of first EWS at presentation 0.668.
e
n
ts 
a
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E
D
, 
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Perera 
2011 (105)
Prospective cohort study 2
4
2 
a
d
ul
t 
p
a
ti
e
n
ts 
a
d
m
it
t
e
d 
t
o 
HDU or ICU admission, 
cardiorespiratory emergency 
or resuscitation, inhospital 
death.
AUROC 0.68 +/- 0.06
M
A
U
HAPT
Barfod 
2012 (88)
Retrospective database review 6
2
7
9 
a
d
m
is
si
o
n
s 
t
o 
E
D 
o
b
s
e
r
v
a
ti
o
n 
ICU admission Vital signs
OR Red: 38.6, Orange: 10.9, Yellow 4.3.
Final triage
Red 40.3, Orange 8.5, Yellow 3.5
Hospital mortality Vital signs OR Red: 20.1, Orange 3.9, 
Yellow 2.2
Final triage OR Red: 24.0, Orange 8.0, 
Yellow 2.8 
w
a
r
d 
o
r 
g
e
n
e
r
al 
w
a
r
d
HOTEL
Kellett 
2008 (89)
Prospective dataset 1
0
2
9
0 
a
c
u
t
e 
m
e
di
Death 15min – 24h AUROC 0.865 derivation, 0.854 validation.
c
al 
a
d
m
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n
s 
(
6
9
4
7 
d
e
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v
a
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o
n
, 
3
3
4
3 
v
al
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a
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n
)
PREEMPT-2 
Carmichae
l 2011 (90)
Prospective dataset 4
3
1
4 
a
c
u
t
e 
m
e
di
c
al 
a
d
m
is
si
o
n
s
ICU admission AUROC 0.89.
REMS
Olsson 
2004 (91)
Prospective dataset 1
1
7
5
1 
a
c
u
t
e 
n
o
n
s
u
r
gi
c
al 
n
o
n
tr
a
u
m
a 
p
r
e
Inhospital death AUROC 0.852.
s
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t
a
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n
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Simple Clinical Score
Li 2012 
(106)
Retrospective chart review 4
1
7 
a
d
m
is
si
o
n
s 
t
o 
A
c
u
Length of stay <0.001
MET call p =0.1
ICU admission p = 0.7
Hospital mortality p <0.001
t
e 
A
d
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o
n 
U
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t
E
x
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d
e
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e
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t
o 
I
C
U
, 
C
C
U 
o
r 
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Kellett 
2011 (107)
Prospective cohort 1
1
6
5 
Inhospital mortality OR 10.10 where SCS was increased 24h 
after admission.
u
n
s
el
e
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e
d 
m
e
di
c
al 
a
d
m
is
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o
n
s 
(
a
g
e
d 
1
4 
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Subbe 
2010 (108)
Retrospective review 1
0
9
8 
p
a
ti
e
n
ts 
a
d
m
it
t
e
d 
t
o 
a
c
u
t
e 
m
e
Death in 48 hours Very low risk 0, low risk 1%, average risk 
0.5%, high risk 2.5%, very high risk 8%.
Death in 7 days Very low risk 0, low risk 2%, average risk 
1.5%, high risk 5%, very high risk 18.5%.
di
ci
n
e
Subbe 
2010 (109)
Prospective data 2
8
1 
p
a
ti
e
n
ts 
a
d
m
it
t
e
d 
a
s 
m
e
di
c
al 
e
m
e
Death in 7 days AUROC 0.85
ICU admission Very low risk 1%, low risk 2%, average risk 
1.5%, high risk 16.5%, very high risk 19%.
r
g
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a
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2
1 
c
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s 
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Kellett 
2006 (92)
Prospective cohort 6
7
3
6 
(
d
e
ri
v
a
ti
o
n
) 
a
n
d 
3
2
Death in 24h AUROC for derivation 0.90; for validation 
0.91.
Death in 30 days AUROC for derivation 0.86; for validation 
0.86.
2
8 
(v
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n
) 
u
n
s
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e
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e
d 
a
d
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South African Triage Score
Rosedale 
2011 (93)
Prospective dataset 5
8
9 
p
a
ti
e
n
ts 
p
r
e
s
e
n
ti
n
g 
t
o 
E
D 
in 
o
Admission or ED death Undertriage (green) 4.4%, overtriage 
(orange/red) 4.3%.
ff
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e 
h
o
u
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Sun score
Sun 2011 
(95)
Retrospective database analysis 3
1
7
5
8
1 
E
D 
vi
si
ts 
(
6
0
% 
d
e
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v
a
ti
o
Hospital admission AUROC 0.85 in derivation set
AUROC 0.849 in validation set
n
, 
4
0
% 
v
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a
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o
n
)
ViEWS
Prytherch 
2010 (97)
Prospective dataset 3
5
5
8
5 
p
a
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e
n
ts 
a
d
m
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t
Hospital mortality within 24h AUROC 0.88.
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Vital Signs Score
Merz 2011 
(96)
Prospective dataset 4
3
8
8 
p
a
ti
e
n
ts 
a
d
m
Inhospital death AUROC 0.72.
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D
Notably, the absence of reporting of AUROC or at least sensitivity and specificity 
limits interpretation of the utility in clinical practice of many of these tools.
2.3.3 Scope of existing clinical decision aids
Clinical decision aids existed for 13 broad diagnostic groups: abdominal aortic 
aneurysm (7 aids), diagnosed or potential acute coronary syndrome (30), asthma 
and chronic obstructive pulmonary disease (6), gastrointestinal bleeding (7), heart 
failure and pulmonary oedema (9), influenza (9), pancreatitis (11), pneumonia (26), 
pulmonary embolism (4), sepsis (10), surgical emergencies (13), syncope (3), 
transient ischaemic attack (2). 13 tools were available for wider diagnostic groups 
(such as patients in ED resuscitation areas or those arriving by ambulance).  Single 
manuscripts addressed prognostication in poisoning, hypothermia, meningitis, 
myxoedema coma, symptomatic atrial fibrillation and Fournier’s gangrene.
Multiple sets of inclusion criteria were used, even within diagnostic groups.  This 
was particularly notable within actual or potential acute coronary syndrome 
patients, and less so amongst patients with abdominal aortic aneurysm and 
pancreatitis.
Data sets were variously purely derivation sets, mixed derivation and validation sets 
(including split sample methodology and temporal validation), external validation 
sets and secondary analysis of other data sets (including disease registries).
Detailed information on patient sets, levels of validation and outcomes considered 
are shown in appendix 2. Briefly, of 136 tools identified, 24 were not disease-
specific.  Several tools were assessed in multiple disease categories.  Of these tools, 
35 had been widely (more than 2 studies) externally validated (McGinn level 2), 72 
had been externally validated in one or two studies (McGinn level 3), 16 had only 
been internally validated (including split sample or temporal validation) and 13 
presented data only on derivation (McGinn level 4) (53). 
2.3.4 Physiological variables in existing clinical decision aids
This analysis scrutinised 103 scores.  They apply to the same 17 broad diagnostic 
categories as in 2.3.2 above.  Only 31 of the scores were purely clinical; 61 of the 
others required some element of laboratory testing and a further 12 required ECG 
analysis. The use of physiological variables in these scores is summarised in table 8 
(full details in appendix 3).
Table 8: Physiological variables in existing scores
Variable Number of 
scores with 
single cutpoint
Number of 
scores with 
multiple 
cutpoints
Number of 
scores using 
continuous 
variable
Number of 
scores with 
non-linear 
association
Age 29 19 10 1 ((Age/10)2)
AVPU 
consciousness
3 4 - -
Diastolic BP 10 1 - 1 (Drop of 
20mmHg from 
baseline)
Glasgow Coma 
Scale
3 11 3 -
Mean arterial 
pressure
2 5 - 2 (1/MAP, 
log(MAP))
Oxygen 
saturation
5 7 - -
Pulse rate 18 21 6 3 (“shock”, 
related to SBP)
Respiratory 
rate
16 13 2 -
Systolic BP 28 26 4 5 (“shock”, 
squared, 
1/SBP)
Temperature 4 13 - -
The use of peripheral oxygen saturation in scoring is more complex, as it can be 
recorded with or without supplemental inspired oxygen.  One score stipulated that 
the SaO2 had to be recorded whilst breathing room air, another rated the use of 
any supplemental oxygen as a risk factor in itself and a third allowed the 
substitution of a PaO2/FiO2 ratio for saturations.
2.3.5 Evidence for the use of individual physiological variables
Within the literature there was minimal standardisation of the timing of 
physiological measurement.  It might be assumed that the variables were measured 
at the earliest possible opportunity, but no studies using hospital data also analysed 
prehospital information.  A significant number also ignored Emergency Department 
observations and treatment, collecting data for assessment at the point of 
admission to a ward or assessment unit.  This is potentially very problematic as little 
or no allowance is made for the potential effect of prehospital and Emergency 
Department interventions on the patient’s level of illness.
The reported predictive ability of individual physiological variables is shown in table 
9 and in detail in appendices 4 and 5.  Where raw data was available, L’Abbé plots 
are shown in appendix 4 in accordance with recommendations from the Cochrane 
group (110).  A L’Abbe plot shows the event rate (in this case proportion of adverse 
outcomes) in one group against the event rate in another group (111).  These are 
often intervention and control groups but in this case the groups are those deemed 
low (x axis) and high (y axis) risk by dichotomisation of a physiological variable.  
Point size represents the size of the trial. From the L’Abbé plots it appears that 
there is consistently an increase in risk of poor outcomes with increasing age, falling 
consciousness, falling oxygen saturations, increasing pulse rate, increasing 
respiratory rate and falling systolic blood pressure although its magnitude and cut 
points are inconsistent. Diastolic blood pressure appears to be associated with poor 
outcomes at both extremes; of note there is no exploration of the potential 
association between high systolic blood pressures and poor outcome. There 
appears to be no consistent association between temperature and poor outcome.
Where odds ratios were reported without raw data these are summarised in 
appendix 5. Findings are generally in line with those where raw data was available.
It is impossible to report with any accuracy the proportions of studies where a 
particular variable was found to be predictive, as the majority of studies only report 
positive associations found without providing information on all potential predictor 
variables that were assessed.
Table 9: Predictive ability of individual physiological variables
Variable Raw data available
(studies; no of 
patients)
Appendix 4
Odds ratio
(studies)
Appendix 5
Non-linear 
relationship 
reported 
(studies)
Means, 
medians  or p 
values reported 
(studies)
Age 120; 730269 115 35 164
AVPU 
consciousness
3; 2396 3 0 0
Diastolic BP 5; 11300 11 5 43
GCS 11; 8916 6 5 10
Mean arterial 
pressure
2; 524 3 3 17
Oxygen 
saturation
12; 9362 12 5 11
Pulse 34; 32420 50 19 63
Respiratory rate 26; 22587 20 8 26
Systolic BP 50; 98473 57 20 61
Temperature 22; 11527 9 16 33
2.4 Conclusions
2.4.1. Format and scope of existing clinical decision aids
There is clearly a wide variation in the patient groups to which scoring systems are 
applied, and an equally wide variation in patient outcomes considered relevant.  
The sheer number of available tools makes it impossible for the working clinician to 
use more than a few in daily practice. The discriminant value of the scores 
(expressed as an AUROC or sensitivity and specificity) often varies between studies 
and is poor in many cases.  Many scores have undergone no external validation, ie 
they have only been tested in the population in which they were developed. The 
combination of poor discriminant value and lack of external validation is likely to 
reduce their value in day-to-day clinical practice.
Review of risk scores is limited by the structure and the lack of information in many 
included papers.  Few were precise about the timing of the assessment, leaving 
potential for lead-time bias.  The majority focus on hospital-specific outcomes and it 
is often unclear to what extent patient-relevant out-of-hospital outcomes have 
been investigated.  The often restricted nature of patient sets (for example, 
requiring consultant radiologist confirmation for the diagnosis of pneumonia) limits 
the generalisability of many of the results to the day-to-day ED population where 
formal diagnosis is often not known initially.
2.4.2. The role of physiological variables in existing clinical decision aids
The origin of the cut-points and variables included in existing decision aids is often 
difficult to extract from the published literature.  In many cases cut-points appear to 
have been selected a priori.  Even where the cut-points were generated from the 
data the methods for this are scantily described and frequently appear to have 
assumed linearity in the relationship between variable and outcome.  
Although there is obviously a huge amount of primary data relating to risk scores 
there have been few attempts to systematically evaluate these data and draw 
broader conclusions for clinical practice. Indeed, one of the characteristics of the 
literature relating to risk scores is that each risk score seems to be developed de 
novo with very little reference to previous studies or other scores. This may reflect 
the tendency for studies developing risk scores to be secondary analyses of existing 
datasets rather than studies undertaken for the primary purpose of developing a 
risk score.
2.4.3 Existing clinical decision aids for unselected medical emergencies
It is clear that the literature relating to severity assessment tools for unselected 
medical emergency patients is lacking.  This is in sharp contrast to the cornucopia of 
scores developed in patient groups of interest to specialist practitioners.
2.4.4. Evidence to support the predictive value of individual physiological variables
As above, much of the literature is limited in its description of the methodology 
underlying selection of significant predictor variables.  Explicit exploration of the 
(non-)linearity of the predictor variable-risk relationship is rare, but when it occurs 
does not support the assumption of linearity seen in the remaining literature.  The 
assumptions discussed in 1.5.3 of a linear or Gaussian distribution of risk have not 
been fully explored or challenged.
It is notable that the literature on death as an outcome greatly exceeds all other 
outcomes.  Although it is easy to see the attraction of this as an incontrovertible 
outcome measure, it cannot reasonably be argued that (if developed in an 
established healthcare system), measures predicting death equate to measures of 
potential to benefit from treatment.  Acutely ill patients may reliably be aided to 
avoid death if identified and high-acuity treatment offered in a timely fashion.
2.5 Objectives arising from the literature review
1. To generate a list of interventions which could be used to define potential to 
benefit from emergency (time-critical) care: section 3.7.3b.
2. To identify variables predicting potential to benefit from emergency care in a 
broader population than disease-specific scores: chapter 5.
3. To identify variables predicting death in emergency patients and explore 
whether these are the same as those predicting potential to benefit: chapter 4.
4. To develop near-patient scoring systems reflecting the variables identified in 2 
and 3: sections 4.10 and 5.12.
5. To explore whether the scoring systems generated in 4 as well as those already 
identified perform adequately in the prediction of death and potential to benefit 
in a broader patient population: sections 6.8 and 7.10.
2.6 Summary
 Clinical decision aids exist in a number of formats.
 Clinical decision aids exist for large numbers of conditions and have been 
derived and validated in multiple data sets from varying sources with varying 
inclusion criteria.
 No well-validated clinical decision aid exists for the assessment of patients with 
medical emergencies.
 Individual physiological variables are used inconsistently in existing clinical 
decision aids.
 Individual physiological variables have performed inconsistently in predicting 
adverse outcomes.
Chapter 3
Methodology and Methods
3.1 Introduction
A vast array of literature exists around clinical aids for risk prediction of various 
adverse outcomes in patients presenting for emergency care.  As discussed in the 
previous chapter, this is diverse in its applicability, generalisability, and 
methodology and in the performance characteristics reported.
The literature surrounding prediction of adverse outcome from individual patient 
variables is equally vast and limited in its applicability to the problem posed in this 
thesis.  Minimal evidence exists to underpin risk prediction in unselected patient 
populations, with diverse presenting complaints and partial and unclear diagnoses.  
A prospective study in an unselected Emergency Department is therefore required.  
Ideally this would involve a multicentre cohort recruited specifically to derive and 
validate a decision aid, or at least analysis of prospective registry data in the 
manner of many cardiology studies.  Pragmatically, the infrastructure is not 
currently established to collect such data within the ED; large datasets of 
physiological variables do exist (for example that used to develop the ViEWS score 
(97)) but data collection only begins once the patient is admitted to a ward area.  
Thus the data accumulated for the DAVROS project provides the best proxy dataset 
for this study although not designed specifically for the purpose.
3.2 Aims and objectives
The study will aim to address whether patient variables available at or immediately 
after arrival at the Emergency Department can reliably be used, either singly or in 
combination, to predict short-term adverse outcomes in unselected emergency 
patients.  The central premise underlying this is that existing scoring systems based 
primarily on risk of death may not function well in emergency as what is in fact 
required is a score that identifies an immediate need for intervention (see 1.4.3).  
3.2.1 Epistemology and assumptions underlying the study
This study assumes a positivist standpoint.  I would argue that conceptions of 
disease and illness and in particular their causation and symptomatology should be 
approached in a post-positivist manner, as their construction and effects are likely 
to be significantly related to culture and personal experience.  I would however 
consider that societal perceptions of physiological variables and of critical illness are 
similar enough across populations that they can be considered as analogous to a 
“truth” and analysed within a positivist paradigm.  The study will therefore assume 
the existence of some physiological variables which are constantly and generalisably 
associated with critical illness. 
The main premise underlying the study is that patient-level variables (such as age, 
diagnosis or blood pressure) have a consistent mathematical relationship with, and 
can therefore predict, the likelihood of a particular outcome (such as death or 
successful response to a treatment).  This premise underlies case-mix adjustment, 
which assumes that each patient’s risk of death is manifested in consistent 
measurable parameters, and clinical decision rules, which assume that the chance 
of the outcome of interest is also predictable from measurable parameters.  It is 
unlikely that the full complexity of Emergency Medicine can be reflected in a 
mathematical model; however it is possible that identifiable characteristics may 
contain enough to predictive value to be clinically useful.  To quote the statistician 
George Box “all models are wrong; the practical question is how wrong do they 
have to be to not be useful” (112).
In this study the outcome of interest is the potential to benefit from a time-
dependent intervention.  The rationales of case-mix adjustment and clinical decision 
rule development are similar enough that it is reasonable to use an overlapping 
data set for both; however the differences in outcome (death versus benefit from 
urgent treatment) and thus the potential differences in parameters of interest 
require analysis specific to each.
3.2.2 Specific aims
The following will therefore be performed:
a. Identification of patient variables which accurately predict short-term (7-day) 
mortality;
b. Combination of these variables into a near-patient scoring system;
c. Assessment of the performance in terms of discrimination and calibration of this 
scoring system;
d. Identification of patient variables which accurately predict critical illness in terms 
of potential to benefit from time-dependent treatment (this is discussed further in 
3.8 below);
e. Combination of these variables into a near-patient scoring system;
f. Assessment of the performance in terms of discrimination and calibration of this 
scoring system.
3.2.2a Originality of this research compared with DAVROS study
This study differs from the main DAVROS work in the following ways:
a. The DAVROS score for death at 7 days was developed for casemix 
adjustment and therefore includes variables (particularly ICD-10) not 
available to the treating clinician in the ED, whereas this study will develop a 
score to predict death at 7 days useable by the bedside clinician.
b. This study will also consider potential to benefit (see 3.8 below), an outcome 
not considered in the DAVROS study and therefore requiring specific 
collection of outcome data within the study cohort; a score will then be 
developed for this outcome.
3.3 Setting
3.3.1 Northern General Hospital, Sheffield
The Northern General Hospital, Sheffield, houses the only adult Emergency 
Department serving the half million population of Sheffield.  It is an acute teaching 
hospital with 1100 beds which, in conjunction with other hospitals in the Sheffield 
Teaching Hospitals Trust and Sheffield Children’s Hospital NHS Trust, offers care 
from all acute specialities.  The Emergency Department at the time of the study had 
98,000 attendances per year.  Coronary Care (including cardiac catheterisation 
facilities), High Dependency and Intensive Care units and acute theatres are all 
available on the Northern General site.  The Northern General patient set was 
selected as the largest cohort within the derivation phase of the DAVROS study 
(which also included Barnsley and Rotherham) which was complete at the time of 
commencement of this study.
3.3.2 Yorkshire Ambulance Service
Yorkshire Ambulance Service (YAS) responds to around 700,000 emergency calls per 
year from a population of 5 million throughout Yorkshire, using 500 vehicles 
operating from 62 ambulance stations.
3.3.3 DAVROS
The DAVROS project, of which this study is an ancillary, was funded by the Medical 
Research Council.  It aimed to identify variables that predict 7-day mortality in 
patients presenting to hospital by emergency ambulance and to develop and 
validate a risk-adjustment tool applicable across a range of settings.  Phases 2 and 3 
(derivation) took place from February to May 2008 and involved collection of data 
in the prehospital and ED phases of care for patients transported by emergency 
ambulance to Northern General Hospital (Sheffield),  Barnsley, and Rotherham 
Hospitals. Phase 4 (validation) collected a further cohort from the same hospitals 
from October to December 2008.  Phase 5 and 6 extended validation of the model 
and assessed its role in risk adjustment across new UK and international sites.  The 
specific DAVROS methodology and its strengths and weaknesses for this study are 
addressed in detail below.
3.4 Subjects
The project relates to unselected adult non-trauma patients with potentially critical 
illness.
3.4.1 Inclusion criteria
Patients were included if they were transported by an emergency ambulance and 
were alive and not in cardiac arrest at the point of ambulance arrival, then either 
died in the ambulance or emergency department or were admitted to hospital.
This ensures a broad range of patients, the use of which has been lacking in the 
literature as discussed above.  It will hopefully facilitate some form of comparison of 
illness severity across different diagnostic groups.
3.4.2 Exclusion of ambulatory patients
Ambulatory patients (ie those who self-present to hospital rather than call for an 
ambulance) have been excluded within the DAVROS dataset.  This was justified in 
terms of ensuring robust data collection at a standardised point in time, and 
minimising the potential confounding effects of emergency treatment.
Ideally, self-presenting patients would be studied in a similar manner as they arrive 
at the ED, and their absence will be a limitation of this study.  It is likely that self-
presenting patients represent a different population in terms of illness severity; 
however, presenting independently of an ambulance does not preclude the 
possibility of serious illness.  It seems logical that self-presenting patients would 
have the same physiological processes and therefore the same predictors of 
adverse outcome as in the ambulance-transported population.  However, it may be 
that having the physiological reserve to allow self-presentation is in itself a 
prognostic factor and therefore this population merits study in its own right.
3.4.3 Exclusion of patients discharged from the Emergency Department
Patients who were not admitted to hospital were excluded from the initial DAVROS 
dataset as the aim was to develop a risk-adjustment tool for emergency admissions 
to hospital.  This limits this substudy in terms of developing a clinical score as there 
is no analysis of patients who were discharged from the ED, which may restrict 
generalisability. 
Ideally a full cohort of presenting patients would be studied and those discharged 
from the ED followed up as outpatients to ensure the absence of post-discharge 
adverse events.  However within the scope of this study that was logistically 
unfeasible.  Rates of short-term death after discharge from the ED have been 
reported as 30/100000 (113) to 50/10000 (114), so the required cohort size to 
investigate this fully would have been impractical.
3.4.4 Exclusion of patient sub-groups
Patients who were considered dead (ie had no vital signs) at the time of ambulance 
arrival to the patient (even if resuscitation was attempted) were excluded. 
Patients aged under 65 transported following trauma were excluded as risk 
prediction in the trauma population has been extensively studied; it is apparent 
from the existing literature that prognostication in trauma is strongly guided by 
anatomical site, type of injury (blunt or penetrating), and severity of individual 
injuries, variables which are not replicated in non-trauma patients.  Increasingly 
systems of care for trauma patients are also differently structured than those for 
non-trauma patients, with prehospital triage to major trauma centres and 
ambulance bypass of smaller units. Patients aged over 65 transported following 
apparent trauma were included in the initial DAVROS data set as many have an 
underlying medical cause for their trauma, but were retrospectively excluded for 
this thesis if found to be admitted for trauma (including fractured neck of femur)..
Children and patients with purely obstetric presentations were excluded as their 
physiology is different and therefore predictors of adverse outcome are likely to be 
different, as are mortality and critical illness rates.  The systems providing 
emergency care in paediatrics and obstetrics are also significantly different from 
those used for most adult patients.
Patients with purely psychiatric problems were excluded as systems of care are 
almost entirely different for them and outcomes of interest are also different.
3.5 Ethical issues
3.5.1 Risks to patients
This research carries minimal risk to patients, as it is purely observational and 
involves no extra or novel interventions.  The main risk would be of breach of 
confidentiality in the handling of their identifiable patient information.  This risk has 
been minimised by the pseudonymisation of the data within the working project 
data set. Linkage data which might be used to identify patients is held only on 
password protected computers at the Northern General Hospital.  All data 
processing has been carried out in compliance with the Data Protection Act under 
the auspices of the University of Sheffield which is a registered data handling body.
3.5.2 Risks to researchers
This study involves minimal researcher risk, as there will be no additional patient 
contact and no use of biological substances or ionising radiation.  It was possible 
that the case note review process outlined in sections 3.7 and 3.8 could have 
identified instances where the patient care provided raised concerns about ongoing 
patient safety.  The project plan was to feed these back to the Clinical Director of 
the relevant specialty in accordance with standard NHS clinical governance 
procedures. In fact no such cases were identified.
3.5.3 Societal risks and benefits
This research primarily raises the issues of using identifiable patient data without 
explicit consent.  This is regulated under section 251 of the NHS Act 2006 
(administered at the time of data collection by the National Information 
Governance Board, which subsequently became the Confidentiality Advisory Group 
of the National Research Ethics Service), and data must be held in accordance with 
the System Level Security Policy approved by the NIGB.  This provides for password-
controlled access to the DAVROS database held at the Clinical Trials Research Unit 
at SCHARR and for password-controlled access to a separate database at the 
Northern General Hospital linking DAVROS reference numbers to NGH patient 
record numbers.
3.5.4 Ethical approval
Ethical approval both for the original DAVROS study and for this study has been 
obtained from the Leeds (East) REC.  Approval to collect use patient identifiable 
data without specific consent was gained from the Patient Information Advisory 
group for the original DAVROS study.  Approval for further data collection and 
analysis in this study has been gained from the National Information Governance 
Board.
3.6 Variable data obtained from the DAVROS database
Variable data was extracted by DAVROS research staff from the Emergency 
Department records and entered directly into the online DAVROS database.  These 
data were linked to data from scanned YAS patient report forms (PRFs) by incident 
number and date. Data entry staff were non-medically-trained clerical staff who 
were provided with specific training on medical abbreviations.   Random sampling 
and rechecking of entered data was undertaken by DAVROS co-ordinating staff 
(Richard Wilson and Martina Santarelli) to ensure data quality.  
3.6.1 Presenting complaint
Data were recorded regarding the complaint as described by the YAS crew at 
handover to the Emergency Department staff.
3.6.2 Physiological variables
Data were available on age, diastolic blood pressure, fingerstick blood glucose (BM), 
Glasgow coma scale, oxygen saturation (breathing air and/or breathing 
supplemental oxygen), pulse rate, respiratory rate and temperature as first 
recorded in the Emergency Department.  These were chosen as they are already 
widely recorded in a relatively standardised manner, so implementation of their 
collection is unlikely to be problematic.  Pulse pressure was calculated from systolic 
and diastolic blood pressures immediately prior to data analysis. As discussed in 
2.1.6 above it is likely that patient physiology will be less sensitive to socio-cultural 
confounders, such as access to health care, than other potentially predictive 
variables.
3.6.3 Historical variables
Also recorded as extracted from the Emergency Department notes was any history 
of heart or chronic respiratory disease (including asthma), malignancy, diabetes and 
epilepsy and use of warfarin or steroid therapy, all as recorded by the attending 
clinician, whatever the source of that information.  If numerical values were missing 
no entry was made on the database and this was later coded as “missing”.  For 
categorical values such as those relating to patient history these were assumed to 
be negative unless specifically marked as positive; in a small number of cases the 
presence of comorbidity was inferred from medication lists (eg the presence of 
diabetes if insulin was a prescribed medication).  
The working diagnosis in the Emergency Department was not collected as it was felt 
to be inconsistently recorded and subject to substantial change during the course of 
a hospital admission.  Although diagnostic ICD-10 codes were available in the initial 
DAVROS data set, they are coded retrospectively after all diagnostic data from the 
patient admission is available and are therefore not pertinent to this study.
3.7 Outcome measures collected for this study
3.7.1 Outcome measures collected for DAVROS study
The original DAVROS study examined mortality in the seven days after hospital 
admission.  Mortality was selected as a clearly-measurable non-biased outcome, 
and avoidance of mortality was felt in most circumstances to be a positive outcome. 
7 days was chosen as a timescale suitable for emergency care as it was hoped to 
reflect the management of an acute crisis rather than the progress of a chronic 
disease process.
3.7.2 Additional outcome measures for this study
The patient group of interest in this study is those where urgent intervention had 
the potential to affect survival, ie where a patient death was or could have been 
prevented.  These patients occupy a “Goldilocks zone” (neither too well nor too ill) 
as per figure 15.
Figure 15: the ‘Goldilocks zone’ of potential patient benefit
Some deaths (in the black zone) will be the inevitable outcome of chronic 
deterioration and emergent high-intensity therapy would not be appropriate for 
these patients as it would be futile.  Identification of these patients is an imperfect 
science but early institution of terminal care (see 3.7.3a below) will be used as a 
proxy.  In other cases high-intensity intervention might ensure survival to 7 days but 
this would not be considered in the patient’s interests due to poor quality of life.  
Thus not all patients who died will be considered to have fulfilled an outcome of 
interest.  
Equally, we would wish to identify patients where emergent therapy has potentially 
prevented death.  The definition of such patients is difficult and still under debate; 
many routinely used urgent therapies have an incomplete evidence base and a 
number of interventions apparently well founded in physiological principles have 
recently been questioned in terms of actual patient benefit (for example, high-flow 
oxygen in myocardial ischaemia (115) and blood transfusion in anaemia induced by 
gastrointestinal bleeding (116)). However, there does appear to be some measure 
of consensus; when Haukoos et al attempted to identify patients benefiting from 
emergency care, the Spearman-Brown coefficient between different raters was 
between 0.83 and 0.87 in different patient sets (117).
The use of preventable or prevented deaths, with inevitable deaths excluded, as the 
primary outcome measure is a significant departure from the bulk of the published 
literature, where all deaths have been included in the outcome measures whether 
or not affected by the intensity of care.  
3.7.3 Collection of outcome data
3.7.3a Death
7-day mortality was recorded by DAVROS research staff using hospital record 
analysis.  Patients who died were assumed to have the potential to benefit from 
emergency care unless a “Do Not Resuscitate” order or terminal care pathway 
(initiated at or before the time of first contact with an inpatient consultant) is 
present in the hospital notes during scrutiny as described below.
3.7.3b Potential to benefit amongst survivors
It was assumed that all patients admitted to intensive care received potentially life-
saving intervention(s).  There is evidence to support the mortality benefit of 
admission to intensive care (118) and also that this may be time-dependent (119).
Notes of other patients were scrutinised for interventions defined a priori as 
potentially life-saving on the basis of their inclusion in evidence-based guidelines for 
acute care listed below by patient group. These guidelines were identified by 
manual searching of the websites of relevant bodies, supplemented by informal 
discussion with colleagues.
 Acute illness: NICE clinical guideline 50
 Acute onset atrial fibrillation: NICE clinical guideline 36, SIGN 94 and 129
 Alcohol-related disease: NICE clinical guideline 100
 Anaphylaxis: College of Emergency Medicine
 Arrhythmia: SIGN 94
 Asthma: SIGN 101
 Cardiac arrest: SIGN 94
 COPD: NICE clinical guideline 101
 DVT: NICE clinical guideline 144 and SIGN 122
 Headache: College of Emergency Medicine and American College of Emergency 
Physicians
 Hypertension: American College of Emergency Physicians
 LVF: American College of Emergency Physicians and European Society of 
Cardiology
 NSTEMI/Unstable angina: NICE clinical guideline 94, SIGN 93, American College 
of Emergency Physicians and European Society of Cardiology
 PE: NICE clinical guideline 144, SIGN 122, American College of Emergency 
Physicians and European Society of Cardiology.
 Pneumonia: American College of Emergency Physicians and British Thoracic 
Society.
 Pneumothorax (spontaneous): British Thoracic Society
 Poisoning: NICE clinical guideline 16, American College of Emergency Physicians 
and College of Emergency Medicine.
 Seizure: American College of Emergency Physicians and College of Emergency 
Medicine.
 Sepsis: NICE clinical guideline 151.
 STEMI: SIGN 93 and European Society of Cardiology.
 Stroke/TIA: NICE clinical guideline 68, SIGN 108.
 Transient loss of consciousness: NICE clinical guideline 109.
 Type 1 diabetes: NICE clinical guideline 15.
 Upper GI bleeding: NICE clinical guideline 141, SIGN 105.
 Urinary tract infection: SIGN 88.
Having scrutinised the above guidelines, the interventions identified as having the 
potential to save patient life were as listed below, and if a patient received any of 
these interventions he or she was considered as having a potentially prevented 
death.
Airway interventions
 Use of airway adjunct or procedure to maintain patent airway.
 Use of intravenous/intramuscular adrenaline to treat or prevent airway 
compromise.
Breathing interventions
 Bag-valve-mask ventilation (unless during procedural sedation), intermittent 
positive pressure ventilation, or non-invasive ventilation.
 Decompression of tension pneumothorax.
 Drainage of significant pleural effusion (>1 litre).
 Insertion of chest drain for pneumothorax in patients with pre-existing lung 
disease.
 Intravenous therapy except steroids for asthma.
Circulation interventions
 Cardioversion (chemical or DC) of ventricular tachycardia or supraventricular 
tachycardia or atrial fibrillation with accessory pathway.
 CPR.
 Emergency endoscopy or surgery for upper GI bleed or use of Sengstaken tube 
or use of vasopressin/terlipressin.
 Infusion of >2 litres of fluid or transfusion for haemodynamic instability.
 Laparotomy for GI bleed/gynaecological bleed (including ectopic)/AAA.
 Sepsis care bundle.
 Thrombolysis for AMI or PE, or percutaneous revascularisation.
 Therapeutic (not diagnostic) pericardiocentesis.
 Transcutaneous or external pacing or administration of atropine (except in 
theatre).
 Vasopressor use (except bolus dosing in theatre).
Disability interventions
 Administration of naloxone or flumazenil (unless related to procedural 
sedation).
 Administration of 10%/50% dextrose.
 Administration of >1 dose benzodiazepines/other anticonvulsants for fitting.
 Neurosurgical intervention.
Other interventions
 Active rewarming (not including Bair hugger warming blanket).
 Laparotomy for sepsis/infarction/obstruction.
 New initiation of renal replacement therapy.
 Specific poisons antidotes including N-acetylcysteine.
It must be noted that many of these interventions are not supported by high quality 
evidence.  They are, however, similar to the list of potentially life-saving 
interventions developed concurrently by another research group (120). 
3.8 Pilot phase of data collection
The pilot phase of data collection was carried out to establish the practicality of the 
data collection plan. Initially it was planned to examine ED records and only access 
hospital casenotes if evidence of interventions as in 3.7.1 above was not found.  It 
became clear during the pilot that the ED notes had been microfiched and were 
only accessible on a single machine in the ED.  This machine was generally only 
accessible out-of-hours due to the competing demands of clinical care and medico-
legal requirements.  Thus for the main study this process was abandoned and full 
hospital casenotes (including photocopied ED records) were examined.
During the pilot phase 21 cases were identified where a patient received an acute 
intervention not identified a priori as above.  These cases were summarised into 
brief vignettes which were examined by two independent experts in Emergency 
Medicine (SG and FM) to adjudicate as to potential to benefit.  However as the 
kappa value for agreement between SG and FM was under 0.1 this process was 
abandoned and the interventions in 3.7.1 adhered to.  The 21 cases were not 
classified as receiving a potentially life-saving intervention.
3.9 Data collection process
The final data collection process involved 4 steps:
1. Translation of the DAVROS database number to the NGH reference number using 
the secure DAVROS database at NGH.
2. Identification of the new STH casenote number from the NGH reference number 
and identifying subsequent patient death from STH patient administration system.  
This was required as the Trust had undergone a casenote reorganisation and 
renumbering process in 2010.  Date of death was required as notes for 
subsequently deceased patients were stored in a different archive.
3. Examination of casenotes at the Medical Records Department at NGH; some had 
to be retrieved from offsite storage, and where sets of notes were unavailable in 
Medical Records due to clinic or inpatient attendance they were sought on multiple 
occasions.
4. Extraction of outcome data as above and entry into secure database.
It was estimated from the pilot phase described in 3.8 above that this process took 
around 30 minutes per patient.
3.10 Sample size
Statistical simulation studies have suggested that for use of logistic regression 
analysis, a cohort including ten outcomes events for interest per variable assessed 
provides an acceptable precision of regression coefficients (80).  This rule has been 
challenged more recently (81), but this thesis will adopt the more conservative 
estimate. 
To develop a score predicting potential to benefit it was planned to analyse 8 
potential predictor variables, with an assumed loss of at least one in multivariate 
analysis, thus requiring a minimum of 70 outcomes of interest (prevented or 
preventable death).  We therefore planned to collect information sequentially until 
100 outcomes of interest were included. From piloting it appeared that around 1 in 
5 patients had an outcome of interest, requiring a sample size of around 500, which 
was logistically achievable given the time requirement identified in piloting.
To develop a score predicting death in 7 days it was expected that around 18 
potential predictor variables would be analysed. Assuming some would be 
eliminated at the multivariate stage, the Northern General Hospital DAVROS phase 
2 dataset, with 128 outcomes of interest (deaths) was deemed to be adequately 
sized.  Using the dataset from the same setting as the subset above enhanced 
comparability.
An alternative power calculation would be to find the number of outcomes of 
interest required to estimate the sensitivity of the predictive tool to within 5%.  
Conservatively assuming the model to be 75% sensitive and using the approximate 
standard error of a proportion as:
SE = √ [p*1-p/n]
where n denotes the number of outcomes of interest.  This then gives
0.05 = √ [0.75*0.25/n]
which can be solved to give a minimum number of outcomes of interest of 75, 
which would also be acceptable for both the above data sets.  The event rate can 
safely be assumed to lie below 50%, meaning that the specificity will be estimated 
to within a standard error less than 5%.
3.11 Variable analysis
As discussed in 1.8 above, we wished to avoid arbitrary dichotomisation of data, 
particularly as there was little evidence to support the linear and monotonic 
relationship between predictor and outcome variables.  Analysis therefore was 
structured around logistic regression rather than recursive partitioning.
3.11.1 Descriptive data
Basic descriptive data is reported, including frequencies for categorical data.  For 
continuous data, a graphical analysis is made of normality of distribution and data 
presented in terms of mean and standard deviation or median and inter-quartile 
range, whichever is appropriate.  The proportion of missing data for each variable is 
also presented. 
3.11.2 Relationship with adverse outcome and categorisation
Where outcomes were unknown the case was excluded from the data set.
The relationship between each potential predictor variable and the primary 
outcome is examined graphically to identify non-linear and non-monotonic 
relationships.  Where a relationship is found to be non-linear, the variable is 
categorised to describe the relationship.  The strength of relationship will be 
described in terms of the odds ratio generated by various categories of the variable.
Specifically, the predictive value of missing variables is explored.  The fact that data 
is missing can be predictive in itself.  Missing data could be “unmeasureable”, for 
example a systolic blood pressure that was so low it could not be detected by health 
care providers.  Alternatively, missing data could be “unmeasured”, either because 
the patient was felt to be so ill that all resources were being expended on care 
rather than documentation, or because the patient was so “obviously” well that the 
practitioner deemed it irrelevant or unnecessary to record specific variables.   It 
cannot be assumed that the characteristics of “missingness” will be the same for all 
variables within one data set; when analysis was undertaken of a trauma registry, 
imputed values for GCS were significantly lower (median 12) than those actually 
observed (median 15), implying that GCS was less likely to be recorded in sicker 
patients. However, imputed and recorded systolic blood pressures did not differ, 
implying failure to record, rather than inability to measure. 
If data is missing because it was assumed to be normal (ie the “missing” category 
predicts good outcome), then it can be replaced with a normal value.  If data is 
missing systematically (ie because the patient was unwell, so that the “missing” 
category predicts poor outcome), it is possible to impute the missing values.  This 
involves calculating the most likely value of the missing data based on the data that 
has been recorded.  This risks overestimation of the predictive power of the 
decision aid. This is explored in chapters 4 and 5.
The aim of this study is to develop a decision aid that can be used in real time, 
rather than retrospectively.  There is therefore less of an issue in terms of data that 
is missing because it is “unmeasured” once the decision aid exists, as required 
variables will be measured. Some data may still be missing as “unmeasurable” and 
the predictive value of this is explored below.
3.11.3 Analysis of univariate significance
The univariate association between each potential predictor variable and the 
primary outcome of interest is determined.  The form of the relationship between 
the variable and outcome, as explored in 3.9.2 above is used to generate clinically-
relevant categories for continuous variables. The first order interaction of variables 
which are significantly related to outcome at p<0.15 is examined.    
3.11.4 Multivariate analysis
Variables found to be significantly predictive of outcome at p<0.1 are entered into 
the multivariate analysis.  A subset of variables independently predictive of 
outcome are selected by removing terms at p>0.05.  Linear coefficients are then 
recalculated for those independently predictive variables and an equation to predict 
poor outcome generated from those coefficients using the general formula 
p(outcome)= ea/1+ea, where a is the sum of coefficients.
3.12 Development of a point-of-care score
As demonstrated in 2.3.2 above, almost no evidence exists to guide the use of 
illness severity scoring in the unselected ED population. It is hoped that a point-of-
care score might aid resource allocation in and after the ED by enabling the 
comparison of illness severity across multiple diagnostic groups.
3.12.1 Variable selection and weighting
Variables found to be independently predictive of outcome in multivariate analysis 
and included in the equation as at 3.11.4 are included in the score. The β-coefficient 
generated in the multivariate analysis is approximated to generate an integer value 
to weight each variable in terms of its explanatory value for poor outcome. The 
integer values for each variable are summed to obtain the bedside score.
This is an attractive principle for clinicians who are unlikely to wish to perform 
unnecessarily complex mental arithmetic at the bedside.  It is however statistically 
flawed, as the predictions generated by logistic regression are not linear (hence the 
need for exponentiation as in 3.11.4 above).  As a hypothetical example, if the risk 
of death from ST elevation myocardial infarction could be explained by two factors: 
anterior MI (yes/no) and hypotension (yes/no), where:
P(death)=-3 + (anterior MI)*1 + (hypotension)*4
then the additional risk conferred by hypotension is:
expit(-3+1+4) – expit(-3+1+0) = 0.76 (if the MI is anterior)
or:
expit (-3+4) – expit(-3+0) = 0.64 (if the MI is not anterior)
where expit(a)=ea/1+ea
Thus the effect of each predictor variable on the probability of the outcome is 
dependent on the other predictor variables and simple summation represents a 
linear approximation to a non-linear equation.  However, this approximation is in 
common use in the development of bedside scoring and has been shown in 
elsewhere not markedly to reduce predictive power (121).
3.13 Score validity
The validity of the score in the development dataset is assessed using two 
techniques.
3.13.1. Discriminant ability. 
Receiver operator characteristic (ROC) curves are used to test the ability of the 
score to discriminate between patients with the primary outcome and those 
without.  ROC curves will be used as they provide a graphic representation of the 
trade-off at different score values between sensitivity and specificity.
3.13.2. Calibration. 
The accuracy of model fit is assessed using Nagelkerke’s pseudo R2, which is a 
measure of the improvement of the model over a null model including no predictor 
variables.  It is analogous to the R2 measure used in linear regression but designed 
specifically for the binary outcome of logistic regression. For the purposes of this 
study, model calibration is of less importance than discriminant ability as it is 
envisaged that the relative risk of two patients (accuracy of which is measured by 
discriminant ability) will be of more clinical use in prioritisation than absolute risk 
(accuracy of which is measured by calibration).
3.14 Temporal validation
Validation of the score will occur using the data collection techniques as above in a 
temporally separate data set collected at the Northern General Hospital from 
October to December 2008.  This will address the issue of over-fitting as discussed 
in 1.10 above.
The calculation of sample size for validation studies is not well established.  
However, a simulation study by Vergouwe et al (122) suggested a minimum sample 
size of 265, including 106 events, to detect a difference in c-statistic from 0.83 to 
0.73.
Vergouwe further calculated that the power for a given sample size is: 
Zβ = √(Nδ2/σ2) – Z1/2α
where N = sample size, δ = difference in model performance, Zβ = value of the 
standard normal distribution corresponding to β, with β = type II error rate, Z1/2α = 
value of the standard normal distribution corresponding to 1/2α, with α = type I 
error rate, σ = standard error of performance measure*√n.
3.15 External validation
External validation of the score at different sites and in different health care 
settings is outwith the scope of this thesis.
3.16 Comparison with other scoring systems
The data set collected for validation as in 3.14 above will also be used to compare 
the performance of the developed score with others identified in the literature 
review to determine which is likely to prove most useful in the patient population in 
question.
The statistical comparison of two ROC curves derived from the same data 
developed by Hanley and McNeil (123) and the technique subsequently 
promulgated by Obuchowski for calculating sample sizes was (124) confirm the 
adequacy of the size of the data set for this purpose.
3.17 Summary
 A prospective cohort design has been used to address the lack of prognostic 
decision aids in unselected medical emergency patients.
 Data on potential predictor variables have been collected in a standardised 
manner.
 Outcome measures have been developed to identify patients at high risk of 
death, and those where emergency care has the potential to have affected 
survival.
Chapter 4
Derivation of a score to predict death at 7 days
4.1 Introduction
This chapter will describe the data set assembled for the derivation of a score 
predicting death at 7 days, and the process of deriving that score.
4.2 Data set
Patients presenting by emergency ambulance to the Emergency Department of the 
Northern General Hospital, Sheffield, from February to May 2008 were identified 
prospectively by DAVROS researchers.  Patients with obstetric, traumatic or purely 
psychiatric presentations were excluded.  The rationale underlying the selection 
criteria for the data set is discussed in 3.4 above. Data on demographics, presenting 
complaint, past medical history (as recorded by the treating clinician) and 
physiological variables were abstracted by trained research assistants.  Data from 
blood tests and ICD-10 coding were later added to the main DAVROS dataset but 
this will not be considered here as it would be unavailable to the clinician at the 
time of presentation to the Emergency Department.  2437 patients were included in 
this derivation cohort. 
4.3 Study population
Characteristics of the study population are in table 10.
Table 10: Characteristics of the derivation study population
Variable Mean (standard deviation) Range
Age 69 (19) 18-103
Pulse 88 (24) 21-215
Respiratory rate 19 (6) 6-60
Systolic BP 136 (29) 24-266
Diastolic BP 75 (15) 30-153
Temperature 36.6 (1.2) 26.0-41.0
Variable Median (interquartile range) Range
GCS 15 (15-15) 3-15
SaO2 breathing air 97 (95-98) 50-100
SaO2 breathing oxygen 98 (95-100) 24-100
Variable Number Percentage
Male 1131 46.4
Active malignancy 110 4.5
Chronic respiratory disease 292 12.0
Heart disease 829 34.0
Asthma 269 11.0
Diabetes 382 15.7
Epilepsy 97 4.0
Warfarin usage 154 6.3
Steroid usage 149 6.1
Outcome
Alive at 7 days 2235 91.6
Dead at 7 days 128 5.2
Unknown status at 7 days 77 3.2
The 77 patients whose outcome was unknown were excluded from further analysis, 
leaving 2363.
4.4 Univariate analysis of potential predictor variables
4.4a Demographic and historical variables
Categorical demographic and historical values were crosstabulated against outcome 
at 7 days and significant associations identified using chi-squared testing.  Full 
details are in table 11 below. Categorical variables significant at p<0.1 were active 
malignancy (p<0.001) and history of chronic respiratory disease (not asthma) 
(p=0.07).
Table 11: Univariate analysis of categorical variables
Variable Number (%age) of deaths Total
Gender p=0.630
Female 72 (5.7) 1260
Male 56 (5.1) 1094
Missing 0 9
Active malignancy p<0.001
No active malignancy 110 (4.9) 2252
Active malignancy 17 (15.6) 109
Chronic respiratory disease p=0.07
No history 105 (5.1) 2073
History present 22 (7.6) 288
Heart disease p=0.885
No history 83 (5.3) 1557
History present 44 (5.5) 804
Asthma p=0.154
No history 118 (5.6) 2103
History present 9 (3.6) 249
Diabetes p=0.618
No history 105 (5.3) 1989
History present 22 (5.9) 372
Epilepsy p=0.308
No history 124 (5.5) 2264
History present 3 (3.1) 97
Warfarin therapy p=0.244
No warfarin 122 (5.5) 2210
Warfarin 5 (3.3) 151
Steroid therapy p=0.664
No steroids 118 (5.3) 2215
Steroids 9 (6.2) 146
4.4b Continuous variables
Continuous physiological variables and age were assessed in three ways: quintiles of 
the study population, quintiles of the variable range and (where included in 
DAVROS) groups defined a priori within the DAVROS project to reflect generally 
accepted clinical definitions of normal.  Full details are in appendix 6. GCS and 
oxygen saturations (both breathing air and on oxygen) were assessed in tertiles and 
quartiles to better reflect their population distributions.  GCS was also assessed in a 
priori groups broadly consistent with currently accepted clinical risk categories.
Continuous variables significant at p<0.1 were pulse, respiratory rate, systolic BP, 
diastolic BP, temperature, pulse pressure, GCS, oxygen saturations and age.  After 
visual inspection of the histograms in appendix 6 population quintiles were chosen 
for all variables except GCS and oxygen saturations where a priori groups were 
used, as shown in table 12. 
Table 12: Univariate analysis of continuous variables
Variable Dead (percentage) Total
Pulse population quintiles p<0.001 
<70 18 (3.8) 475
70-79 11 (2.7) 415
80-89 23 (5.1) 447
90-105 23 (5.1) 451
>105 44 (9.2) 479
Missing 9 (9.4) 96
Respiratory rate population quintiles p<0.001
<15 11 (3.1) 357
15-16 11 (2.4) 467
17-18 11 (2.6) 421
19-22 19 (6.3) 301
>22 52 (15.6) 333
Missing 24 (5.0) 484
Systolic BP population quintiles p<0.001
<110 46 (11.6) 397
110-129 25 (4.6) 545
130-139 12 (3.5) 346
140-160 9 (1.6) 573
>160 22 (5.5) 398
Missing 14 (13.5) 104
Diastolic BP population quintiles p<0.001
<65 47 (10.1) 466
65-69 14 (3.6) 391
70-75 13 (3.4) 381
76-90 22 (3.1) 713
>90 16 (5.3) 300
Missing 16 (14.3) 112
Temperature population quintiles p=0.012
<36 42 (9.0) 469
36-36.3 19 (5.1) 373
36.4-36.8 22 (4.6) 477
36.9-37.3 15 (4.2) 358
>37.3 17 (4.5) 377
Missing 13 (4.2) 309
Pulse pressure population quintiles p<0.001
<40 35 (9.4) 373
40-52 25 (5.0) 505
53-64 14 (3.1) 456
65-80 16 (3.2) 498
>80 21 (5.0) 417
Missing 17 (14.9) 114
GCS a priori groups p<0.001
3-5 13 (54.2) 24
6-8 7 (26.9) 26
9-12 26 (23.4) 111
13-14 18 (5.5) 327
15 40 (2.6) 1564
Missing 24 (7.7) 311
Oxygen saturations breathing air a priori groups p<0.001
Very low (<90) 22 (16.8) 131
Low (90-3) 7 (4.0) 174
Normal (94-100) 28 (2.0) 1417
Missing 71 (11.1) 641
Oxygen saturations breathing supplemental oxygen population tertiles p<0.001
<95 17 (15.2) 112
95-8 17 (7.7) 220
99-100 15 (6.9) 219
Missing 79 (4.4) 1812
Age population quintiles p<0.001
<50 4 (1) 435
50-69 17 (3.4) 504
70-78 27 (5.4) 498
79-85 30 (6.4) 466
>85 50 (10.9) 460
Where visual inspection of the groups suggested similar risk profiles across different 
groups, these were collapsed.  Thus the variables in table 13 remained for further 
analysis.
Table 13: Simplified variables for further analysis
Variable Simplified groups
Pulse <80, 80-105, >105
Respiratory rate <19, 19-22, >22
Systolic blood pressure <110, 110-139, 140-160, >160
Diastolic blood pressure <65, 65-90, >90
Temperature <36, >35.9
Pulse pressure <40, 40-52, 53-80, >80
GCS 3-5, 6-12, 13-14, 15
Oxygen saturations Low risk: >95 breathing air
Moderate risk: 90-95 breathing air or >94 breathing oxygen 
High risk: <90 breathing air or <95 breathing oxygen
Age <50, 50-69, 70-85, >85
4.5 Handling of missing data
In 79 cases with known outcomes all physiological variables were missing.  The 
number of deaths was 6 (8%) among those with missing data compared with 122 
(6%) without.  This gives a Χ2 value of 0.757 (df=1, p=0.384) for missingness of all 
variables being associated with poor outcome and thus it was not assumed that 
missingness was systematically associated either with “obvious wellness” or severe 
illness as discussed in 3.9.2 above.
Each variable was therefore assessed visually using the histograms in appendix 6 
and missing data collapsed into the most closely comparable risk group.  Thus 
missing pulse, systolic blood pressure, diastolic blood pressure, oxygen saturations 
and pulse pressure were treated as the highest risk groups (>105, <110, <65, high 
risk and <40 respectively).  Missing respiratory rate and GCS were treated as 
moderate risk (19-23 and 13-14), while missing temperature was treated as low risk 
(>36).  It is plausible that this reflects pragmatic practice, where pulse, blood 
pressure and oxygen saturations are measured using an automated machine and 
therefore their absence indicates “unmeasurability” (see 3.9 above), while 
respiratory rate, GCS and temperature need to be measured manually and often 
require a specific patient-based trigger to be recorded and therefore their absence 
indicates “unmeasuredness”.  High rates of missingness in respiratory rate 
recording have also been noted in the TARN trauma dataset, leading that research 
group to abandon a prognostic model that requires respiratory rate (125).
4.6 Univariate logistic regression analysis of predictor variables
Binary logistic regression was used with the simplified groups as developed above 
to generate estimated odds ratios (expressed as exp(B)) for each of the risk groups.  
Where multiple groups existed for a variable, the odds ratio was calculated in 
comparison with the lowest risk group.  Variables reaching significance at the 90% 
level are highlighted in red in table 14.
Table 14: Univariate logistic regression analysis
Variable exp(B) p 95% CI for exp(B)
Active malignancy present 3.59 <0.001 2.072 6.248
Age (ref <50) <0.001
50-69 3.76 1.256 11.264
70-85 6.771 2.441 18.783
>85 13.140 4.704 36.710
Pulse (ref <80) <0.001
80-105 1.603 0.998 2.576
>105 3.014 1.892 4.802
Respiratory rate (ref <19) <0.001
19-23 2.221 1.405 3.513
>23 6.582 4.162 10.410
Systolic BP (ref 140-60) <0.001
<110 8.526 4.185 17.370
110-139 2.715 1.300 5.669
>160 3.667 1.670 8.050
Diastolic BP (ref 65-90) <0.001
<65 3.585 2.435 5.277
>90 1.651 0.926 2.944
GCS (ref 15) <0.001
3-5 45.027 19.013 106.634
6-12 12.089 7.319 19.970
13-14 2.685 1.724 4.182
SaO2 (ref low >95 breathing air) <0.001
High (<90 air/<95 O2) 9.721 5.903 16.008
Moderate (90-5 air/ >94 O2) 2.490 1.472 4.213
Temperature <36 2.133 <0.001 7.019 10.157
Pulse pressure (ref 53-80) <0.001
<40 3.682 2.316 5.853
40-52 1.604 0.933 2.759
>80 1.633 0.924 2.888
Respiratory disease present 1.550 0.072 0.962 2.498
Heart disease present 1.028 0.885 0.706 1.497
Asthma present 0.608 0.158 0.305 1.213
Diabetes present 1.128 0.619 0.702 1.811
Epilepsy present 0.551 0.315 0.172 1.763
Warfarin therapy 0.586 0.250 0.236 1.456
Steroid therapy 1.167 0.664 0.580 2.350
4.7 Interactions between significant variables 
Logistic regression was used to examine first order interactions between variables 
significant at the 10% level by assessing the predictive significance of both variables 
and their interaction term.  Wald and p-values for the non-significant interactions 
are in appendix 7.  Significant interactions are in table 15.
Table 15: Significant interactions
Interaction term Wald Degrees of freedom P
Active malignancy by age 182.419 3 <0.001
Active malignancy by GCS 51.059 3 <0.001
Active malignancy by temperature 144.752 1 <0.001
Active malignancy by pulse pressure 25.060 3 <0.001
Age by temperature 90.820 3 <0.001
Pulse by temperature 319.717 2 <0.001
Respiratory rate by temperature 186.342 2 <0.001
SBP by temperature 29.071 3 <0.001
DBP by temperature 156.644 2 <0.001
GCS by temperature 15.375 3 0.002
SaO2 by temperature 216.794 2 <0.001
Temperature by pulse pressure 19.101 3 <0.001
Temperature by respiratory disease 158.828 1 <0.001
Pulse pressure by respiratory disease 46.431 3 <0.001
Full details are in appendix 7, but briefly it appears that active malignancy is more 
predictive of poor outcome in younger patients, and those with a low GCS and 
temperature or normal pulse pressure; that tachycardia, hypoxia and extremes of 
SBP and pulse pressure are more predictive of poor outcome in patients with a low 
temperature; that low temperature is less predictive of poor outcome in patients 
with a very low GCS; and that widened pulse pressure is less predictive of poor 
outcome in patients with respiratory disease.
4.8 Multivariate analysis of predictor variables
Variables and interactions significant at the 10% level were block entered into a 
multivariate logistic regression analysis.  This produced estimated odds ratios 
(Exp(B)) and p values as in table 16. Variables significant at the 95% level are 
highlighted in red.
Table 16: Multivariate analysis of predictor variables
Exp(B) p
Active malignancy 230.974 <0.001
Age (ref <50) 0.906
50-69 20253 0.998
70-85 29027 0.998
>85 24519 0.998
Pulse (ref <80) 0.295
80-105 1.406 0.293
>105 1.735 0.123
Respiratory rate (ref <19) 0.001
19-23 1.482 0.190
>23 3.731 <0.001
Systolic BP (ref 140-60) 0.040
<110 9.543 0.007
110-139 5.682 0.010
>160 4.243 0.053
Diastolic BP (ref 65-90) 0.380
<65 1.399 0.301
>90 1.514 0.340
GCS (ref 15) 0.116
3-5 7.01*e8 0.997
6-12 4.190 0.022
13-14 0.920 0.881
SaO2 (ref low risk >95 breathing air) <0.001
High risk (<90 air/<95 O2) 3.639 <0.001
Moderate risk (90-5 air/ >94 O2) 1.400 0.327
Temperature <36 2.417 0.218
Pulse pressure (ref 53-80) 0.790
<40 1.368 0.702
40-52 1.886 0.399
>80 0.825 0.867
Respiratory disease present 0.821 0.640
Active malignancy by age interaction 0.258
Active malignancy and age 50-69 59232852 0.999
Active malignancy and age 70-85 21081320 0.999
Active malignancy and age >85 4100951 0.999
Active malignancy by GCS interaction 0.545
Active malignancy and GCS 3-5 5.189*e1
4
0.997
Active malignancy and GCS 6-12 0.369 0.424
Active malignancy ad GCS 13-14 0.222 0.166
Active malignancy by temperature interaction 5.306 0.083
Active malignancy by pulse pressure interaction 0.139
Active malignancy and pulse pressure <40 4.472 0.276
Active malignancy and pulse pressure 40-52 13.782 0.045
Active malignancy and pulse pressure >80 1.633 0.777
Age by temperature interaction 0.582
Age 50-69 and temperature <36 0.761 0.841
Age 70-85 and temperature <36 0.296 0.338
Age >85 and temperature <36 0.433 0.506
Pulse by temperature interaction 0.076
Pulse 80-105 and temperature <36 0.234 0.025
Pulse >105 and temperature <36 0.535 0.382
Respiratory rate by temperature interaction 0.956
Respiratory rate 19-23 and temperature <36 1.09 0.885
Respiratory rate >23 and temperature <36 0.893 869
SBP by temperature interaction 0.307
SBP <110 and temperature <36 6.723 0.253
SBP 110-139 and temperature <36 5.514 0.207
SBP >160 and temperature <36 15.385 0.067
DBP by temperature interaction 0.841
DBP <65 and temperature <36 1.185 0.794
DBP >90 and temperature <36 0.635 0.603
GCS by temperature interaction 0.470
GCS 3-5 and temperature <36 0.146 0.154
GCS 6-12 and temperature <36 1.216 0.776
GCS 13-14 and temperature <36 1.16 0.804
SaO2 by temperature interaction 0.134
High risk (<90 air/<95 O2) and temperature <36 4.171 0.046
Moderate risk (90-5 air/ >94 O2) and temperature <36 2.270 0.228
Pulse pressure by temperature interaction 0.799
Pulse pressure <40 and temperature <36 0.884 0.9
Pulse pressure 40-52 and temperature <36 0.475 0.398
Pulse pressure >80 and temperature <36 1.210 0.881
Respiratory disease by temperature interaction 1.264 0.761
Pulse pressure by respiratory disease interaction 0.061
Pulse pressure <40 and respiratory disease 0.255 0.061
Pulse pressure 40-52 and respiratory disease 0.292 0.159
Pulse pressure >80 and respiratory disease 0.112 0.077
Taking the model at face value, some combinations of factors lead to inevitable 
death (see, for example, the coefficients for malignancy, age 50 and above, or GCS 
between 3 to 5). However, these very large odds ratios are suggestive of a model 
which has failed to converge; in other words, there are combinations of these 
factors with few and/or no events, causing the model to ascribe non-finite event 
probabilities. The likeliest explanation is in the interaction terms, of which five 
produced at least one category containing one or no events.  Thus after taking 
statistical advice the following interaction terms were removed:
Active malignancy by age
Active malignancy by GCS
Active malignancy by pulse pressure
SBP by temperature
Pulse pressure by respiratory disease
The rerun multivariate logistic regression analysis produced results as in table 17
Table 17: Rerun multivariate analysis
Exp(B) p
Active malignancy 0.141 0.001
Age (ref <50) 0.062
50-69 0.125 0.021
70-85 0.461 0.172
>85 0.472 0.081
Pulse (ref <80) 0.797
80-105 1.021 0.968
>105 0.764 0.622
Respiratory rate (ref <19) 0.134
19-23 0.328 0.045
>23 0.485 0.178
Systolic BP (ref 140-60) 0.053
<110 0.425 0.132
110-139 1.799 0.469
>160 1.324 0.666
Diastolic BP (ref 65-90) 0.535
<65 1.203 0.754
>90 1.887 0.347
GCS (ref 15) <0.001
3-5 0.669 0.389
6-12 9.75 0.013
13-14 4.656 0.002
SaO2 (ref low risk >95 breathing air) <0.001
High risk (<90 air/<95 O2) 0.461 0.148
Moderate risk (90-5 air/ >94 O2) 3.684 0.002
Temperature <36 0.556 0.475
Pulse pressure (ref 53-80) 0.778
<40 0.538 0.399
40-52 0.790 0.779
>80 0.587 0.505
Respiratory disease present 1.407 0.566
Active malignancy by temperature interaction 2.526 0.197
Age by temperature interaction 0.477
Age 50-69 and temperature <36 0.407 0.462
Age 70-85 and temperature <36 0.494 0.335
Age >85 and temperature <36 1.37 0.546
Pulse by temperature interaction 0.088
Pulse 80-105 and temperature <36 0.374 0.158
Pulse >105 and temperature <36 1.47 0.54
Respiratory rate by temperature interaction 0.890
Respiratory rate 19-23 and temperature <36 0.795 0.728
Respiratory rate >23 and temperature <36 0.739 0.633
DBP by temperature interaction 0.536
DBP <65 and temperature <36 0.494 0.335
DBP >90 and temperature <36 0.422 0.271
GCS by temperature interaction 0.531
GCS 3-5 and temperature <36 0.935 0.905
GCS 6-12 and temperature <36 5.017 0.199
GCS 13-14 and temperature <36 0.736 0.628
SaO2 by temperature interaction 0.134
High risk (<90 air/<95 O2) and temperature <36 2.252 0.206
Moderate risk (90-5 air/ >94 O2) and temperature <36 0.573 0.295
Pulse pressure by temperature interaction 0.529
Pulse pressure <40 and temperature <36 2.153 0.288
Pulse pressure 40-52 and temperature <36 1.517 0.573
Pulse pressure >80 and temperature <36 2.785 0.175
Respiratory disease by temperature interaction 0.671 0.565
4.8b Recalculated linear coefficients
Variables significant at the 95% level in the multivariate analysis were block re-
entered into a multivariate analysis to develop linear coefficients for the final 
model, with results as in table 18.
Table 18: Multivariate analysis for linear coefficients
Exp(B) p 95% CI for exp (B)
Active malignancy 13.320 <0.001 8.36 21.22
GCS (ref 15) <0.001
3-5 342.163 <0.001 143.854 813.851
6-12 13.433 <0.001 8.122 22.217
13-14 2.200 <0.001 1.421 3.405
SaO2 (ref low risk >95 breathing air) <0.001
High risk (<90 air/<95 O2) 5.815 <0.001 3.579 9.449
Moderate risk (90-5 air/ >94 O2) 1.455 0.134 0.891 2.374
4.8c Rerun model
Given the very large coefficient for GCS 3-5 in the previous model and the small 
numbers in the GCS 3-5 group (24, with 13 deaths), the multivariate regression was 
rerun with the GCS categories 3-5 and 6-12 combined, with results as in table 19.
Table 19: Model with GCS categories collapsed
p Exp(B) 95% CI for Exp(B)
Age (ref <50) <0.001
50-69 0.124 0.608 0.322 1.147
70-85 <0.001 0.348 0.201 0.603
>85 0.787 0.924 0.520 1.642
Respiratory rate (ref <19) <0.001
19-23 0.012 1.753 1.129 2.721
>23 <0.001 2.791 1.730 4.5
Diastolic BP (ref 65-90) <0.001
<65 <0.001 3.172 2.090 4.815
>90 <0.001 5.204 3.250 8.333
SaO2 (ref low risk >95 breathing air) <0.001
High risk (<90 air/<95 O2) <0.001 3.202 1.956 5.243
Moderate risk (90-5 air/ >94 O2) 0.754 0.932 0.598 1.452
Temperature <36 <0.001 4.714 3.104 7.158
GCS (ref 15) <0.001
3-12 <0.001 29.372 18.674 46.197
13-14 <0.001 5.311 3.403 8.291
Respiratory disease present <0.001 12.355 8.202 18.609
Respiratory disease and 
temperature <36
<0.001 7.466 3.134 17.784
4.9 Equation to predict death at 7 days
The coefficients generated in stage 4.8c were entered into an equation to generate 
a scaled probability of death:
P(death) = ea/1+ea 
where a = (age50-69*0.608) + (age70-85*0.348) + (age>85*0.924) + 
(respiratoryrate19-23*1.753) + (respiratoryrate>23*2.791) + (DBP<65*3.172) + 
(DBP>90*5.204) + (sao2high*3.202) + (sao2mod*0.932) + (temperature<36*4.714) 
+ (GCS3-12*29.372) + (GCS13-14*5.311) + (respiratorydisease*12.355) + 
(respiratorydisease^temperature * 7.466).
Entering the value generated by the equation as the sole variable in a logistic 
regression analysis generated a Nagelkerke R2 value of 0.778, indicating adequate 
calibration.
4.10 Generating a bedside score to predict death at 7 days
In order to generate a score useable at the bedside, the coefficients generated in 
4.8c were approximated to integers as discussed in 3.12 above, resulting in the 
score in table 20.
Table 20: Bedside score to predict death at 7 days
Exp (B) Rounded
Age (ref <50)
50-69 0.608 1
70-85 0.348 1
>85 0.924 1
Respiratory rate (ref <19)
19-23 1.753 2
>23 2.791 3
Diastolic BP (ref 65-90)
<65 3.172 3
>90 5.204 5
SaO2 (ref low risk >95 
breathing air)
High risk (<90 air/<95 O2) 3.202 3
Moderate risk (90-5 air/ >94 
O2)
0.932 1
Temperature <36 4.714 5
GCS (ref 15)
3-12 29.372 30
13-14 5.311 5
Respiratory disease present 12.355 12
Respiratory disease and 
temperature <36
7.466 7
4.10a Performance of bedside score in predicting death
The performance of the bedside score was assessed using a ROC curve, which had 
an area under the curve (c-statistic) of 0.847 (95% confidence interval 0.8-0.894), 
indicating no loss of discrimination during the rounding process. The ROC curve is 
shown in figure 15 superimposed on that of the equation for comparison.  It is 
possible that the slight improvement in performance from the equation to the 
bedside score highlights a small degree of overfitting in the equation, particularly in 
the age categories.
Figure 15: ROC curves for equation and bedside score to predict death in 7 days
4.11 Limitations
The major limitation of this section of the study is its single-site nature. Ideally data 
from multiple hospitals would have been examined, with site of care included in 
logistic regression analysis, to explore whether predictors of death were consistent 
across all sites and address the constant risk fallacy (72). The full DAVROS study in 
fact found that some variables (particularly oxygen saturations) were not 
consistently predictive of death in all sites (76). However the Northern General 
dataset was selected in order that the subset of patients used for chapter 5 would 
be as close to this dataset as possible.
4.12 Summary
 Data from 2437 patients including 128 who died within 7 days of ED 
presentation was collected.
 Multivariate analysis identified 7 readily available factors and one interaction 
(age, respiratory rate, diastolic blood pressure, oxygen saturation, temperature, 
GCS, pre-existing respiratory disease and respiratory disease by temperature 
interaction) predicting death within 7 days.
 These factors were used to generate an equation with adequate discrimination 
and calibration: P(death) = ea/1+ea 
where a = (age50-69*0.608) + (age70-85*0.348) + (age>85*0.924) + 
(respiratoryrate19-23*1.753) + (respiratoryrate>23*2.791) + 
(DBP<65*3.172) + (DBP>90*5.204) + (sao2high*3.202) + (sao2mod*0.932) + 
(temperature<36*4.714) + (GCS3-12*29.372) + (GCS13-14*5.311) + 
(respiratorydisease*12.355) + (respiratorydisease^temperature * 7.466).
 The equation was simplified to integer values to enable use at the bedside with 
no loss of discriminatory ability.
Chapter 5
Derivation of a score to predict potentially preventable or potentially prevented 
death at 7 days
5.1 Introduction
This chapter will describe the data set assembled for derivation of a score predicting 
potentially prevented and preventable deaths (“potentially preventable” deaths), or 
solely potentially prevented deaths, and the process of deriving those scores.
5.2 Data set 
Sets of casenotes relating to patients presenting to the Northern General Hospital 
by ambulance from February to May 2008, as described in 4.2 above, were 
screened in date order until 99 outcomes of interest (death or potentially prevented 
death) were included, for a sample size as discussed in 3.10 above.  In total 697 
cases were assessed, presenting between 11/2/08 and 4/03/08.  242 sets of notes 
were inaccessible due to changes in the casenote numbering system.  57 sets of 
notes were scrutinised and the case then excluded as the patient had sustained 
trauma (18), or a fractured neck of femur (22) or there was no entry in the notes for 
the relevant attendance (17).  398 cases were therefore included in the derivation 
set.
5.3 Study population
Characteristics of the study population are in table 21.  To explore the 
representativeness of the data set, comparison was made of the recorded 
physiological variables between included patients and those with missing outcomes. 
Characteristics of the population with missing outcomes are also in table 21. The 
only notable difference is in the proportion of patients with active malignancy, 
which may reflect that patients with malignancy are more likely to be followed up, 
and their casenotes therefore to be active and accessible.
Table 21: Characteristics of the derivation study population
Study population Missing
Variable Mean (sd) Range Mean (sd) Range
Age 66.5 (20.2) 18-102 67.2 (18.5) 18-97
Pulse 92 (24) 35-188 87 (24) 37-196
Respiratory rate 20 (7) 6-45 19 (6) 12-46
Systolic BP 133 (29) 45-243 132 (27) 62-208
Diastolic BP 75 (15) 36-130 75 (15) 35-124
Temperature 36.5 (1.2) 26.0-40.0 36.5 (1.1) 30.5-39.7
Variable Median (IQR) Range Median (IQR) Range
GCS 15 (15-15) 3-15 15 (15-15) 3-15
SaO2 breathing air 97 (94-98) 66-100 97 (95-98) 71-100
SaO2 breathing 
oxygen
97 (96-99) 71-100 97 (95-99) 73-100
Variable Number Percentage Number Percentage
Male 183 46 117 48.3
Active malignancy 23 5.8 7 2.9
5.4 Patients considered to have outcomes of interest
The patient group of interest in this study is those where emergency care had the 
potential to affect survival (or non-survival), ie where a patient death was 
potentially preventable or potentially prevented as discussed in 3.7.2 above.  4 
outcomes have been recorded: 
 inevitable death, where the patient died within 7 days of presentation and a 
decision was made within 24 hours of admission not to attempt CPR in the 
event of cardiac arrest;
 potentially preventable death, where the patient died within 7 days of 
presentation, but no decision was made to withdraw or limit care;
 potentially prevented death, where the patient survived for 7 days following 
presentation, but within those 7 days received a potentially life-saving 
intervention (as defined in 3.7.3b);
 non-critical illness, where the patient survived for 7 days following 
presentation without receiving a potentially live-saving intervention.
Full details of the patients are given in appendix 8. 15 patients were judged to have 
sustained inevitable death, 5 patients were judged to have sustained potentially 
preventable death and in 79 patients death was judged to have been potentially 
prevented.  
5.5 Univariate analysis of potential predictor variables
Each analysis was carried out for two outcomes: potentially prevented death alone, 
and potentially prevented death plus potentially preventable death. It was 
hypothesised at the outset that there might be some physiological indicators of 
reversibility of the patient’s condition such that factors which predicted potentially 
prevented death would not be the same as those which predicted potentially 
preventable death. 
5.5a Demographic and historical variables
Categorical demographic and historical values were crosstabulated against outcome 
at 7 days and significant associations identified using chi-squared testing.  Full 
details are in table 22 below. No categorical variables were significant at the 90% 
level.
Table 22: Univariate analysis of categorical variables
Variable Potentially preventable and 
potentially prevented death
Total
Gender p=0.194
Female 39 (18.5) 211
Male 45 (24.6) 183
Missing 0 4
Active malignancy 
p=0.653
No active malignancy 80 (21.3) 375
Active malignancy 4 (17.4) 23
Variable Potentially prevented death Total
Gender p=0.334
Female 38 (18) 211
Male 41 (22.4) 183
Missing 0 4
Active malignancy 
p=0.761
No active malignancy 75 (20) 375
Active malignancy 4 (17.4) 23
5.5b Continuous variables
Continuous physiological variables and age were assessed in three ways: quintiles of 
the study population, quintiles of the variable range and (where included in 
DAVROS) groups defined a priori within the DAVROS project to reflect generally 
accepted clinical definitions of normal.  Full details are in appendix 9. GCS and 
oxygen saturations (both breathing air and on oxygen) were assessed in tertiles and 
quartiles to better reflect their population distributions.  GCS was also assessed in a 
priori groups broadly consistent with currently accepted clinical risk categories.
After visual inspection of the histograms in appendix 9 population quintiles were 
chosen for all variables except systolic blood pressure, GCS and oxygen saturations 
where a priori groups were used.
 
Continuous variables significant at the 90% level for potentially prevented and 
potentially preventable death were pulse, respiratory rate, systolic blood pressure, 
pulse pressure, GCS, oxygen saturations and age, as shown in table 23.
Table 23: Univariate analysis of continuous variables to predict potentially 
preventable and potentially prevented death
Variable Potentially preventable and 
potentially prevented death
Total
Pulse population quintiles p<0.001 
<71 6 (8) 76
71-82 15 (20) 76
83-95 16 (20) 80
96-110 11 (14) 81
>110 34 (44) 77
Missing 2 (25) 8
Respiratory rate population quintiles p=0.016
<16 7 (12) 59
16-17 17 (21) 80
18 13 (17) 76
19-23 15 (25) 60
>23 25 (35) 72
<16 7 (14) 51
Systolic BP a priori groups p=0.003
Very low (<100) 15 (36) 42
Low (100-120) 22 (26) 84
Normal (120-180) 37 (15) 244
High (>180) 7 (39) 18
Missing 3 (30) 10
Pulse pressure population quintiles p=0.005
<40 21 (28) 76
40-50 26 (30) 86
51-62 7 (10) 72
63-76 10 (13) 75
>76 16 (21) 77
Missing 4 (33) 12
GCS a priori groups p=0.015
3-5 2 (66) 3
6-8 4 (57) 7
9-12 7 (33) 21
13-14 10 (20) 49
15 49 (18) 275
Missing 12 (28) 43
Oxygen saturations breathing air a priori groups p=0.056
Very low (<90) 10 (32) 31
Low (90-3) 8 (33) 24
Normal (94-100) 39 (17) 231
Missing 27 (24) 112
Oxygen saturations breathing supplemental oxygen population tertiles p=0.439
<96 7 (32) 22
96-99 16 (25) 63
100 4 (19) 21
Missing 57 (20) 292
Age population quintiles p=0.039
<45 22 (28) 78
 45-64 15 (19) 79
 65-75 21 (29) 72
 76-85 18 (19) 97
 >85 8 (11) 72
To predict potentially prevented death alone, pulse, respiratory rate, systolic blood 
pressure, pulse pressure, oxygen saturations and age were significant at the 90% 
level (table 24).
Table 24: Univariate analysis of continuous variables to predict potentially 
prevented death
Variable Potentially prevented Total
Pulse population quintiles p<0.001 
<71 6 (8) 76
71-82 13 (17) 76
83-95 15 (19) 80
96-110 10 (12) 81
>110 33 (43) 77
Missing 2 (25) 8
Respiratory rate population quintiles p=0.056
<16 6 (10) 59
16-17 17 (21) 80
18 13 (17) 76
19-23 14 (23) 60
>23 22 (31) 72
Missing 7 (14) 51
Systolic BP a priori groups p=0.005
Very low (<100) 14 (33) 42
Low (100-120) 20 (24) 84
Normal (120-180) 35 (14) 244
High (>180) 7 (39) 18
Missing 3 (30) 10
Pulse pressure population quintiles p=0.003
<40 21 (28) 76
40-50 24 (28) 86
51-62 6 (8) 72
63-76 8 (11) 75
>76 16 (21) 77
Missing 4 (33) 12
Oxygen saturations breathing air population quartiles p=0.05
<95 20 (27) 73
95-6 13 (19) 67
97-8 13 (16) 79
99-100 6 (9) 67
Missing 27 (24) 112
Oxygen saturations breathing supplemental oxygen population tertiles p=0.264
<96 7 (32) 22
96-99 16 (25) 63
100 4 (19) 21
Missing 52 (18) 292
Age population quintiles p=0.047
<45 22 (28) 78
 45-64 15 (19) 79
 65-75 18 (25) 72
 76-85 17 (18) 97
 >85 7 (10) 72
Where visual inspection of the groups suggested similar risk profiles across different 
groups, these were collapsed.  Thus the variables as in table 25 remained for further 
analysis.
Table 25: Simplified variables for further analysis
Potentially preventable and potentially prevented death
Age <45, 45-64, 65-75, 75-85, >85
Pulse <71, 71-110, >110
Respiratory rate <16, 16-18, 19-23, >23
SBP <100, 100-120, 121-180, >180
Pulse pressure <51, 51-76, >76
GCS 3-8, 9-12, 13-15
Oxygen saturations High (<95 air or <96 O2), moderate (95-98 air or >95 O2), low 
(99-100 air)
Potentially prevented death
Age <45, 45-64, 65-75, 75-85, >85
Pulse <71, 71-110, >110
Respiratory rate <16, 16-18, 19-23, >23
SBP <100, 100-120, 121-180, >180
Pulse pressure <51, 51-76, >76
Oxygen saturations High (<95 air or <96 O2), moderate (95-98 air or >95 O2), low 
(99-100 air)
5.6 Handling of missing data
Each variable was assessed visually using the histograms in appendix 9 and missing 
data collapsed into the most closely comparable risk group.
Thus missing pulse, systolic blood pressure, and pulse pressure were treated as the 
highest risk groups (>110, <110, and <51 respectively).  Missing GCS was treated as 
moderate risk (9-12), while missing respiratory rate was treated as low risk (<16). If 
both oxygen saturations breathing air and oxygen were missing the variable was left 
as missing.
As discussed in chapter 4, it is plausible that this reflects pragmatic practice, where 
the absence of pulse and blood pressure indicates “unmeasurability”, while 
respiratory rate and GCS need to be measured manually and therefore their 
absence indicates “unmeasuredness”.
5.7 Univariate logistic regression analysis of predictor variables
Binary logistic regression was used with the simplified groups as developed above 
to generate estimated odds ratios (expressed as exp(B)) for each of the risk groups.  
Where multiple groups existed for a variable, the odds ratio was calculated in 
comparison with the lowest risk group.  Variables reaching significance at the 90% 
level are highlighted in red in tables 26 and 27.
Table 26:Univariate logistic regression analysis of predictor variables for potentially 
preventable and potentially prevented death
Variable exp(B) p 95% CI for exp(B)
Age (ref <45) 0.104
45-64 0.733 0.341 0.387 1.390
65-75 1.031 0.925 0.545 1.950
75-85 0.538 0.044 0.295 0.983
>85 0.554 0.074 0.290 1.058
Pulse (ref <71) <0.001
71-110 0.522 0.011 0.316 0.862
>110 3.756  <0.001 1.930 7.309
Respiratory rate (ref <16) <0.001
16-18 1.009 0.973 0.605 1.683
19-23 3.463 <0.001 1.819 6.594
>23 3.991 <0.001 2.140 7.443
Systolic BP (ref 121-180) <0.001
<100 4.461 <0.001 2.397 8.302
100-120 2.140 0.006 1.250 3.665
>180 31.475 <0.001 13.479 73.496
Pulse pressure (ref 51-76) <0.001
<51 1.791 0.011 1.143 2.805
>76 3.540 <0.001 2.030 6.174
GCS (ref 13-15) <0.001
3-8 34.446 <0.001 16.607 71.447
9-12 2.203 0.007 1.235 3.930
SaO2 (ref low risk) <0.001
High 1.583 0.156 0.839 2.987
Moderate 0.470 0.004 0.283 0.781
Table 27: Univariate logistic regression analysis of predictor variables for potentially  
prevented death
Variable exp(B) p 95% CI for exp(B)
Age (ref <45) 0.123
45-64 0.734 0.345 0.387 1.394
65-75 0.880 0.693 0.466 1.663
75-85 0.511 0.029 0.279 0.933
>85 0.526 0.052 0.275 1.005
Pulse (ref <71) <0.001
71-110 0.495 0.007 0.297 0.825
>110 4.583 <0.001 2.289 9.180
Respiratory rate (ref <16) <0.001
16-18 0.560 0.053 0.311 1.008
19-23 1.660 0.171 0.803 3.431
>23 1.744 0.117 0.870 3.497
Systolic BP (ref 121-180) <0.001
<100 5.294 <0.001 2.703 10.368
100-120 2.050 0.010 1.186 3.542
>180 34.284 <0.001 14.209 82.723
Pulse pressure (ref 51-76) <0.001
<51 1.947 0.004 1.230 3.081
>76 3.966 <0.001 2.262 6.953
SaO2 (ref low risk) <0.001
High 1.352 0.350 0.718 2.545
Moderate 0.427 0.001 0.257 0.710
5.8 Interactions between significant variables 
Logistic regression was used to examine first order interactions between variables 
significant at the 10% level by assessing the predictive significance of both variables 
and their interaction term.  Wald and p-values for the non-significant interactions 
are in appendix 10 (potentially preventable and potentially prevented death) and 
appendix 11 (potentially prevented death alone).  Significant interactions are in 
tables 28 and 29.
Table 28: Significant interactions: potentially preventable and potentially prevented 
death
Interaction term Wald Degrees of freedom P
Pulse by respiratory rate 19.290 6 0.004
Pulse by SBP 19.200 6 0.004
Pulse by SaO2 20.088 4 <0.001
Respiratory rate by pulse pressure 16.431 6 0.012
Respiratory rate by SaO2 14.071 6 0.029
SBP by pulse pressure 32.734 4 <0.001
SBP by SaO2 20.303 6 0.002
Pulse pressure by SaO2 17.221 4 0.002
Full details are in appendix 10, but briefly it appears that hypoxia confers increased 
risk if tachycardia is absent or if tachypnoea is present, and that normal pulse 
pressure confers increased risk in the presence of systolic hypotension.
Table 29: Significant interactions: potentially prevented death
Interaction term Wald Degrees of freedom p
Pulse by respiratory rate 16.646 6 0.011
Pulse by SBP 21.388 6 0.002
Respiratory rate by pulse pressure 14.386 6 0.026
Respiratory rate by SaO2 16.403 6 0.012
SBP by pulse pressure 36.601 4 <0.001
SBP by SaO2 22.282 6 0.001
Pulse pressure by SaO2 19.012 4 0.001
Again, full details are in appendix 11. It seems that hypoxia becomes of increasingly 
higher risk at higher respiratory rates.
5.9 Multivariate analysis of predictor variables 
Variables significant at the 90% level were block entered into a multivariate logistic 
regression analysis. Based on a discernible pattern, interactions of oxygen 
saturations with pulse and respiratory rate were also entered for potentially 
prevented and preventable death, and interaction of oxygen saturation with 
respiratory rate for potentially prevented death alone. This produced estimated 
odds ratios (Exp(B)) and p values as in tables 30 and 31. Variables significant at the 
95% level are highlighted in red.
Table 30: Multivariate analysis of predictor variables for potentially preventable and  
potentially prevented deaths
Variable exp(B) p 95% CI for exp(B)
Pulse (ref <71) 0.02
71-110 0.371 0.419 0.034 4.101
>110 5.176 0.035 1.125 23.816
Respiratory rate (ref <16) 0.228
16-18 4.814 0.128 0.636 36.443
19-23 19.144 0.047 1.035 354.172
>23 6.664 0.094 0.723 61.405
Systolic BP (ref 121-180) 0.061
<100 3.687 0.036 1.089 12.481
100-120 1.112 0.836 0.407 3.043
>180 2.468 0.203 0.615 9.905
Pulse pressure (ref 51-76) 0.536
<51 1.479 0.440 0.548 3.992
>76 1.729 0.302 0.611 4.894
GCS (ref 13-15) <0.001
3-8 23.013 0.001 3.806 139.163
9-12 4.060 0.034 1.114 14.790
SaO2 (ref low risk) 0.971
High 0.946 0.954 0.146 6.123
Moderate 0.840 0.834 0.164 4.300
Pulse/SaO2 interaction 0.210
Respiratory rate/SaO2 
interaction
0.210
Table 31: Multivariate analysis of predictor variables for potentially prevented 
deaths
Variable Exp(B) p 95% CI Exp(B)
Pulse (ref <71) <0.001
71-100 0.809 0.587 0.376 1.739
>110 3.607 0.006 1.446 9.0
Respiratory rate (ref <16) 0.342
16-18 0.864 0.778 0.314 2.379
19-23 1.861 0.276 0.609 5.686
>23 1.552 0.449 0.497 4.845
Systolic BP (ref 121-180) <0.001
<100 3.432 0.014 1.287 9.151
100-120 1.489 0.335 0.662 3.349
>180 15.342 <0.001 4.410 53.374
Pulse pressure (ref 51-76) 0.554
<51 1.458 0.371 0.638 3.332
>76 1.495 0.378 0.611 3.654
SaO2 (ref low risk) 0.257
High 0.954 0.926 0.353 2.580
Moderate 0.572 0.201 0.243 1.346
Respiratory rate/SaO2 
interaction
0.434
5.9b Recalculated linear coefficients
Variables significant at the 95% level in the multivariate analysis were block re-
entered into a multivariate analysis to develop linear coefficients for the final 
model, with results as in tables 32 and 33.
Table 32: Multivariate analysis for linear coefficients to predict potentially 
preventable and potentially prevented death
Exp(B) p 95% CI for exp (B)
Pulse (ref <71) <0.001
71-110 2.373 0.068 0.937 6.010
>110 9.533 <0.001 3.440 26.418
Systolic BP (ref 120-180) 0.015
<100 3.614 0.004 1.521 8.586
100-120 1.488 0.252 0.754 2.934
>180 2.888 0.062 0.947 8.810
GCS (ref 13-15) <0.001
3-8 13.280 <0.001 4.543 38.819
9-12 2.770 0.045 1.022 7.508
Table 33: Multivariate analysis for linear coefficients to predict  potentially 
prevented death
Exp(B) p 95% CI for exp (B)
Pulse (ref <71) <0.001
71-110 0.883 0.707 0.462 1.690
>110 4.595 <0.001 2.158 9.784
Systolic BP (ref 120-180) <0.001
<100 4.700 <0.001 2.306 9.580
100-120 1.928 0.028 1.075 3.459
>180 21.700 <0.001 8.636 54.531
5.10 Equation to predict potentially preventable or potentially prevented death
The coefficients generated in stage 5.9b were entered into an equation to generate 
a scaled probability of potentially preventable or potentially prevented death:
P(potentially preventable or potentially prevented death) = ea/1+ea 
where a = (pulse[71-110]*2.373) + (pulse[>110]*9.533) + (sbp[<100]*3.614) + 
(sbp[100-120]*1.488) + (sbp[>180]*2.888) + (gcs[3-8]*13.28) + (gcs[9-12]*2.770)
 
Entering the value generated by the equation as the sole variable in a logistic 
regression analysis generated a Nagelkerke R2 value of 0.383, indicating poor 
calibration. 
5.11 Equation to predict potentially prevented death
The coefficients generated in stage 5.9b were entered into an equation to generate 
a scaled probability of potentially prevented death:
P(potentially prevented death) = ea/1+ea 
where a = (pulse[71-110]*0.883) + (pulse[>110]*4.595) + (sbp[<100]*4.7) + 
(sbp[100-120]*1.928) + (sbp>[180]*21.7)
 
Entering the value generated by the equation as the sole variable in a logistic 
regression analysis generated a Nagelkerke R2 value of 0.368, indicating poor 
calibration.
5.12 Generation of bedside scores
The coefficients generated in 5.9b above were approximated to integers (see 3.12 
above) for ease of use in a bedside score as in tables 34 and 35.
Table 34: Bedside score to predict potentially preventable and potentially prevented 
death
Exp(B) Rounded
Pulse (ref <71)
71-110 2.373 2
>110 9.533 10
Systolic BP (ref 120-180)
<100 3.614 4
100-120 1.488 1
>180 2.888 3
GCS (ref 13-15)
3-8 13.280 13
9-12 2.770 3
Table 35: Bedside score to predict potentially prevented death
Exp(B) Rounded
Pulse (ref <71)
71-110 0.883 1
>110 4.595 5
Systolic BP (ref 120-180)
<100 4.700 5
100-120 1.928 2
>180 21.700 22
5.12b Performance of score in predicting potentially preventable and potentially 
prevented death
The performance of the score was assessed using a ROC curve (figure 16), which 
had an area under the curve (c-statistic) of 0.737 (95% confidence interval 0.671-
0.804), indicating no loss of discrimination during the rounding process. 
Figure 16: ROC curve for bedside score to predict potentially preventable and 
potentially prevented death
5.12c Performance of score in predicting potentially prevented death
The performance of the score was assessed using a ROC curve (figure 17), which 
had an area under the curve (c-statistic) of 0.720 (95% confidence interval 0.658-
0.782), indicating no loss of discrimination during the rounding process. 
Figure 17: ROC curve for bedside score to predict potentially prevented death
5.13 Limitations
This part of the study is limited by the exclusion of patients who were not admitted 
to hospital. This limits this study in terms of the development of a clinical score as 
there is no analysis of patients who were discharged from the ED, which may 
restrict generalisability.  Ideally a full cohort of presenting patients would be studied 
and those discharged from the ED followed up as outpatients to ensure the absence 
of post-discharge adverse events.  However within the scope of this study that was 
logistically unfeasible.
We did not analyse whether this standardized score added value in the detection of 
the at-risk patient to clinician gestalt. The original DAVROS protocol planned to 
collect paramedic impressions of severity of illness but this had to be abandoned 
due to poor rates of completion. 
5.14 Summary
 Data from 398 patients including 5 who suffered potentially preventable death 
and 79 in whom death was potentially prevented within 7 days of ED 
presentation was collected.
 Multivariate analysis identified 3 readily available factors predicting potentially 
preventable or potentially prevented death within 7 days.
 These factors were used to generate an equation with reasonable discrimination 
but poor calibration: P(potentially preventable or potentially prevented death) = 
ea/1+ea 
where a = (pulse[71-110]*2.373) + (pulse[>110]*9.533) + (sbp[<100]*3.614) 
+ (sbp[100-120]*1.488) + (sbp[>180]*2.888) + (gcs[3-8]*13.28) + (gcs[9-
12]*2.770).
 This was noted to differ from the equation predicting all deaths: P(death) = 
ea/1+ea 
where a = (age50-69*0.608) + (age70-85*0.348) + (age>85*0.924) + 
(respiratoryrate19-23*1.753) + (respiratoryrate>23*2.791) + 
(DBP<65*3.172) + (DBP>90*5.204) + (sao2high*3.202) + (sao2mod*0.932) + 
(temperature<36*4.714) + (GCS3-12*29.372) + (GCS13-14*5.311) + 
(respiratorydisease*12.355) + (respiratorydisease^temperature * 7.466).
 The equation was simplified to integer values to enable use at the bedside with 
minimal loss of discriminatory ability.
Chapter 6
Validation of scores to predict death at 7 days
6.1 Introduction
This chapter will describe the data set assembled for validation of a score predicting 
death at 7 days, and the process of validating that score.  As discussed in 1.10 and 
3.14 above, the process of validation addresses the issue of overfitting of a model, 
whereby a model fits the sampled data closely but misrepresents the true 
relationship between predictor and outcome variables.
This chapter will also describe the assessment of other published scores in 
predicting death at 7 days.  As discussed in 2.3.2, a number of scoring systems have 
been developed and proposed for risk stratification in the undifferentiated 
emergency population. However as noted earlier there is little external validation of 
these systems and minimal head-to-head comparison to enable an informed choice 
between the scores in a clinical setting.
6.2 Data set
Patients presenting by emergency ambulance to the Emergency Department of the 
Northern General Hospital, Sheffield, from October to December 2008 were 
identified prospectively by DAVROS researchers, and data abstracted and recorded 
as in section 4.2 above.  2322 patients were included.  This cohort was collected 
using the same setting and patient selection processes as the derivation cohort, but 
was temporally separate.
Characteristics of the study population are presented in table 36 (with the values of 
the derivation set for comparison):
Table 36: Characteristics of validation and derivation cohorts
Variable Mean (sd; range in 
validation cohort)
Mean (sd; range) in 
derivation cohort
Difference between 
means (p-value)
Age 69.5 (19.1; 18-103) 69 (19; 18-103) 0.5 (0.51)
Respiratory rate 20 (6.6; 8-80) 19 (6; 6-60) 1 (0.564)
Systolic BP 139 (28.4; 44-261) 136 (29; 24-266) 3 (0.572)
Diastolic BP 76 (15; 11-151) 75 (15; 30-153) 1 (0.532)
Pulse rate 88 (23; 20-180) 88 (24; 21-215) 0
Temperature 36.5 (1.14; 25.2-40.5) 36.6 (1.2; 26.0-41.0) 0.1 (0.495)
Mean arterial pressure 97 (17.8; 32-186)
Variable Median (IQR; range) 
in validation cohort
Median (IQR;range) 
in derivation cohort
SaO2 breathing air 97 (95-98; 45-100) 97 (95-98; 50-100)
SaO2 breathing oxygen 98 (95-100; 60-100) 98 (95-100; 24-100)
GCS 15 (15-15; 3-15) 15 (15-15; 3-15)
Variable Number (percentage) 
in validation cohort
Percentage in 
derivation cohort
p-value for 
difference in 
proportions
Male 1093 (46.5) 46.4 0.944
Active malignancy 96 (4.1) 4.5 0.503
Chronic respiratory 
disease
247 (10.5) 12.0 0.105
Heart disease 694 (29.5) 34.0 <0.001
Asthma 236 (10.0) 11.0 0.268
Diabetes 349 (14.9) 15.7 0.447
Epilepsy 63 (2.7) 4.0 0.014
Warfarin usage 139 (5.9) 6.3 0.569
Steroid usage 127 (5.4) 6.1 0.303
Outcome
Alive at 7 days 2210 (94) 91.6
Dead at 7 days 141 (6.0) 5.2
The differences in characteristics between the derivation and validation sets are 
interesting; physiologically the groups were very similar, but the validation set had a 
slightly lower recorded incidence of pre-existing cardiac morbidity.  This might 
reflect a different patient demographic in presentations, whereby previously well 
patients present early in the winter with seasonal problems, while by the spring 
many presentations are of patients with acute decompensation of chronic disease.
6.3 Statistical considerations
As discussed in 3.13 above, the performance of the various scores will be assessed 
using a ROC curve, as this provides information about the trade-off between 
sensitivity and specificity across all values of the score.
6.3a Sample size for validation
Using the Vergouwe calculation (122) discussed in 3.14 above:
Zβ = √(Nδ2/σ2) – Z1/2α
where N = sample size, δ = difference in model performance, Zβ = value of the 
standard normal distribution corresponding to β, with β = type II error rate, Z1/2α = 
value of the standard normal distribution corresponding to 1/2α, with α = type I 
error rate and σ = standard error of performance measure*√n.
Solving this for N, for a 10% difference in model performance (δ=0.1), and using 
α=0.05, β=0.2, σ=0.019*√2361=0.9232 would require a total sample size of 53.  The 
standard error of the performance measure was approximated from the ROC curve 
at 4.9. The apparently small sample size is related to the narrow confidence 
intervals of the original ROC and the statistical assumption that the rate of death 
would be the same in derivation and validation sets.
6.3b Sample size for comparison of scores
Using the Obuchowski tables (124) as discussed in 3.14 above and her closest 
assumptions to this data (moderate accuracy of test, six observers, small observer 
variability and 4:1 ratio of control:event patients), 103 patients would be required 
to detect a 0.1 difference in AUROC, and 424 to detect a 0.05 difference in AUROC.
6.4 Performance of equation in predicting death at 7 days
The equation generated in stage 4.9:
P(death) = ea/1+ea 
where a = (age50-69*0.608) + (age70-85*0.348) + (age>85*0.924) + 
(respiratoryrate19-23*1.753) + (respiratoryrate>23*2.791) + (DBP<65*3.172) + 
(DBP>90*5.204) + (sao2high*3.202) + (sao2mod*0.932) + (temperature<36*4.714) 
+ (GCS3-12*29.372) + (GCS13-14*5.311) + (respiratorydisease*12.355) + 
(respiratorydisease^temperature * 7.466).
was applied to this data set.  The performance of the equation was assessed using a 
ROC curve (figure 18), which had an area under the curve (c-statistic) of 0.741 (95% 
confidence interval 0.685-0.806), indicating moderate discrimination.
Figure 18: ROC curve for equation to predict death at 7 days in validation cohort
Entering the value generated by the equation as the sole variable in a logistic 
regression analysis generated a Nagelkerke R2 value of 0.821, indicating good 
calibration.
6.5 Performance of bedside score in predicting death at 7 days
The bedside score generated in 4.10 (table 37) was applied to the data set.
Table 37: Bedside score to predict death at 7 days
Age
50 or above 1
Respiratory rate
19-23 2
>23 3
Diastolic BP
<65 3
>90 5
SaO2
High risk (<90 breathing air/<95 with supplemental O2) 3
Moderate risk (90-5 breathing air/ >94 with supplemental O2) 1
Temperature <36 5
GCS
3-12 30
13-14 5
Respiratory disease present 12
Respiratory disease and temperature <36 7
The frequency of occurrence of various scores is shown in figure 19, subdivided by 
outcome. The distribution is heavily skewed to the lower scores.
Figure 19: Frequency distribution of scores in the validation cohort
The performance of the score was assessed using a ROC curve which is shown in 
figure 20 superimposed on that of the equation for comparison.  The area under the 
curve (c-statistic) is 0.753 (95% confidence interval 0.691-0.815), indicating minimal 
loss of discrimination during the rounding process. 
Figure 20: ROC curves for equation and bedside score in predicting death at 7 days 
in the validation cohort
6.6 Selection of other scores for analysis of performance
The scores identified in 2.3.2 and described in appendix 1 were examined for 
suitability for this section. They were identified in the literature review as having 
been developed or advocated for use in the setting of undifferentiated patients, the 
population of interest in this study and represented by this cohort.  The RCP NEWS 
score (figure 21) was also assessed as its use has been advocated in all acute care 
settings.
Figure 21: RCP National Early Warning Score
Not all scores identified could be calculated as some variables required for the 
scores were not available in the data set.  These were HOTEL, PRE-EMPT2, the 
simple clinical score and the Sun score and the missing variables are shown in table 
38.
Table 38: Scores which could not be calculated
HOTEL ECG, mobility status
PRE-EMPT 2 PaCO2, H+
Simple clinical score Clinical features, ECG, premorbid functional status
Sun score Racial group, recent hospitalisation, unstructured triage
However, adequate information was available to calculate the majority of scores, 
which are shown with their constituent variables in table 39. Throughout, where an 
AVPU was required, GCS was converted to AVPU as 15=A, 13-14=V, 9-12=P, 3-8=U.
Table 39: Scores analysed for prediction of death at 7 days
Structure Variables included
Bispebjerg (87) Weighted summative 
score
Consciousness (AVPU)
Heart rate
Respiratory rate
Systolic blood pressure
Temperature
Hillerød (88) 
(Vital signs 
section)
Multiple level all-or-
nothing
Consciousness (GCS)
Heart rate
Oxygen saturation
Respiratory rate
Systolic blood pressure
Temperature
Rapid Emergency 
Medicine Score 
(91)
Weighted summative 
score
Consciousness (GCS)
Heart rate
Mean arterial pressure
Oxygen saturation
Respiratory rate
Temperature
South African 
Triage Score (93) 
and Cape Triage 
Score (94)
(TEWS component 
excluding mobility)
Weighted summative 
score 
Consciousness (AVPU)
Heart rate
Respiratory rate
Systolic blood pressure
Temperature
Vital Signs Score 
(96)
(excluding airway 
and fitting)
Unweighted summative 
score
Consciousness (GCS)
Heart rate
Oxygen saturation
Respiratory rate
Systolic blood pressure
VitalPACTM EWS 
(ViEWS) (97)
Weighted summative 
score
Consciousness (AVPU)
Heart rate
Inspired oxygen
Oxygen saturation
Respiratory rate
Systolic blood pressure
Temperature
6.7 Frequency distribution of other scores
Full details of the distribution of scores calculated from the data set are shown in 
appendix 10.  Briefly, for all scores except the Hillerod score, higher scores are 
expected to be associated with a higher risk of poor outcome.  Generally the 
majority of patients were scored as low risk on all the scores, although the higher 
weighting of any impaired consciousness in NEWS reduced the number of very low 
risk patients.
6.8 Performance of scores in predicting death at 7 days
The performance of the scores was assessed using ROC curves (figure 22 and table 
40), which had areas under the curve (c-statistics) of 0.658 to 0.762, indicating poor 
to moderate discrimination.
Figure 22: ROC curves for scores to predict death at 7 days
Table 40: Performance of scores in predicting death at 7 days
Score AUROC 95% confidence interval
Bispebjerg 0.728 0.662-0.794
Hillerod 0.658 0.605-0.710
REMS 0.663 0.586-0.739
TEWS 0.711 0.640-0.782
Vital signs score 0.692 0.616-0.767
ViEWS 0.762 0.703-0.821
NEWS 0.761 0.702-0.821
New bedside score 0.753 0.691-0.815
6.9Limitations
Some scores could not be calculated as not all variables were included in the data 
set. Of these only one of the four was designed for non-selective use in the 
emergency department.
6.10 Summary
 Data from 2322 patients including 383 who died within 7 days of ED 
presentation was collected.
 The equation derived earlier was validated in this data set and demonstrated 
moderate discrimination and calibration (AUROC 0.731).
 The simplified integer score derived earlier demonstrated minimal loss of 
discriminatory ability (AUROC 0.719).
 Other scores identified earlier were validated in this data set and demonstrated 
moderate discrimination, with AUROC from 0.658 – 0.762.
Chapter 7
Validation of score to predict potentially prevented and potentially preventable 
death
7.1 Introduction
This chapter will describe the data set assembled for validation of a score predicting 
potentially prevented and potentially preventable deaths, or solely potentially 
prevented deaths, and the process of validating those scores.  As discussed in 
chapter 6, the process of validation addresses the issue of overfitting of a model.
It will also describe the assessment of other published scores in predicting 
potentially prevented and potentially preventable death at 7 days.  As discussed 
previously, a number of scoring systems have been developed and proposed for risk 
stratification in the undifferentiated emergency population. However as noted 
there is even less data regarding their validation and performance in predicting non-
death outcomes.
7.2 Data set
Sets of casenotes relating to patients presenting by emergency ambulance to the 
Emergency Department of the Northern General Hospital from October to 
December 2008 (those described in 6.2 above) were screened in date order.  In 
total 498 cases were assessed.  252 sets of notes were inaccessible due to changes 
in the casenote numbering system.  19 sets of notes were scrutinised and the case 
then excluded as the patient had sustained trauma (3) or a fractured neck of femur 
(6) or there was no entry in the notes for the relevant attendance (10).  227 cases 
were therefore included in the validation set.
7.3 Study population
Characteristics of the study population are in table 41, with characteristics of the 
derivation set for comparison. The striking difference is the drop in numbers of 
patients receiving supplemental oxygen, given that the distributions of oxygen 
saturations breathing air are similar; it may be that this represents a change in 
practice following the publication of the British Thoracic Society guideline for 
emergency use of oxygen in 2008 (126).
Table 41: Characteristics of validation and derivation cohorts
Variable Mean (standard 
deviation)
Range Mean (sd; range) in 
derivation set
Age 71.3 (18.3) 19-96 66.5 (20.2; 18-102)
Respiratory rate 20 (5.8) 12-40 20 (7; 6-45)
Systolic BP 138 (28.6) 60-249 133 (29; 45-243)
Diastolic BP 74 (15) 36-142 75 (15; 36-130)
Pulse rate 89 (21.9) 35-152 92 (24; 35-188)
Temperature 36.6 (1.40) 26.4-39.6 36.5 (1.2; 26.0-40.0)
Mean arterial pressure 95 (18.3) 46-178 94 (17; 39-158)
Variable Median 
(interquartile 
range)
Range Median (IQR; range) 
derivation set
SaO2 breathing air 96 (94-98) 45-100 97 (94-98; 66-100)
SaO2 breathing oxygen 98 (96-100) 84-100 97 (96-99; 71-100)
GCS 15 (15-15) 7-15 15 (15-15; 3-15)
Variable Number Percentage Percentage in 
derivation set
Male 94 42 46
Active malignancy 6 2.7 5.8
Receiving supplemental 
oxygen
34 14.9 26.6
7.3a Comparison of missing with included patients
To explore the representativeness of the data set, comparison was made of the 
recorded physiological variables between included patients and those with missing 
outcomes (table 42).  There do not appear to be any notable differences, probably 
reflecting that casenotes tended to be missing relating to a casenote renumbering 
issue rather than due to any clinical matters.
Table 42: Comparison of validation population with those with missing outcomes
Variable Mean (sd) included Mean (sd) missing
Age 71.3 (18.3) 70.1 (17.8)
Respiratory rate 20 (5.8) 21 (6.9)
Systolic BP 138 (28.6) 138 (28.5)
Diastolic BP 74 (15) 75 (15)
Pulse rate 89 (21.9) 89 (23.6)
Temperature 36.6 (1.40) 36.5 (1.38)
Mean arterial pressure 95 (18.3) 96 (17.9)
Variable Median (IQR) included Median (IQR) missing
SaO2 breathing air 96 (94-98) 96 (94-98)
SaO2 breathing oxygen 98 (96-100) 98 (94-100)
GCS 15 (15-15) 15 (14-15)
Variable Number (%) included Number (%) missing
Male 94 (42) 121 (45.8)
Active malignancy 6 (2.7) 13 (4.9)
Receiving supplemental 
oxygen
34 (14.9) 52 (19.7)
7.3b Missing data for individual variables
Amongst included cases, data was missing for the following variables: pulse (23), 
respiratory rate (61), systolic blood pressure (24), diastolic blood pressure (24), GCS 
(53), oxygen saturations breathing air (62), oxygen saturations breathing 
supplemental oxygen (192) and temperature (39).
7.4 Patients considered to have outcomes of interest
The same four outcomes as in chapter 5 above have been recorded: 
 inevitable death, where the patient died within 7 days of presentation and a 
decision was made within 24 hours of admission not to attempt CPR in the 
event of cardiac arrest;
 potentially preventable death, where the patient died within 7 days of 
presentation, but no decision was made to withdraw or limit care;
 potentially prevented death, where the patient survived for 7 days following 
presentation, but within those 7 days received a life-saving intervention (as 
defined in 3.7.1);
 non-critical illness, where the patient survived for 7 days following 
presentation without a requirement for live-saving intervention.
2 patients were judged to have sustained inevitable death, 1 patient was judged to 
have sustained potentially preventable death and in 35 patients death was judged 
to have been potentially prevented.  Full details of the patients are given in 
appendix 13.
7.5 Statistical considerations
As discussed in 3.11 above, the performance of the various scores will be assessed 
using a ROC curve, as this provides information about the trade-off between 
sensitivity and specificity across all values of the score.
7.5a Sample size for validation
Using the calculation discussed in 3.14 above:
Zβ = √(Nδ2/σ2) – Z1/2α
where N = sample size, δ = difference in model performance, Zβ = value of the 
standard normal distribution corresponding to β, with β = type II error rate, Z1/2α = 
value of the standard normal distribution corresponding to 1/2α, with α = type I 
error rate and σ = standard error of performance measure*√n.
Solving this for N, for a 10% difference in model performance (δ=0.1), and using 
α=0.05, β=0.2, σ=0.032*√386=0.629 would require a sample size of 255.
7.5b Sample size for comparison of scores
Using the Obuchowski tables (124) as discussed in 3.14 above and her closest 
assumptions to this data (moderate accuracy of test, six observers, small observer 
variability and 4:1 ratio of control:event patients), 103 patients would be required 
to detect a 0.1 difference in AUROC, and 424 to detect a 0.05 difference in AUROC.
7.6 Performance of equation for predicting potentially preventable and  death
The equation generated in stage 5.8c above:
P(potentially preventable or potentially prevented death) = ea/1+ea 
where a = (pulse71-110*2.373) + (pulse>110*9.533) + (sbp<100*3.614) + (sbp100-
120*1.488) + (sbp>180*2.888) + (gcs3-8*13.28) + (gcs9-12*2.770)
 
was applied to this data set.  The performance of the equation was assessed using a 
ROC curve (figure 23), which had an area under the curve (c-statistic) of 0.707 (95% 
confidence interval 0.594 - 0.820), indicating moderate discrimination.
Figure 23: ROC curve for equation in predicting potentially preventable or 
potentially prevented death at 7 days
Entering the value generated by the equation as the sole variable in a logistic 
regression analysis generated a Nagelkerke R2 value of 0.545, indicating reasonable 
calibration.
7.7 Performance of bedside score in predicting potentially preventable and 
potentially prevented death at 7 days
The bedside score generated in 5.12 (table 43) was applied to the data set.
Table 43: Bedside score to predict potentially preventable and potentially prevented 
death at 7 days
Pulse
71-110 2
>110 10
Systolic BP
<100 4
100-120 1
>180 3
GCS
3-8 13
9-12 3
The frequency of occurrence of various scores is shown in figure 24, subdivided by 
outcome. The distribution is skewed to the lower scores.
Figure 24: Frequency distribution of bedside scores in the validation cohort
The performance of the score was assessed using a ROC curve (figure 25), which 
had an area under the curve (c-statistic) of 0.686 (95% confidence interval 0.568-
0.804), indicating some loss of discrimination during the rounding process. 
Figure 25: ROC curve for performance of the bedside score in predicting potentially 
preventable and potentially prevented death at 7 days
7.8 Selection of other scores for analysis of performance
The scores identified in 2.3.2 and described in appendix 1 were examined for 
suitability for this section. They were identified in the literature review as having 
been developed or advocated for use in the setting of undifferentiated patients.  
The RCP NEWS score (see section 6.6 above) was also assessed as its use has been 
advocated in all acute care settings.
7.9 Frequency distribution of other scores
Full details of the distribution of scores within the data set are shown in appendix 
14.  Generally one third to one half of patients were scored as low risk on all the 
scores, although as before the higher weighting of any alteration in consciousness in 
NEWS reduced the number of very low risk patients.
7.10 Performance of scores in predicting potentially preventable or potentially 
prevented death at 7 days
The performance of the scores was assessed using ROC curves (table 44), which had 
areas under the curve (c-statistics) of 0.559 to 0.684, indicating poor to moderate 
discrimination.
Table 44: Performance of scores in predicting potentially preventable and 
potentially prevented death at 7 days
Score AUROC (95% CI) AUROC in previous publications
Bispebjerg 0.684 (0.521-0.848) Not previously assessed
Hillerod 0.613 (0.506-0.721) Not previously assessed
REMS 0.615 (0.442-0.787) 0.852 (inhospital death from ED) (91)
0.74 (inhospital death in ED patients 
brought by ambulance) (127)
0.723 (14-day mortality in ED resus 
patients) (128)
0.771 (30-day mortality in ED resus 
patients) (129)
0.696 (7-day mortality or ICU 
admission in ED resus patients) (129)
TEWS 0.681 (0.523-0.839) Not previously assessed
Vital signs score 0.589 (0.382-0.797) 0.72 (inhospital death) (96)
ViEWS 0.559 (0.357-0.762) 0.88 (death in 24hours on MAU) (97)
NEWS 0.637 (0.457-0.817) Not previously assessed
New bedside score 0.686 (0.568-0.804)
7.11 Limitations
This section of the study was greatly hampered by the non-availability of both ED 
records and complete patient notes, despite repeated attempts and hand-searching 
of the casenote library and archive at Northern General.  Fortunately it appears (see 
7.3a above) that this should not have skewed the results, although their power will 
have been affected.
 
7.12 Summary
 Data were collected from 227 patients including 36 patients where death was 
potentially prevented or potentially preventable.
 The equation derived earlier was validated in this data set and demonstrated 
moderate discrimination and calibration.
 The simplified integer score derived earlier demonstrated some loss of 
discriminatory ability.
 Other scores identified earlier were validated in this data set and demonstrated 
poor to moderate discrimination, with AUROC from 0.559 – 0.684.
Chapter 8
Operationalisation and implications
8.1 Introduction
This chapter will describe the process of using two expert groups to develop 
thresholds and responses for the implementation of the score developed in chapter 
5.  A formal cost-benefit analysis to develop explicit thresholds is outwith the scope 
of this thesis, both in terms of complexity and availability of data.  The process will 
therefore involve implicit threshold setting by clinically credible active 
professionals.  The operational implications of these thresholds will then be 
explored.
The score as developed might conceivably be used in a number of settings or for 
different purposes (at triage to stream patients to a co-located primary care 
provider, within the majors area of the ED to structure the order in which patients 
are assessed by a clinician, after treatment to determine whether patients should 
be admitted to a monitored area within an assessment unit etc). The process 
described in this chapter aims to explore how it might be used in a typical ED to 
prioritise patients and determine their location within the ED. This relates to the 
concepts of over- and under-triage discussed in 1.2.3 above; setting thresholds for 
various responses to a score requires consideration of the relative risks of over- and 
under-triaging to individual patients and across the ED. It is possible, indeed likely, 
that thresholds may not be absolute but may vary dependent on circumstances; 
most ED clinicians will recognise the scenario of having a patient they would rather 
be treating in the resuscitation area if only all the resuscitation beds were not 
already full.  This is a necessary part of the research as realistically if 
implementation of the score resulted in more patients being located in the 
resuscitation area than in the waiting room, adoption would be unpopular and 
limited.
8.2 Settings
Two groups of emergency medicine consultants were assembled, one at the 
Northern General Hospital in Sheffield, as described in chapter 3.  A second group 
was assembled at Lancashire Teaching Hospitals Trust.  This is a trust which 
operates Emergency Departments at two sites (Preston and Chorley), seeing 
120,000 patients per year. Chorley is a District General Hospital with a limited range 
of services, while Preston is a teaching hospital of the University of Manchester with 
the regional neurosurgical service, an adult major trauma centre and a hyperacute 
stroke centre. Interventional cardiology is provided outside the Trust by transfer to 
Blackpool.  Consultants and foundation trainees rotate between the two Emergency 
Departments, while middle grades and nursing staff are generally site-specific.
8.3 Methods
Eventually it would be ideal to validate the score as developed empirically in a 
functioning ED. This would, however, be well beyond the scope of this thesis. It was 
therefore decided to use the consensus opinion of experienced clinicians as a partial 
proxy for this. 
Both processes as described below received ethical approval via the University of 
Sheffield.  A number of techniques for achieving group consensus have been 
described; the first choice method for this study was a nominal group technique, as 
it allows face to face discussion but the structured process aims to reduce 
domination of the group by more senior or vocal individuals (130).  The silent 
generation of responses (see 8.3a below) may also be useful in encouraging 
contributions from participants who prefer to consider then articulate their 
opinions. It is also logistically feasible with a group of clinicians, as it requires only a 
single group meeting.  Initially it was hoped to carry out a nominal group process at 
both sites. However, due to service pressures at the Northern General Hospital it 
was not possible to gather all the consultants at the same time.  The process was 
therefore amended to be performed electronically.
Both groups considered the same briefing document (appendix 15) including 
background information on the role of severity assessment and resources currently 
available for assessing patients in the ED, together with the score developed in 
chapter 5. The document included a deliberately non-specific description of an 
older patient presenting with lightheadedness and “weakness” and generating 10 
different scores at presentation.  The presenting complaint was intentionally non-
specific to reduce the chance of participants presuming a diagnosis which might 
affect their responses; it was hoped that use of a consistent scenario with varying 
scores would ensure that threshold decisions were based as much as possible on 
the score alone.  It was also deliberately chosen to be potentially compatible with 
the full range of scores on the triage tool. The sets of observations were selected 
from the original data sets to include the minimum and maximum scores occurring 
in the data set (0 and 23) and various representative values across the possible 
range.  It was felt to be impractical to ask for responses to all 36 possible scores, so 
a limit of 10 was set.
Participants were asked to consider each clinical vignette, addressing four specific 
points:
 Where in the ED should this patient be accommodated (resuscitation, majors, 
waiting room etc). This may include streaming to primary care if appropriate.
 How often should this patient have observations repeated?
 Which staff should be informed about the patient (nurse in charge, doctor in 
charge, any nurse, any doctor, no specific need to inform anyone)?
 How soon should the patient be assessed by a doctor or nurse practitioner?
8.3a Nominal group technique, Lancashire Teaching Hospitals
Consultants were recruited by email before a monthly meeting.  No formal 
prespecified sample size or selection criteria were set, but the date of the meeting 
was selected to maximise the number of attendees.
At the meeting, the participants took part in a nominal group technique as 
described by Jones (131), facilitated by KC.  After a welcome participants were 
asked to write their responses to each clinical vignette silently. Responses were 
entirely open, with no suggested options provided with the vignettes.  Participants 
were then asked to share in turn their responses, without debate at this stage.  
Following this the group discussed their responses to reach consensus.
8.3b Electronic consensus process, Northern General Hospital
Consultants were recruited by email via a link consultant (Dr Shammi Ramlakhan).  
Participants were sent the same briefing document and vignettes and asked to 
respond to the vignettes via email.
Initially it was intended to return anonymised responses to participants for further 
consideration to reach consensus but this did not prove necessary.
8.3c Analysis
Formal statistical analysis of the nominal group data was not undertaken. 
Responses from the two sites was tabulated and compared visually to generate 
thresholds for various systematic and clinical responses to the score.
8.4 Results
8.4a Lancashire Teaching Hospitals
7 consultants (of 14) attended the nominal group session, with time in post ranging 
from just over 1 year to over 15 years. The group’s initial responses are in table 45. 
The table shows the range of responses given to each request for opinion.  As the 
aim was to reach consensus by discussion rather than weighting, frequencies of 
each response are not shown.
Table 45: Initial responses to clinical vignettes from Lancashire Teaching Hospitals
Area of ED Routine repeat 
observations
Staff to be informed Timeliness of 
assessment
Case 1; P70, BP 130/72, GCS 15; score 0  
Waiting room
Primary care
3 hourly
2 hourly
Hourly/when 
assessed
None
None
Nurse
1 hour
1-2 hour
2 hours
4 hours
No urgency
Case 2; P61, BP 120/65, GCS 15; score 1
Waiting room
Primary care
3 hourly
1-2 hourly
Hourly/when 
assessed
None
None
Any nurse
1 hour
1-2 hour
4 hours
No urgency
Case 3; P84, BP 111/64, GCS 15; score 3
Waiting room
Waiting 
room/majors
Hourly
2-hourly
3-hourly
None
Any nurse
Nurse in charge
1 hour
1-2 hours
2 hours
4 hours
Case 4; P63, BP 93/69, GCS 14; score 4
Majors
Majors 
telemetry
Resus
5 mins
15 mins
30 mins
Nurse in charge + any doctor
Nurse in charge + doctor in 
charge
Doctor in charge
Any doctor
Any doctor + any nurse
10 mins
15-30 mins
30 mins
1 hour
Case 5; P102, BP 99/56, GCS 14; score 6
Majors
Resus
5 mins
15 mins
30 mins
Nurse in charge
Nurse in charge + any doctor
Nurse in charge + doctor in 
charge
Any doctor
Any doctor + any nurse
10 mins
15 mins
30 mins
1 hour
Case 6; P35, BP 70/40, GCS 12; score 7
Resus 5 mins
10 mins
15 mins
On resus 
monitor
Nurse in charge + doctor in 
charge
Doctor in charge
Immediate
10 mins
15 mins
Case 7; P134, BP 149/80, GCS 15; score 10
Resus
Majors
10 mins
15 mins
20 mins
30 mins
Nurse in charge
Nurse in charge + any doctor
Any doctor
Any nurse
10 mins
15 mins
30 mins
1 hour
Case 8; P123, BP 199/94, GCS 15; score 13
Resus
Majors
10 mins
15 mins
20 mins
Nurse in charge
Nurse in charge + senior doctor
Nurse in charge + any doctor
10 mins
15 mins
30 mins
30 mins Any doctor
Any nurse
1 hour
Case 9; P129, BP 82/57, GCS 12; score 17
Resus 5 mins
On resus 
monitor
Nurse in charge + doctor in 
charge
Doctor in charge
Immediate
10 mins
Case 10; P114, BP 133/92, GCS 8; score 23
Resus 5 mins
10 mins
On resus 
monitor
Nurse in charge + doctor in 
charge
Doctor in charge
Immediate
P: pulse; BP: blood pressure; GCS: Glasgow Coma Scale
Consensus was reached easily with brief discussion; issues recurrent in the 
discussion were:
 mismatches between responses that the respondents would have considered 
ideal and those achievable in terms of resources and external constraints (eg 
targets)
 respondents’ perceptions of patient risk notwithstanding the score (particularly 
in cases 5 and 6).
The consensus achieved is shown in table 46. Notably there appear to be clear 
thresholds at case 2 (suitability for primary care streaming), case 3 (safety of the 
waiting room) and case 5 (need for resuscitation care). Interestingly case six, with a 
score of 7 (generated by a bradycardia of 35 and hypotension at 70/40), provoked 
more concern than cases seven (tachycardic at 134) and eight (tachycardic 123 and 
hypertensive 199/94). One respondent explicitly quoted the risk of death in 
undifferentiated hypotension whilst discussing case six. However, given that all 
respondents felt that cases seven and eight could only be managed in majors with 
continuous telemetry, this was not felt to be grossly inconsistent.
Table 46: Summary consensus at Lancashire Teaching Hospitals
Case Area Routine 
repeat 
observations
Personnel to be 
informed
Time to be 
seen
1 Primary 
care/waiting 
room
None None 1-2 hours
2 Primary 
care/waiting 
room
None None 1-2 hours
3 Waiting room 1-2 hours Nurse 1-2 hours
4 Majors 
telemetry
15-30 mins Nurse in charge + any 
doctor
15-30 mins
5 Majors 
telemetry
15-30 mins Nurse in charge + any 
doctor
15-30 mins
6 Resus Continuous Nurse in charge + 
doctor in charge
Up to 10 mins
7 Resus/majors 15-30 mins Nurse in charge + any 
doctor
15-30 mins
8 Resus/majors 15-30 mins Nurse in charge + any 
doctor
15-30 mins
9 Resus Continuous Nurse in charge + 
doctor in charge
Immediately
10 Resus Continuous Nurse in charge + 
doctor in charge
Immediately
8.4b Northern General Hospital
3 consultants (of 17) responded to the questionnaire. The group’s initial responses 
are in table 47.
Table 47: Initial responses to clinical vignettes from Northern General Hospital
Area of ED Routine repeat 
observations
Staff to be informed Timeliness of 
assessment
Case 1; P70, BP 130/72, GCS 15; score 0
Waiting room
Majors
None
2 hours
None
Any nurse
2 hours
Case 2; P61, BP 120/65, GCS 15; score 1
Waiting room
Majors
None
2 hours
None
Any nurse
2 hours
Case 3; P84, BP 111/64, GCS 15; score 3
Waiting room
Majors
None
1 hour
2 hours
None
Any nurse
2 hours
Case 4; P63, BP 93/69, GCS 14; score 4
Majors 15 mins
30 mins
1 hour
Any doctor
Any doctor or nurse in charge
Any nurse in majors
30 mins
1 hour
Case 5; P102, BP 99/56, GCS 14; score 6
Majors 15 mins
30 mins
1 hour
Any doctor
Any doctor or nurse in charge
Any nurse in majors
30 mins
1 hour
Case 6; P35, BP 70/40, GCS 12; score 7
Resus 5 mins
Continuous
Doctor in charge Immediate
1 min
5 mins
Case 7; P134, BP 149/80, GCS 15; score 10
Majors
Majors/resus
30 mins
Continuous 
pulse 
monitoring
Any nurse
Any doctor
Doctor in charge
30 mins
30-60 mins
Case 8; P123, BP 199/94, GCS 15; score 13
Majors
Majors/resus
30 mins
Continuous 
pulse 
monitoring
Any nurse
Any doctor
Doctor in charge
30 mins
30-60 mins
Case 9; P129, BP 82/57, GCS 12; score 17
Resus 5 mins
15 mins
Continuous
Doctor in charge Immediate
1 min
5 mins
Case 10; P114, BP 133/92, GCS 8; score 23
Resus 10 mins
15 mins
Continuous
Doctor in charge Immediate
5 mins
Given the low levels of response and the broad agreement with results from 
Lancashire Teaching Hospitals (apart from a single respondent who felt that the 
presenting complaint merited a majors assessment irrespective of physiological 
findings), a decision was taken not to undertake a second round of consensus 
development.
8.4c Summary thresholds
After examination of the consensus responses in table 45, it was apparent that 
several broader groups of patient risk were perceived by clinicians.  The categories 
and responses were therefore collapsed to:
 Score 0 or 1: suitable for primary care streaming if available; no routine repeat 
observations required.
 Score 2 or 3: to wait in waiting room; 1-2 hourly repeat observations; a nurse to 
be aware of the patient.
 Score 4-6: to be allocated to majors area, preferably with telemetry; 
observations every 15-30 minutes; the nurse in charge and a doctor to be aware 
of the patient.
 Score 7 or above: to be allocated to the resuscitation area with continuous 
monitoring; the nurse and doctor in charge to be aware of the patient.
8.5 Implications for the running of the Emergency Department
In order to explore the potential implications of using the thresholds as developed 
above, the entire data set from the Northern General Hospital, as described in 4.2 
and 6.2, was pooled. This totalled 4758 patients, with adequate data to calculate 
the score in 3880.
Frequencies of scores are as shown in figure 26. As noted in chapter 7, the 
distribution is generally skewed towards lower scores, although the spike with a 
value of 10 presumably represents a group of patients with an isolated tachycardia.
Figure 26: Distribution of bedside scores in the pooled data set
Applying the thresholds described in 8.4 above would result in 713 patients (18.4%) 
being allocated to the resuscitation area, 451 (11.6%) to majors, 1984 (51.1%) to 
the waiting room and 732 (18.9%) being streamed to primary care if available 
(figure 27).  Over the 163 days of the study this approximates to 4.4 patients per 
day allocated to the resuscitation area, 2.8 to majors, 12.2 to the waiting room and 
4.5 to primary care. This is of course a broad approximation as of course local 
policies may be presentation-dependent; for example that all patients with a focal 
neurological deficit must be seen in the resuscitation area (for potential stroke 
thrombolysis) or that no patients complaining of chest pain can be streamed to 
primary care.
Without formal assessment it seems that the score directs a much lower proportion 
of ambulance patients to the resuscitation or majors areas than currently happens 
in standard practice. This may represent an artefact from the deliberately non-
specific nature of the case description, whereby non-physiologic moderating factors 
such as pain or vomiting were not included. It might also be a feature of the 
consensus process used, whereby responding clinicians were inclined to 
demonstrate their robust nature while when relatively isolated in actual clinical 
practice they might be more conservative. It must also be remembered that all 
patients in the data set were admitted to hospital; this provides further support for 
the premise that potential to benefit in the longer term is not the same as acuity in 
the Emergency Department, as discussed in 1.4.3.
Figure 27: Potential allocation of patients using bedside score
8.5a Temporal distribution of severity
It is possible that patterns of patient acuity may differ by times of day, due to 
multiple factors (availability or lack of it of other services, changing patient 
thresholds for calling for help, reluctance of ambulance crews not to transport 
apparently vulnerable patients at antisocial hours). Crosstabulation was therefore 
carried out of acuity of presentation by time of presentation as recorded in the 
dataset. Results of this are in table 48. Rates of presentation per hour were 
calculated by dividing the total by the 163 days of data collection. 
Table 48: Presentations crosstabulated by acuity and time of presentation
Time Primary 
care (score 
0-1)
Waiting 
room 
(score 2-3)
Majors 
(score 4-6)
Resuscitation 
(score >6)
Total
00-08 148
0.1/hr
454
0.3/hr
95
0.1/hr
148
0.1/hr
845
08-12 162
0.25/hr
413
0.6/hr
99
0.15/hr
167
0.25/hr
841
12-17 196
0.25/hr
490
0.6/hr
137
0.2/hr
162
0.2/hr
985
17-21 127
0.2/hr
398
0.6/hr
74
0.1/hr
135
0.2/hr
734
21-00 97
0.2/hr
224
0.5/hr
46
0.1/hr
100
0.2/hr
467
Total 730 1979 451 712
It appears that presentations are fairly consistent across the day, apart from in the 
early hours where they decrease.  Obviously this does not take into account self-
presenting patients, those who were brought by ambulance but not admitted to 
hospital and trauma patients, all of whom were excluded from the dataset.
8.6 Limitations
This section of the study was limited by the non-inclusion of senior nursing staff. 
This decision was based on two factors: firstly that we wished to gather the 
opinions of senior clinicians with significant experience and not all the nursing staff 
in band 6 or 7 (sister) roles have this experience. Secondly it was a pragmatic 
decision based on their availability which was low due to clinical commitments. 
The non-specific nature of the case vignette was deliberately structured to remove 
non-physiological cues (such as abdominal pain which might have made 
respondents concerned to exclude a rupturing aneurysm). However it is possible 
that the non-reporting of features such as pain, pallor or sweating may have made 
the respondents assume their absence and therefore be more reassured than they 
might have been in day-to-day practice.
8.7 Summary
 Consensus methodology was used in two hospital sites to develop threshold 
responses to the bedside score.
 Four levels of response were constructed, with linked levels of monitoring and 
urgency of clinical review: waiting room or primary care if available, waiting 
room, majors, resuscitation.
 Just under one-third of patients in the DAVROS dataset would be allocated to 
one of the two highest acuity categories (score 4 or above), representing around 
one patient every 2-3 hours presenting by ambulance and being admitted to 
hospital. 
Chapter 9
Discussion
9.1 Introduction
Chapters 1 to 8 have described the current state of the literature regarding 
assessment of risk in unselected non-trauma Emergency Department patients, the 
derivation and validation of a bedside score to identify those patients at high risk of 
needing life-saving treatment within 7 days of presentation, and the thresholds set 
by a group of clinicians in terms of responses to that score.  This chapter will explore 
the meaning and implications of this research for the NHS, potential limitations in 
the research and priorities for future research.
9.2 Existing evidence
Despite the significant and increasing logistical challenges presented by acute illness 
and acute severe illness to the NHS, proportionately minimal research has 
addressed the issue of identifying the acutely ill patient at high risk of adverse 
outcome and the acutely ill patient who has the potential to benefit from time-
sensitive emergency care.
9.2.1 Clinical tools for the identification of the patient at risk
Of 136 clinical tools identified which had been developed for, or whose use had 
been advocated, in the emergency setting, only ten could reasonably be applied to 
the undifferentiated population which arrives in the Emergency Department and 
only two of these had been prospectively externally validated (table 7).  The clinical 
utility of an instrument which requires a firm diagnosis to the general emergency 
physician is highly questionable, except in certain very limited circumstances such 
as ST-elevation myocardial infarction.  The use of these tools also risks 
miscalculation of risk where an aberrant diagnosis is made initially.
 The quality of the literature is alarmingly poor, with inadequately described data 
sets and statistical analysis. Where statistical analysis is described, it appears that 
there are generally unsafe assumptions of a monotonic linear relationship between 
most predictor variables and poor outcome. Many studies appear to have been 
conducted de novo without reference to existing literature and hence there is 
minimal external validation of scores other than in specific diagnostic groups, 
notably community-acquired pneumonia and acute coronary syndromes. 
Even less information exists regarding the impact on patients of these scores; the 
value of a score with perfect prediction might still be questioned if the identification 
of high-risk patients does not result in an intervention to reduce their risk. It often 
seems to be assumed in the literature that the risk of poor outcome (usually death) 
is the same as potential to benefit from treatment; as discussed in 1.4.3 above this 
is unlikely to be true in all patient populations. It may be that this will become more 
of a limitation as the emergency population becomes older with more chronic 
illness and the prediction of death becomes less helpful.
No well-validated clinical decision aid could be identified for the assessment of 
patients with medical emergencies.
9.2.2 Individual physiological variables in the prediction of poor outcome
Although vast numbers of publications report relationships between various 
physiological variables and assorted poor outcomes (again, usually death), accurate 
assessment of the true impact of alterations in physiology is impossible for a 
number of reasons: a) incomplete reporting; the majority of studies report only 
those variables found to be predictive in that study, with no description of other 
variables which were assessed; b) poor statistical reporting; as can be seen in table 
8, means and p values are often reported as demonstrating a “significant” 
relationship between variables and outcome without fully exploring the nature of 
that relationship and whether it might be clinically useful; c) inadequate analysis; as 
above, odds ratios for risk are often constructed around either an arbitrary cut-off 
value or one derived using an assumption of linearity in the data.
Cautious analysis of the literature as reported does not seem to indicate any 
consistently reported effect of physiological derangement on the risk of adverse 
outcome, although such an effect would be biologically plausible. 
9.3 New findings from this research
9.3.1 Objective 1: to generate a list of interventions which could be used to define 
potential to benefit from emergency (time-critical) care: section 3.7.3b.
We have, in this study, defined a priori a group of interventions which appear on 
best available evidence to be potentially life-saving and time-sensitive. However, 
the evidence supporting these is incomplete and our beliefs underlying many 
frequently-used interventions would bear further scrutiny; patients who could 
benefit could then be more reliably identified. Although our definitions of time-
sensitive interventions might be criticized for being defined arbitrarily, the concept 
of an “Emergency Care Sensitive Condition” is being more widely embraced and 
supports our methodology (132).  
9.3.2 Objective 2: to identify variables predicting potential to benefit from 
emergency care in a broader population than disease-specific scores: chapter 5.
This study adds the findings from a prospectively collected cohort where a bedside 
score including only readily-available data (pulse, systolic blood pressure and 
Glasgow Coma Score) could predict potentially prevented or potentially preventable 
death in the next seven days with moderate discrimination (AUROC 0.737), which 
fell to AUROC 0.686 in a validation set. Potential presentations of the score for 
clinical practice are shown in appendix 16.
9.3.3 Objective 3: to identify variables predicting death in emergency patients and 
explore whether these are the same as those predicting potential to benefit: chapter  
4.
A bedside score to predict death within seven days was more complex, requiring 
age, respiratory rate, diastolic blood pressure, oxygen saturations, temperature, 
Glasgow Coma Score and a pre-existing diagnosis of respiratory disease. However, it 
had good discrimination (AUROC 0.847) although this fell to 0.753 in the validation 
set. 
It is apparent in other published work that patterns of physiological derangement 
differ between patients who die and those who receive life-saving intervention 
(133). The most significant finding of this study is the discrepancy between 
prediction of all deaths and prediction of potentially preventable or potentially 
prevented death. The two scores developed differed both in included variables 
(age, respiratory rate, diastolic blood pressure, oxygen saturation, temperature, 
GCS and pre-existing respiratory disease versus the simpler pulse, systolic blood 
pressure and GCS) and weightings (although included in both scores, the lowest 
values of GCS indicated death far more strongly than potential to benefit).
9.3.4 Objective 4: to develop near-patient scoring systems reflecting the variables 
identified in 2 and 3: sections 4.10 and 5.12 and objective 5: to explore whether the 
scoring systems generated in 4 as well as those already identified perform 
adequately in the prediction of death and potential to benefit in a broader patient 
population: sections 6.8 and 7.10.
The score to predict potential to benefit outperformed all others identified in the 
validation set (AUROCs 0.559-0.684) and the single existing published analysis (table 
44). The score to predict death outperformed all other decision aids except ViEWS 
and NEWS (AUROCs 0.658-0.762) in the validation set.
9.4 Strengths of the study
This is the first study specifically to address the identification of at-risk patients in a 
multi-diagnosis emergency department population who had not already undergone 
triage, and to use the provision of a life-saving intervention as an outcome measure. 
It therefore addresses two of the major flaws inherent in applying the existing 
literature in emergency care; firstly, the lack of data from an emergency setting and 
failure to recognise the prognostic significance of emergency care and 
(non-)response to that care and secondly, the danger of assuming that variables 
which predict death will predict successful response to treatment.
9.5 Limitations of the study
Specific limitations are discussed in each chapter. There are a number of features of 
the study which might, in retrospect, have been structured differently. 
It was felt at the outset that use of the existing DAVROS dataset of physiological 
variables would strengthen the study by easing the data collection load (effectively 
restricting it to identification of outcomes) and therefore enabling a larger, and 
more statistically powerful, study cohort. The study was greatly hampered by the 
non-availability of both ED records and complete patient notes.  This was 
multifactorial but the major underlying problem, that of casenote renumbering and 
subsequent loss of notes at Sheffield Teaching Hospitals, was outwith the control of 
the study team and not predictable at the inception of the project.  In retrospect it 
might have been as effective to collect a data set de novo, particularly if one or 
more sites could have been identified with a robust electronic patient record such 
that the issue of missing data and sets of notes could have been minimised.  It is 
possible that this might have affected the interpretation of outcomes in that 
automatically extracted data from an electronic record might have missed some 
subtleties of treatment obvious to a clinician reading the full notes. This is unlikely, 
however, as specific treatments of interest were defined a priori in this study and 
specifically sought in the paper records.
 
Patients who were not admitted to hospital were excluded from the initial DAVROS 
dataset as the aim was to develop a risk-adjustment tool for emergency admissions 
to hospital.  This limits this study in terms of developing a clinical score as there is 
no analysis of patients who were discharged from the ED, which may restrict 
generalisability.  Ideally a full cohort of presenting patients would be studied and 
those discharged from the ED followed up as outpatients to ensure the absence of 
post-discharge adverse events.  However within the scope of this study that was 
logistically unfeasible.  Rates of short-term death after discharge from the ED have 
been reported as 30/100000 (113) to 50/10000 (114), so the required cohort size to 
investigate this fully would have been impractical.  No data was collected on 
potential non-death adverse outcomes in patients who were discharged from the 
ED; the international literature would suggest a 7-day bounce-back readmission 
rate of around 2.5% (134) but it is unclear how many of those patients receive a 
potentially life-saving intervention; it is likely to be low.
As a single-site study it may be that these results are not generalisable; 
interpretation of vital sign derangement is not only affected by patient factors but 
also by the health care system, staffing levels and types and time available for 
patient care (135). Thus a process of external validation might find that life-saving 
interventions are provided differently in other settings. It also appears from the 
parent DAVROS study that, in the prediction of death, even physiological 
measurements are subject to the constant risk fallacy (76), which is likely also to 
limit generalisability of any decision aid developed in a single-site population.
It was not possible to analyse whether this standardized score added value in the 
detection of the at-risk patient to clinician gestalt; initial attempts were made in the 
DAVROS study to collect paramedic impressions of severity of illness but had to be 
abandoned due to poor rates of completion. A purpose-designed data set would 
ideally collect real-time impressions of patient acuity from nursing and medical staff 
to assess whether a decision aid contributed added value. Where this has been 
done in the existing literature (for assessing risk of acute coronary syndrome and 
pulmonary embolus), clinicians overestimated risk compared with a machine-based 
attribute matching system, but their discrimination (assessed using ROC curves) was 
the same (136). Interestingly, physician performance did not improve with 
experience, raising queries about the need for formalised risk assessment “to 
support junior staff”.
The consensus methods used in chapter 8 to derive thresholds for responding to 
the score only involved doctors at two institutions and did not include nursing staff. 
This clearly has potential to be unrealistic in terms of non-physiological factors 
which may affect interpretation of risk in day-to-day clinical practice, particularly 
the holistic “end of the bed” assessment.
 
9.6 Implications for clinical practice and policy
This study has added to the volume of literature a purpose-derived score which 
identifies patients with the potential to benefit from time-sensitive care.  It has 
potential to be valuable in clinical practice by enabling the prioritisation of patients 
for whom urgency of treatment will be beneficial.  There are, however, a number of 
reasons why it should not yet be widely applied in standard practice.  Green et al 
have recently updated the standards for the application of clinical decision rules 
originally developed by Stiell and Wells and discussed at 1.3.6 (137) and this study 
has not fully addressed all their requirements. The score clearly needs wider 
validation, ideally including comparison with unstructured clinician (doctor or triage 
nurse) gestalt and with NEWS as the currently mandated standard of care. There 
must also be careful consideration as the score is applied of whether the outcomes 
used to develop definitions of urgency are still valid; the interventions listed at 
3.7.3b were acknowledged at the time to be based on incomplete evidence; it is to 
be hoped that as the evidence base for emergency care is developed these can be 
refined (for example, intravenous magnesium in acute severe asthma would no 
longer be considered a potentially life-saving intervention (138)).
This leaves the working emergency clinician in the situation of not having a score 
developed for and demonstrated to work in the emergency setting. He or she has a 
number of options: firstly to use one of the existing scores (of which NEWS is 
probably the most appropriate) but to recognise its limitations in the emergency 
department; secondly not to use a score but to rely on the unstructured judgement 
of clinical staff. In the current politicomanagerial climate of high regard for 
standardised paperwork easily amenable to retrospective audit this is unlikely to be 
managerially palatable, despite the lack of supporting evidence.  Given the current 
state of equipoise over the utility of standardised scores in terms of patient benefit 
in the ED clinicians should also be encouraged to participate in formal research to 
address the issue.
These results highlight the potential flaws in applying clinical scores to predict 
outcomes other than those for which they were originally derived.  It is clear that in 
this data set variables which predict death are not the same as those which predict 
life-saving intervention, similar to the findings of Churpek et al, who found that 
amongst 291 deaths and 2638 emergency admissions to critical care from general 
wards, patterns of vital sign derangement differed (133). As the health economist 
Tony Culyer said “capacity to benefit is not identical to need” (139), and clinicians 
should be clear about the reasons for which a score is being used. 
The importance of appropriate choice of outcomes is also relevant where acuity 
scores are used at an organisational level. If a scoring system is used during a 
process of  casemix adjustment in an attempt to assess or improve quality, it should 
be clear that it identifies conditions and outcomes which are amenable to alteration 
with good care (132).  The small proportion of deaths deemed to be potentially 
preventable in this data set calls into question the practice of using mortality rates 
(even if standardised) to identify apparent extremes of organisational performance, 
due to an inappropriate signal to noise ratio, which has been modelled elsewhere 
(140).
The logistical issues encountered during this study highlight the need for the 
development of an agreed minimum data set for emergency care to enable more 
indepth analysis of care provided and its usefulness. Currently it is labour-intensive, 
if not impossible, to identify fundamental aspects of care provided (such as fluids 
and drugs administered), and diagnoses made and excluded. The College of 
Emergency Medicine Informatics Group has recognised this and is working on a 
minimum data set to demonstrate the “added value” of ED care.
Far more patients were deemed to have benefited from life-saving treatment than 
to have died, with 114 patients identified where death was potentially prevented 
versus 23 who died.  Despite our liberal definition of potentially preventable death 
(any death where end of life care or “do not attempt resuscitation” was not 
specified within 24 hours of admission), only around 1 in 4 deaths (6 of 23) met our 
criteria for potential preventability.  Although higher than previously reported 
“preventable deaths”, deemed to be around 5% of all deaths in a larger UK cohort 
(141), this is still low and supports concerns about the use of mortality rates, 
however well standardised, as indicators of quality of care.
9.7 Implications for research
The variables we have identified as predictive of a need for life-saving intervention 
are not the same as those in use in many standardized early warning scores; this 
may well reflect the difficulty of using data sets which have been collected using 
death as an outcome.  We used a single snapshot set of physiological data; it has 
been demonstrated in the acute medicine setting that changes in physiological 
scores are of value in prognostication (142); ideally ongoing research would 
examine the prognostic value of response (or non-response) to treatment provided 
prehospitally or in the Emergency Department.  Even a score developed to predict 
response to life-saving intervention does not perform more than adequately; it is 
likely that this outcome represents a heterogenous group of patients and this 
complexity should be recognised and explored in the ED setting.
Clearly identification of and response to the patient at risk requires more than a 
reliable scoring system; complex psychosocial and cognitive factors are at play in 
decision-making, particularly in the pressured environment of the ED (143), and 
examination of the interaction of these factors should be a priority for future 
research (144) .
The first issue requires a larger multisite cohort study with prospective data 
collection, including clinician gestalt from prehospital, nursing and medical staff. 
This would currently be very resource-intensive in terms of collecting outcome data 
due to the lack of an integrated robust patient record system in many hospitals. 
However it is likely to become more feasible as health information technology 
continues to develop.
The second and third issues could be addressed with a programme of research 
conceptualising assessment and response to risk in the ED patient as a complex 
intervention (145) and described in more detail below.
9.7.1 Development of a consensus regarding factors which should affect 
prioritisation in emergency care.
Patient-only focus groups would enable patients to contribute factors they feel are 
relevant to patient prioritisation without contamination from professional 
participants.  
Discrete choice experimental technique formally addresses the issue of multiple 
potentially conflicting criteria (146) and is well established as a means of eliciting 
patient preferences (147). It has been used successfully to assess features of an 
emergency primary care service of importance to patients (148). For example, the 
respondent might be asked “Of 2 patients, one with severe pain but no risk of 
death, and the other with mild pain but a high risk of death, who should be treated 
first?”.  A pair of experiments, one recruiting members of the public and the other 
recruiting healthcare professionals working in UK EDs could explore similarities and 
differences between public and professionals in the prioritisation of patients in the 
ED. 
9.7.2 Literature review to identify time-critical interventions
Once data on care provided in UK EDs can be collected from evolving IT systems, 
the most-frequently provided interventions could be the subject of a systematic 
literature review to examine the strength of the evidence base for the effectiveness 
and time-dependent benefit of these interventions. 
9.7.3 Qualitative study of staff attitudes and behaviour
Face-to-face interviews and observational study along ethnographic principles could 
explore particularly attitudes to and constructs of patient prioritisation and how this 
relates to time-dependence of treatments.  They would need to include staff across 
all professional groups in the ED (including medical and nursing staff from other 
specialities providing care and assessment within the ED). These staff would need 
be selected to represent professional attributes which might feasibly influence 
attitudes to patient risk (profession, specialty, grade and length of time in post) and 
EDs studied would need to be diverse in terms of size, training status and specialist 
services (such as trauma centre status, hyperacute stroke services). 
9.7.4 Design and piloting of a toolkit
A toolkit might potentially include a scoring system, presentation-specific "red flag" 
reminders, or flowcharts. Based on findings from the earlier stages of the 
programme, it might include paper-based, website or app-based components, or 
parts may be integrated into an electronic patient record. It is likely to be designed 
to be used multiple times during the patient's ED stay, unlike current triage tools 
which are only used at initial presentation. 
Piloting could involve toolkit implementation at several sites at varying times in a 
stepped wedge design to mitigate against external confounders such as central 
targets or initiatives. Outcomes should include:
 Observational study as conducted before the intervention
 Process measures of time-critical interventions identified earlier (for 
example antibiotics in sepsis).
 Other markers of healthcare resource use, such as the avoidable admission 
rate as developed by O'Cathain et al (149), which reflects the proportion of 
patients who present to acute hospitals with specific conditions who are 
then admitted to inpatient care. The conditions have previously been 
identified as those being amenable to ambulatory care (ie where admission 
might potentially be avoided).
 Critical incident reports generated within and relating to the ED which 
reflect issues around patient risk assessment or communication (for example 
a patient arriving on a general ward then requiring early transfer to a high 
dependency area), or prioritisation (for example delays in transfer to an 
operating theatre). Incident reporting can provide insight into both 
organizational culture and staff perceptions of risk and causation (150).
9.7.5 Formal trial of toolkit
Should the pilot trial demonstrate feasibility of implementing the toolkit, further 
research would require multicentre analysis of its effectiveness in improving 
patient-centred outcomes.
9.8 Summary
 No previously published tool has been developed and validated which addresses 
identification of the patient at risk of adverse outcome from the unselected ED 
population.
 Mixed, often conflicting, evidence exists for the prognostic value of multiple 
physiological variables in different patient sets.
 It cannot be assumed that the implementation of early warning scores suitable 
for inpatient areas of the hospital will benefit ED patients.
 Further research is required, ideally with a standardised minimum data set, to 
address the limitations of this study, particularly which patients will benefit from 
time-critical interventions.
Appendix 1
Decision aids for undifferentiated patient populations
The Bispebjerg Early Warning Score (BEWS) was developed in Denmark and involves a two-
step nursing assessment; initially immediately life-threatening conditions such as 
uncontrolled haemorrhage or respiratory arrest are identified.  If the patient does not have  
any of these a vital signs assessment is used to calculate the BEWS and a score of over 4 
triggers an emergency call (87).
Bispebjerg Early Warning Score
3 2 1 0 1 2 3
Respiratory 
rate
- ≤8 - 9-14 15-20 21-30 >30
Heart rate - ≤40 41-50 51-100 101-110 111-130 >130
SBP ≤70 71-80 81-100 101-
199
- >199 -
Temperature - ≤35 35.1-
36
36.1-38 38.1-39 >39 -
Level of 
consciousnes
s
- - - Awake Respond
s to voice
Respond
s to pain
Unresponsive
The Hillerød Acute Triage (HAPT) system (88) identifies high risk patients according to 
standardised vital signs monitoring and presentation-specific high risk criteria. Where the 
two are discordant, the patient is considered to be in the higher risk category.
Hillerød Acute Triage (HAPT) system
1 Red
Resuscitation 
2 Orange 
Urgent 
3 Yellow 
Less urgent 
4 Green 
Not urgent 
Vital signs
A Obstructed 
airway
Stridor
Threatened 
airway
B SpO2 <80
RR >35 or <8
SpO2 80-89
RR 31-35
SpO2 90-94
RR 26-30
SpO2 ≥95
RR 8-25
C HR >130
SBP <80
HR 121-30 or <40
SBP 80-89
HR 111-120 or 
40-49
HR 50-110
D GCS ≤8 GCS 9-13 GCS 14 GCS 15
E Temp >40 or <32 Temp 38.1-40 or 
32-34
Temp 34-38
Presentation-specific
ECG changes Lifethreatening High risk Low risk Minor/normal
Ongoing chest 
pain
Very severe 
(VAS 10)
Severe (VAS 6-9) Moderate 
(VAS 1-5)
No pain
Chest pain in 
last 24 hours
Ischaemic type Non-ischaemic 
type
Dyspnoea on 
exertion
Very severe Severe None
Severe 
comorbidity
Yes No
The HOTEL score was developed in Ireland to predict early mortality amongst acute medical 
patients.  It allocates a point for each of Hypotension (SBP<100mmHg), low Oxygen 
saturation (<90%), Temperature (<35C), abnormal ECG and Loss of ability to stand unaided 
(89).
PREEMPT-2 was developed in Scotland as a response to the loss of ICU provision at one 
hospital site and the subsequent need to triage patients for transfer (90).
PREEMPT-2 = 0.39713 + f1(x1) + f2 (x2) + f3(x3) + f4(x4) + f5(x5) + f6(x6) +f7(x7), where:
x1 = age f1(x1) = 15.03253 x (x1/100)2 – 19.37260 x (x1/100)3
x2 = respiratory 
rate
f2(x2) = 123.31922 x (1/x2)2 + 19.29794 x (x2/100)3
x3 = SBP f3(x3) = - 0.335839 x x31/2 
x4 = AVPU f4(x4) = 1.60142 x (x4=V) + 1.90037 x (x4=P) + 3.15080 x (x4=U)
x5 = SpO2 f5(x5) = 1.90957 x (100/x5)2
x6 = PaCO2 f6(x6) = 0.76629 x (x6/10)3
x7 = H+ f7(x7) = - 95.22595 x (1/x7)
The Rapid Emergency Medicine Score is a modification of the Intensive Care APACHE II 
score (64) designed to be calculable in the Emergency Department (91).
Rapid Emergency Medicine Score
0 1 2 3 4
Temperature 36-38.4 38.5-38.9
34-35.9
32-33.9 39-40.9
30-31.9
>40.9
<30
MAP 70-109 - 110-129
50-69
130-159 >159
<49
Heart rate 70-109 - 110-139
55-69
140-179
40-54
>179
<39
Respiratory rate 12-24 25-34
10-11
6-9 35-49 >49
<6
Peripheral oxygen 
saturation
>89 86-89 75-85 <75
GCS >13 11-13 8-10 5-7 3-5
The Simple Clinical Score was based on a large cohort from a small rural Irish hospital and 
designed specifically to include only variables immediately available or discernible at 
presentation (92).
Simple Clinical Score
Age
≥50 (men) ≥55 (women) 2
>75 (men and women) 4
SBP
81-100 2
71-80 3
<70 4
Pulse rate > SBP 2
Temperature <35 or ≥39 2
Respiratory rate
21-30 1
>30 2
Oxygen saturation
90-94 1
<90 2
Breathless on presentation 1
Abnormal ECG 2
Diabetes (type I or II) 1
Coma without intoxication or overdose 4
Altered mental status without coma, intoxication or overdose and aged >49y 2
New stroke 3
Unable to stand unaided, or nursing home resident 2
Prior to current illness, spent some part of daytime in bed 2
The South African triage score was developed to address the combined issues of ED 
overcrowding and a high population burden of chronic disease. It combines a physiological 
score (TEWS) with specific discriminator features (93). 
South African Triage Score physiological score (TEWS)
0 1 2 3
Mobility Walking With help Stretcher 
/immobile
RR 9-14 15-20 <9
21-29
>30
HR 51-100 41-50
101-110
<41
111-129
>129
SBP 101-199 81-100 71-80
>199
<71
Temperature 35-38.4 COLD or <35
HOT or >38.4
AVPU Alert Voice Pain
Confused
Unresponsive
Trauma No Yes
South African Triage Score discriminator features
Red Orange Yellow Green
TEWS 7 or more 5-6 3-4 <3
Target time to 
treat
Immediate <10 min <60 min <4 hours
Mechanism of 
injury
High energy transfer All other 
patients
Presentation Acute shortness of 
breath
Coughing blood
Chest pain
Uncontrolled 
haemorrhage
Controlled 
haemorrhage
Current seizure Postictal
Acute focal 
neurology
Reduced 
consciousness
Psychosis/aggression
Threatened limb
Dislocation – other Dislocation – 
finger or toe
Fracture – 
compound
Fracture – 
closed
Burn – face / 
inhalational
Burn over 20%
Burn – electrical
Burn – 
circumferential
Burn – chemical
Poisoning/overdose
Glucose <3 Glucose >11 and 
ketonuria
Glucose >17 
(no ketonuria)
Vomiting – fresh 
blood
Vomiting – 
persistent
Pregnancy – 
abdominal 
trauma/pain
Pregnancy – 
trauma
Pregnancy – PV 
bleed
Pain Severe Moderate Mild
The Cape Triage Score also uses TEWS, with slightly different discriminators (94). 
Cape Triage Score discriminators
Red Orange Yellow Green
TEWS 8 or more 6-7 3-5 2 or less
Mechanism of 
injury
Entrapment Impact – high Impact – low
Pain Severe Moderate Mild
Respiratory Asthma – status Asthma
Cardiac Chest pain
Vascular Arterial 
haemorrhage
Neurological Current seizure Postictal
Unresponsive Responds to pain Responds to 
voice
Alert
Psychiatric Psychosis/aggression
Orthopaedic Threatened limb
Dislocation – major 
joint
Dislocation – 
minor joint
Fracture – open Fracture – 
closed
Burn Face/inhalation >20% Minor
Metabolic Glucose <2.2 Overdose/poisoning
Intestinal Haematemesis Abdominal 
pain
Obstetric Pregnancy – trauma Pregnancy – 
PV bleed
Anatomy Airway trauma Head/neck/torso/ 
evisceration trauma
Limb trauma
The Sun score (95) predicts the likelihood of hospital admission at the point of ED triage, 
using an equation including age, racial group, acuity as allocated in an unstructured manner 
by the triage nurse (PAC), and past history or comorbidities.  The natural log of p/1-p 
(where p is probability of admission) is calculated using a constant of -2.903 and scores as 
below. Of note it was developed in Singapore, so the risks related to racial group are 
probably not generalisable to UK practice.
Sun score
Age group
<15 -1.698
15-24 -0.453
35-44 0.233
45-54 0.423
55-64 0.580
65-74 0.921
75-84 1.280
>84 1.662
Racial group
Malay -0.127
Indian 0.091
Other 0.028
Arrival by ambulance 0.537
PAC group
1 3.007
2 1.488
Prior ED visit 3 months 0.220
Prior hospital admission 3 months 0.360
Chronic conditions
Diabetes only 0.760
Hypertension only 0.383
Dyslipidaemia only 0.633
Diabetes and hypertension 0.979
Diabetes, hypertension and dyslipidaemia 0.965
Diabetes and dyslipidaemia 0.719
Dyslipidaemia and hypertension 0.642
The Vital Signs Score was developed in Bern to be applied at ED presentation and involves 
summation of seven parameters derived from Medical Emergency Team calling criteria 
(96).
Vital Signs Score
Airway - threatened Need for intratracheal suctioning, oro or nasopharyngeal 
tubes, intubation, bronchoscopy.
Breathing – respiratory rate <6/min or >36/min
Breathing – SaO2 <90% despite supplemental oxygen
Circulation – SBP <90mmHg
Circulation – heart rate <40/min or >140/min
Neurology – GCS <13
Neurology – seizures Repeated or prolonged (>5 min)
The VitalPACTM EWS (ViEWS) was developed in Portsmouth from a large database of 
computerised vital signs recordings on a medical assessment unit and has since formed the 
basis for the RCP-approved National Early Warning Score (97).
VitalPACTM EWS (ViEWS)
0 1 2 3
Pulse 51-90 41-50
91-110
<41
111-120
>120
Breathing rate 12-20 9-11 21-24 <9
>24
Temperature 36.1-38 35.1-36
38.1-39
>39 <35.1
SBP 111-249 101-110
>249
91-100 <91
SaO2 >95 94-95 92-93 <92
Inspired O2 Air Any O2
AVPU Alert Any other
Appendix 2 Existing clinical decision aids for specific patient populations
Abdominal aortic aneurysm
APACHE II
Lazarides 1997 (151) External validation 40 patients in theatre for repair of 
ruptured infrarenal AAA
Hospital mortality Mean APACHE II for 
mortality 14.5 (SD 5.1) vs 
11.3 (SD 3.6) p=0.02
Edinburgh aneurysm score
Tambyraja 2007 (152) Derivation 105 patients undergoing repair of 
ruptured AAA
Hospital mortality Score 0-1 29%, score 2 50%, 
score 3 80%
Tambyraja 2008 (153) External validation 84 patients undergoing repair of 
ruptured AAA
Hospital or 30-day mortality AUROC 0.72 (0.61-0.83)
Glasgow aneurysm score
Tambyraja 2005 (154) External validation 82 patients undergoing repair of 
ruptured AAA
Hospital mortality AUROC 0.606 (0.483-0.729)
Leo 2006 (155) External validation 114 patients undergoing repair of 
ruptured AAA
“Immediate” post-operative 
mortality
AUROC  0.906 (0.85-0.962)
Tambyraja 2008 (153) External validation 84 patients undergoing repair of 
ruptured AAA
Hospital or 30-day mortality AUROC 0.64 (0.52-0.76)
Hardman score
Prance 1999 (156) External validation 69 patients undergoing repair of 
ruptured AAA
Hospital mortality Score 0 18%, score 1 28%, 
score 2 48%, score 3 100%
Neary 2003 (157) External validation 188 patients undergoing repair of 
ruptured AAA
Hospital mortality Score 0 35%, score 1 55%, 
score 2 74%, score 3 90%
Calderwood 2004 (158) External validation 137 patients undergoing repair of 
ruptured AAA
Hospital mortality Score 0 40%, score 1 46%, 
score 2 77%, score 3 92%, 
score 4 100%
Tambyraja 2005 (154) External validation 82 patients undergoing repair of 
ruptured AAA
Hospital mortality Score 0 15%, score 1 55%, 
score 2 38%, score >2 33% 
p=0.211
Leo 2006 (155) External validation 114 patients undergoing repair of 
ruptured AAA
“Immediate” post-operative 
mortality
AUROC 0.834 (0.759-0.91)
Sharif 2007 (159) External validation 52 patients undergoing EVAR for 
ruptured AAA
Hospital mortality Score 0 15%, score 1 27%, 
score 2 50%, score 3/4 66%
74 patients undergoing open repair of 
ruptured AAA
Score 0 41%, score 1 46%, 
score 2 61%, score 3/4 70%
Karkos 2008 (160) External validation 41 patients undergoing EVAR for 
ruptured AAA
30-day mortality Χ2 for trend p=0.02
Tambyraja 2008 (153) External validation 84 patients undergoing repair of 
ruptured AAA
Hospital or 30-day mortality AUROC 0.69 (0.57-0.8)
Hardman score (modified)
Calderwood 2004 (158) Derivation 137 patients undergoing repair of 
ruptured AAA
Hospital mortality Score 0 22%, score 1 47%, 
score 2 67%, score 3 84%, 
score 4 100%
POSSUM
Lazarides 1997 (151) External validation 40 patients in theatre for repair of 
ruptured infrarenal AAA
Hospital mortality Mean POSSUM for mortality 
66.5 (SD 7.2) vs 63.3 (SD 7.6) 
p=0.18
RAAA-POSSUM
Neary 2003 (157) External validation 188 patients undergoing repair of 
ruptured AAA
Hospital mortality X2 for trend p<0.001
AAA: Abdominal aortic aneurysm; EVAR: endovascular aneurysm repair
Acute coronary syndrome (suspected or confirmed)
Acute physiology score (APS)
Moreau 1989 (161) External validation 76 patients admitted to hospital 
with AMI
Hospital mortality AUROC 0.749 +/- 0.075
APACHE II
Moreau 1989 (161) External validation 76 patients admitted to hospital 
with AMI
Hospital mortality AUROC 0.823 +/- 0.067
Alemi 1990 (162) External validation 775 patients hospitalised with 
AMI
Hospital mortality AUROC 0.7
Australia/New Zealand
Macdonald 2011 (163) External validation 1714 ED patients with potential 
ACS having troponin sampling
30-day MACE AUROC 0.82 (0.8-0.84)
Bazzino
Bazzino 1999 (164) Derivation 1038 patients hospitalised with 
unstable angina
Hospital mortality or AMI 
(pre-troponin definition)
AUROC 0.59 +/- 0.03
Chang score
Chang 2006 (165) Derivation
Secondary analysis of RCT
6066 patients hospitalised with 
STEMI
30-day mortality AUROC 0.8 (0.77-0.82)
Cheshire Merseyside and North Wales score
Rawlings 2012 (166) External validation 104 patients hospitalised with 
NSTEACS
30-day mortality AUROC 0.845
Coronary prognostic index
Moreau 1989 (161) External validation 76 patients admitted to hospital 
with AMI
Hospital mortality AUROC 0.816 +/- 0.068
EMMACE
Gale 2009 (167) External validation
National registry
100686 patients hospitalised 
with ACS (including STEMI)
30-day mortality AUROC 0.78 (0.77-0.78)
Freedom-from-event score
Brieger 2009 (168) Derivation
International registry
16127 patients admitted for 24h 
with ECG change, biomarker 
change or previous coronary 
artery disease
Hospital mortality or 
heart failure, shock, AF, 
VF, cardiac arrest, VT, 
MI, stroke, major bleed
AUROC 0.77
Validation
International registry
6820 patients admitted for 24h 
with ECG change, biomarker 
change or previous coronary 
artery disease
AUROC 0.77
Soderholm 2012 (169) External validation 559 ED patients admitted with 
suspicion of ACS
Inpatient complications AUROC 0.69 (0.6-0.79)
Get with the guidelines score
Chin 2011 (170) Derivation
National registry
65668 patients admitted with 
STEMI or STEMI
Hospital mortality AUROC 0.85 (0.8-0.9)
Internal validation
National registry
16336 patients admitted with 
STEMI or STEMI
AUROC 0.84
Goldman index
Goldman 1996 (171) Derivation 10682 patients presenting to ED 
with chest pain unexplained by 
trauma or CXR
VF, cardiac arrest, 
complete heart block, 
PPM, emergency 
cardioversion, shock, 
IABP, ETT, CABG/PTCA 
predischarge
AUROC 0.82
Temporal validation 4676 patients presenting to ED 
with chest pain unexplained by 
trauma or CXR
AUROC 0.80
Durairaj 2001 (172) External validation 1061 patients with ACS admitted 
to inpatient telemetry
Major complication (VF, 
cardiac arrest, new 
complete AV block, 
temporary PPM, 
emergency 
cardioversion, shock, 
IABP, ETT, CABG or PCI)
NPV for very low risk with 
chest pain 1 (0.988-1) and 
without chest pain 0.995 
(0.974-0.999)
Limkakeng 2001 (173) External validation 998 ED patients with chest pain 
prompting ECG
30-day MACE Goldman >4% sens 0.54 
(0.47-0.6) spec 0.74 (0.72-
0.76) PPV 0.16 (0.13-0.19) 
NPV 0.95 (0.94-0.96)
Hollander 2004 (174) External validation 1029 patients with ACS admitted 
to telemetry beds
Mortality preventable by 
monitoring or VF/VT 
requiring treatment
Goldman risk <8%, no 
outcomes of interest (CI 0-
3%)
Manini 2009 (175) External validation
Secondary analysis of diagnostic 
study
148 ED patients with chest pain 
and non-diagnostic ECG
Hospital diagnosis of ACS High or intermediate risk 
sensitivity 0.53 (0.29-0.77) 
specificity 0.72 (0.64-0.79) 
PPV 0.2 (0.08-0.31) 
NPV 0.92 (0.87-0.97)
Soderholm 2012 (169) External validation 559 ED patients admitted with 
suspicion of ACS
Inpatient complications AUROC 0.6 (0.49-0.72)
GRACE
de Araujo Goncales 2002 
(176)
External validation 460 hospitalised patients with 
NSTEACS
30-day mortality or AMI AUROC 0.672 (0.627-0.714)
Yan 2004 (177) External validation
National registry
2925 patients hospitalised with 
NSTEACS
Hospital mortality AUROC 0.83 (0.77-0.89)
Rahimi 2006 (178) External validation 558 patients hospitalised with 
NSTEMI
Hospital mortality AUROC 0.578 (0.457-0.699)
Malignant arrhythmia AUROC 0.573 (0.444–0.701)
Lyon 2007 (179) External validation 1000 ED patients with NSTEACS 30-day MACE AUROC 0.8 (0.75-0.85)
Sinclair 2007 (180) External validation 149 patients hospitalised with 
chest pain and biomarker or ECG 
change or history of coronary 
artery disease
Hospital complications Recurrent ACS p<0.05, 
arrhythmia p<0.02, CCF 
p<0.02, PCI p<0.05
Yan 2007 (181) External validation
National registry
1728 patients hospitalised with 
NSTEACS
Hospital mortality AUROC 0.81 (0.73-0.89)
Lev 2008 (182) External validation 855 patients with STEMI 
undergoing PCI
30-day MACE AUROC 0.544
30-day mortality AUROC 0.471
Elbarouni 2009 (183) Temporal validation
International registry
11118 patients hospitalised with 
NSTEACS
Hospital mortality AUROC 0.842 (0.823-0.861)
Gale 2009 (167) External validation
National registry
85771 patients hospitalised with 
ACS (including STEMI)
Hospital mortality AUROC 0.8 (0.8-0.81)
Goodacre 2011 (184) External validation 1772 ED patients with chest pain  
in previous 12 hours without ECG 
30-day MACE AUROC 0.722
change or high-risk coronary 
artery disease
Goodacre 2012 (185) External validation 2243 ED patients with chest pain  
in previous 12 hours without ECG 
change or high-risk coronary 
artery disease
30-day MACE AUROC 0.717 (0.698-0.735)
Soderholm 2012 (169) External validation 559 ED patients admitted with 
suspicion of ACS
Inpatient complications AUROC 0.76 (0.65-0.85)
Hasdai
Hasdai 2000 (68) Derivation
Secondary analysis of RCT
38942 patients thrombolysed for 
STEMI
Development of 
cardiogenic shock
AUROC 0.761
Validation
Secondary analysis of RCT
14960 patients thrombolysed for 
STEMI
AUROC 0.796
IDHI
Alemi 1990 (162) External validation 775 patients hospitalised with 
AMI
Hospital mortality AUROC 0.69
Mayo score
Williams 2006 (67) Derivation
Hospital registry
809 patients hospitalised with 
AMI (including STEMI)
30-day mortality AUROC 0.81
Internal validation
Hospital registry
403 patients hospitalised with 
AMI (including STEMI)
AUROC 0.79
MINAP
Gale 2008 (186) Derivation
National registry
34722 patients hospitalised with 
STEMI
Hospital mortality AUROC 0.8 (0.79-0.8)
Normand
Normand 1996 (187) Derivation 10936 patients hospitalised with 
ACS (including STEMI)
30-day mortality AUROC 0.79
Internal validation 3645 patients hospitalised with 
ACS (including STEMI)
AUROC 0.78
North American Chest Pain Rule
Hess 2012 (188) Derivation 2718 ED patients with chest pain 
and possible ACS
30-day MACE Sensitivity 100 (97.2-100), 
specificity 20.9 (16.9-24.9) if 
using a cutoff of 50y
PAMI
Lev 2008 (182) External validation 855 patients with STEMI 
undergoing PCI
30-day MACE AUROC 0.65
30-day mortality AUROC 0.742
PIMI
Alemi 1990 (162) External validation 775 patients hospitalised with 
AMI
Hospital mortality AUROC 0.44
PREDICT
Rahimi 2006 (178) External validation 558 patients hospitalised with 
NSTEMI
Hospital mortality AUROC 0.829 (0.744-0.914)
Malignant arrhythmia AUROC 0.531 (0.366–0.697)
PURSUIT
Boersma 2000 (189) Derivation
Secondary analysis of RCT
9461 hospitalised patients with 
NSTEACS
30-day mortality AUROC 0.814
30-day mortality or 
reinfarct
AUROC 0.669
de Araujo Goncales 2002 
(176)
External validation 460 hospitalised patients with 
NSTEACS
30-day mortality or AMI AUROC 0.615 (0.569-0.660)
Brilakis 2003 (190) External validation 337 patients admitted to 
coronary care with NSTEMI
30-day mortality AUROC 0.78
Yan 2004 (177) External validation
National registry
2925 patients hospitalised with 
NSTEACS
Hospital mortality AUROC 0.84 (0.79-0.89)
Rahimi 2006 (178) External validation 558 patients hospitalised with 
NSTEMI
Hospital mortality AUROC 0.86 (0.778-0.942)
Malignant arrhythmia AUROC 0.523 (0.358–0.688)
Yan 2007 (181) External validation
National registry
1728 patients hospitalised with 
NSTEACS
Hospital mortality AUROC 0.8 (0.71-0.88)
Gale 2009 (167) External validation
National registry
49995 hospitalised patients with 
NSTEACS
30-day mortality AUROC 0.79 (0.78-0.8)
Sanchis
Manini 2009 (175) External validation 148 ED patients with chest pain Hospital diagnosis of ACS Sanchis >1 
Secondary analysis of diagnostic 
study
and non-diagnostic ECG sensitivity 0.41 (0.18-0.65) 
specificity 0.86 (0.8-0.92) 
PPV 0.28 (0.1-0.46) 
NPV 0.92 (0.87-0.97)
SAPS
Moreau 1989 (161) External validation 76 patients admitted to hospital 
with AMI
Hospital mortality AUROC 0.869 +/- 0.059
Selker
Selker 1991 (191) Derivation 4099 patients aged >29 (men) or 
>39 (women) hospitalised with 
potential ACS
Hospital mortality AUROC 0.82
Split sample validation 1387 patients aged >29 (men) or 
>39 (women) hospitalised with 
potential ACS
AUROC 0.85
Simple risk index
Rathore 2003 (192) External validation 49711 patients age >65 with 
STEMI
30-day mortality AUROC 0.62
Das 2006 (193) External validation
Registry data
2153 patients hospitalised with 
AMI (NSTEMI or STEMI)
30-day mortality AUROC 0.77 (0.74-0.79)
AUROC in STEMI subset 0.76 
(0.72-0.8) 
Gale 2009 (167) External validation
National registry
100686 patients hospitalised 
with ACS (including STEMI)
30-day mortality AUROC 0.79 (0.78-0.8)
TIMI risk index
Wiviott 2004 (194) External validation
National registry
153486 patients hospitalised 
with STEMI
Hospital mortality AUROC 0.79
Ilkhanoff 2005 (195) External validation 719 patients hospitalised with 
suspected ACS
30-day mortality AUROC 0.79
Bradshaw 2007 (196) External validation
Secondary analysis of RCT
10487 hospitalised patients with 
AMI (NSTEMI or STEMI) 
excluding patients with overt 
shock
30-day mortality AUROC 0.81 (0.79-0.82)
Garcia-Almagro 2008 External validation 661 ED patients with potential 1-month MACE HR per unit increase 1.3 (1.0-
(197) ACS 1.6) p=0.007
TIMI score NSTEMI
Antman 2000 (66) Derivation
Secondary analysis of RCT
1953 patients with ACS including 
ST changes or raised biomarkers
14-day mortality AUROC 0.74
14-day mortality or AMI AUROC 0.63
AMI in 14 days AUROC 0.66
Urgent revascularisation 
in 14 days
AUROC 0.68
Samaha 2002 (198) External validation
Secondary analysis of RCT
919 patients with NSTEMI 30-day MACE AUROC 0.59 (0.63 for RIP, 
0.61 for AMI)
de Araujo Goncales 2002 
(176)
External validation 460 hospitalised patients with 
NSTEACS
30-day mortality or AMI AUROC 0.551 (0.504-0.597)
Foussas 2005 (199) External validation 985 hospitalised patients with 
NSTEACS
14-day mortality, AMI or 
recurrent ischaemia
Score 1-2 9%, score 3 16.5%, 
score 4 21.5%, score 5 26.7%, 
score 6-7 36.6% p for trend 
<0.001
Conway Morris 2006 
(200)
External validation 954 ED patients with ACS 30-day MACE AUROC 0.79 (0.75-0.84)
Pollack 2006 (201) External validation 3929 ED patients with chest pain 
prompting ECG
30-day MACE Chi-square p<0.001
Rahimi 2006 (178) External validation 558 patients hospitalised with 
NSTEMI
Hospital mortality AUROC 0.638 (0.515-0.760)
Malignant arrhythmia AUROC 0.486 (0.328–0.645)
Soiza 2006 (202) External validation 834 patients hospitalised with 
ACS (including STEMI) or 
potential ACS
Hospital mortality, AMI 
or revascularisation
Chi-square for trend p<0.001
Chase 2007 (203) External validation 238 patients with chest pain 
within 1 week of cocaine use
30-day mortality, AMI or 
revascularisation
TIMI 0, 3.7% (1-8.3), 
TIMI I 13.2% (5.7-20.7), 
TIMI 2 17.1% (4.3-29.8), TIMI 
3 21.4% (4.4-38.4), TIMI 4 
20.0% (0.1-43.6), TIMI 5/6 
50.0% (0.1-100)
Jaffery 2007 (204) External validation 947 ED patients with potentially 
cardiac chest pain
30-day MACE TIMI >2 sens 0.537 (0.449-
0.623) spec 0.752 (0.721-
0.782) PPV 0.266 (0.215-
0.323) NPV 0.906 (0.882-
0.927)
Karounos 2007 (205) External validation 2022 ED patients age >30 with 
chest pain prompting ECG
30-day MACE p<0.001 for trend
Lyon 2007 (179) External validation 1000 ED patients with NSTEACS 30-day MACE AUROC 0.79 (0.74-0.85)
Yan 2007 (181) External validation
National registry
1728 patients hospitalised with 
NSTEACS
Hospital mortality AUROC 0.68 (0.59-0.77)
Body 2009 (206) External validation 796 ED patients with NSTEACS 30-day MACE AUROC 0.77 (0.73-0.8)
Campbell 2009 (207) External validation 3169 ED patients with chest pain 
prompting ECG
30-day MACE TIMI <2 RR 0.21 (0.18-0.31)
Manini 2009 (175) External validation
Secondary analysis of diagnostic 
study
148 ED patients with chest pain 
and non-diagnostic ECG
Hospital diagnosis of ACS TIMI >2 
sensitivity 0.35 (0.13-0.58) 
specificity 0.85 (0.79-0.91) 
PPV 0.23 (0.07-0.39) 
NPV 0.91 (0.86-0.96)
Goodacre 2011 (184) External validation 1772 ED patients with chest pain  
in previous 12 hours without ECG 
change or high-risk coronary 
artery disease
30-day MACE AUROC 0.67
Macdonald 2011 (163) External validation 1714 ED patients with potential 
ACS having troponin sampling
30-day MACE AUROC 0.76 (0.73-0.79)
Goodacre 2012 (185) External validation 2243 ED patients with chest pain  
in previous 12 hours without ECG 
change or high-risk coronary 
artery disease
30-day MACE AUROC 0.682 (0.662-0.701)
Rawlings 2012 (166) External validation 104 patients hospitalised with 30-day mortality AUROC 0.67
NSTEACS
TIMI score STEMI
Morrow 2000 (208) Derivation
Secondary analysis of RCT
14114 patients with STEMI 30-day mortality AUROC 0.779
Validation
Secondary analysis of RCT
3687 patients with STEMI AUROC 0.746
Foussas 2005 (199) External validation 861 patients with STEMI 30-day mortality Score 0-1 3.3%, score 2-3 
7.4%, score 4-5 12%, score 
>5 25.6% p for trend <0.001
Lev 2008 (182) External validation 855 patients with STEMI 
undergoing PCI
30-day MACE AUROC 0.635
30-day mortality AUROC 0.724
Troponin prediction score
Januzzi 2006 (209) Derivation
Secondary analysis of RCT
769 patients with NSTEACS and 
negative troponin on 
presentation
Troponin rise at 12h AUROC 0.76
External validation
Secondary analysis of cohort
493 patients with NSTEACS and 
negative troponin on 
presentation
AUROC 0.73
AF: atrial fibrillation; AMI: acute myocardial infarction; CABG: coronary artery bypass grafting; ETT: endotracheal tube; IABP: intra-aortic 
balloon pump; MACE: major adverse cardiac event; NSTEACS: non-ST-elevation acute coronary syndrome; NSTEMI: non-ST-elevation acute 
myocardial infarction; PCI: percutanous coronary intervention; PPM: pacemaker; PTCA: percutaneous transluminal coronary angioplasty; 
STEMI: ST-elevation myocardial infarction; VF: ventricular fibrillation; VT: ventricular tachycardia
Asthma and COPD (chronic obstructive pulmonary disease)
BAP-65
Tabak 2009 (210) Derivation 43893 patients hospitalised with 
acute exacerbation of COPD
Hospital mortality AUROC 0.72 (0.7-0.74)
Secondary endpoint in derivation 
cohort
Need for mechanical 
ventilation
AUROC 0.77 (0.75-0.79)
Internal validation 44181 patients hospitalised with 
acute exacerbation of COPD
Hospital mortality AUROC 0.71 (0.7-0.73)
Need for mechanical 
ventilation
AUROC 0.77 (0.75-0.79)
Shorr 2011 (211) External validation 34669 patients admitted with 
acute exacerbation of COPD
Inpatient mortality AUROC 0.77 (0.76-0.78)
Need for invasive 
ventilation
AUROC 0.78 (0.78-0.79)
CHOP
Tsai 2010 (212) Derivation
Observational study
1824 ED patients age 18-54 with 
acute asthma
Hospitalisation AUROC 0.72
External validation
Observational study
1335 ED patients age 18-54 with 
acute asthma
AUROC 0.65
CURB-65
Chang 2011 (213) External validation 249 patients admitted with 
exacerbation of COPD
30-day mortality AUROC 0.7334
Steer 2012 (214) External validation 920 patients admitted with 
exacerbation of COPD
Hospital mortality AUROC 0.717 (0.66-0.77)
Extended MRC dyspnoea scale
Steer 2012 (214) External validation 920 patients admitted with 
exacerbation of COPD
Hospital mortality AUROC 0.794 (0.75-0.84)
National Asthma Guidelines
Kelly 2004 (215) External validation 831 ED patients with acute 
asthma
Hospitalisation At presentation 13% mild, 
57% moderate, 89% severe, 
At 1 hour 18% mild, 84% 
moderate, 86% severe
Rodrigo Index
Rodrigo 1997 (216) Derivation 184 ED patients age 18-50 with 
acute asthma
Hospitalisation AUROC 0.91
Temporal validation 91 ED patients age 18-50 with 
acute asthma
AUROC 0.9
GI bleed
Blatchford
Gralnek 2004 (217) External validation 175 inpatients undergoing OGD Rebleed requiring OGD, 
surgery or readmission
Blatchford 0 - no recurrence 
or mortality
Chen 2007 (218) External validation 354 patients undergoing OGD for 
non-variceal UGIB
Mortality Sensitivity 1 (0.44-1) 
specificity 0.08 (0.06-0.13) 
PPV 0.01 (0.003-0.03) 
NPV 1 (0.88-1)
Rebleed requiring OGD, 
surgery or readmission
Sensitivity 1 (0.86-1) 
specificity 0.09 (0.06-0.12)
PPV 0.07 (0.05-0.1)
NPV 1 (0.88-1)
Masaoka 2007 (219) External validation 93 patients undergoing 
emergency OGD
Transfusion, operative or 
endoscopic intervention
AUROC 0.628
Stanley 2009 (220) External validation 647 patients admitted for UGIB Mortality or need for 
intervention
AUROC 0.92 (0.9-0.94)
Chandra 2012 (221) External validation 171 ED patients with UGIB 30-day mortality or 
intervention
AUROC 0.79
Farooq 2012 (222) External validation 195 ED patients with UGIB Requirement for 
endoscopic therapy
Cutoff >0 sensitivity 100, 
specificity 4
Cutoff >5 sensitivity 87, 
specificity 33
Blatchford (modified)
Romagnuolo 2007 (223) External validation
Registry data
1869 patients undergoing OGD 
for non-variceal UGIB
High-risk stigmata at 
OGD
mBRS <2 OR 0.4 (0.3-0.6)
Rebleed or death before 
OGD
mBRS <2 5% vs 19% p<0.001
BLEED
Kolleff 1997 (224) External validation 465 patients admitted via ED 
with GI bleed
Mortality, recurrent 
bleed or need for surgery
AUROC 0.72
Bordley
Bordley 1985 (225) Derivation 110 inpatients with UGIB Mortality, urgent Low risk poor outcome 0/52, 
surgery, rebleed or 
complication
high risk 26/58
Retrospective validation 52 inpatients with UGIB Low risk poor outcome 0/22, 
high risk 8/30
Prospective validation 52 inpatients with UGIB Low risk poor outcome 2/52, 
high risk 29/59
Rockall
Church 2006 (226) External validation
Secondary analysis of trial
247 undergoing OGD for peptic 
ulcer with age>60, shock, 
comorbidity or haemoglobin<10
30-day rebleed AUROC 0.634
30-day mortality AUROC 0.843
Sarwar 2007 (227) External validation 402 patients admitted for UGIB Mortality AUROC 0.834
Rebleeding AUROC 0.798
Rockall (clinical element)
Sanders 2002 (228) External validation 162 inpatients undergoing OGD 
for bleeding peptic ulcer
Mortality 0/51 score <3 vs 5/30 score 3 
vs 7/41 score 4 vs 5/26 score 
5 vs 5/14 score 6 p=0.01
196 inpatients undergoing OGD 
for bleeding varices
7/131 score <4 vs 7/39 score 
4 vs 9/26 score 5 p<0.0005
Gralnek 2004 (217) External validation 175 inpatients undergoing OGD Rebleed requiring OGD, 
surgery or readmission
Clinical Rockall 0 - no 
recurrence or mortality
Chen 2007 (218) External validation 354 patients undergoing OGD for 
non-variceal UGIB
Mortality Sensitivity 1 (0.44-1) 
specificity 0.19 (0.15-0.23)
PPV 0.01 (0.004-0.03) 
NPV 1 (0.94-1)
Rebleed requiring OGD, 
surgery or readmission
Sensitivity 0.69 (0.49-0.84)
specificity 0.18 (0.14-0.22)
PPV 0.06 (0.03-0.09) 
NPV 0.89 (0.79-0.94)
Das 2008 (229) External validation 200 patients admitted for UGIB Need for OGD to control 
bleeding
AUROC 0.65 (0.56-0.74)
194 patients admitted for UGIB AUROC 0.53 (0.43-0.62)
Stanley 2009 (220) External validation 647 patients admitted for UGIB Mortality or need for 
intervention
AUROC 0.72 (0.68-0.76)
Chandra 2012 (221) External validation 171 ED patients with UGIB 30-day mortality or AUROC 0.62
intervention
Farooq 2012 (222) External validation 195 ED patients with UGIB Requirement for 
endoscopic therapy
Cutoff >0 sensitivity 95, 
specificity 9
Cutoff >2 sensitivity 84, 
specificity 29
Strate
Strate 2005 (230) Derivation 254 patients admitted for LGIB >2 unit blood 
transfusion, fall >20% 
haematocrit in 24h, 
recurrence after 24h
AUROC 0.761
Temporal validation 275 patients admitted for LGIB AUROC 0.754
LGIB: lower gastrointestinal bleed; OGD: oesophagogastroduodenoscopy; UGIB: upper gastrointestinal bleed
Heart failure
3CPO
Gray 2010 (121) Derivation
Secondary analysis of RCT
1069 patients admitted with 
acute cardiogenic pulmonary 
oedema
1-week mortality AUROC 0.794 (0.745-0.843)
3CPO (simplified)
Gray 2010 (121) Derivation
Secondary analysis of RCT
1069 patients admitted with 
acute cardiogenic pulmonary 
oedema
1-week mortality AUROC 0.754 (0.701-0.807)
ADHERE decision tree
Auble 2007 (231) External validation
State database
33533 patients admitted for 
heart failure
Inpatient mortality AUROC 0.68 (0.67-0.7)
Inpatient mortality or 
lifethreatening event
AUROC 0.58 (0.57-0.59)
ADHERE logistic regression
Auble 2007 (231) External validation
State database
33533 patients admitted for 
heart failure
Inpatient mortality AUROC 0.73 (0.72-0.75)
Inpatient mortality or 
lifethreatening event
AUROC 0.61 (0.6-0.62)
Brigham
Auble 2007 (231) External validation
State database
33533 patients admitted for 
heart failure
Inpatient mortality AUROC 0.61 (0.59-0.62)
Inpatient mortality or 
lifethreatening event
AUROC 0.61 (0.6-0.62)
EFFECT
Lee 2003 (232) Derivation
Secondary analysis of trial
2624 patients admitted for acute 
heart failure
30-day mortality AUROC 0.8
Internal validation
Secondary analysis of trial
1407 patients admitted for acute 
heart failure
AUROC 0.79
Auble 2007 (231) External validation
State database
33533 patients admitted for 
heart failure
Inpatient mortality AUROC 0.74 (0.72-0.75)
Inpatient mortality or 
lifethreatening event
AUROC 0.62 (0.61-0.63)
Get with the guidelines score
Peterson 2010 (233) Combined derivation and 
validation
39783 patients admitted for LVF Hospital mortality AUROC 0.75
Registry data
Le Conte
Le Conte 1999 (234) Derivation 186 patients admitted with acute 
pulmonary oedema
Hospital mortality Correct classification 89.8% 
NPV 98% PPV 41%
Pulmonary edema prognostic score
Fiutowski 2008 (235) Derivation 276 patients admitted with 
pulmonary oedema
Hospital mortality AUROC 0.78
Influenza
CAP
Muller 2010 (236) External validation 607 patients admitted with 
influenza A or B
Hospital mortality AUROC 0.65 (0.58–0.71)
ICU admission AUROC 0.65 (0.59–0.71)
CURB-65
Muller 2010 (236) External validation 607 patients admitted with 
influenza A or B
Hospital mortality AUROC 0.66 (0.60–0.72)
ICU admission AUROC 0.58 (0.52–0.64)
Mulrennan 2010 (237) External validation 35 ED patients with H1N1 ICU admission 82% ICU adm (9/11) had 
score 0 or 1
MEDS
Muller 2010 (236) External validation 607 patients admitted with 
influenza A or B
Hospital mortality AUROC 0.77 (0.71–0.83)
ICU admission AUROC 0.67 (0.61–0.73)
NHAP
Muller 2010 (236) External validation 607 patients admitted with 
influenza A or B
Hospital mortality AUROC 0.68 (0.62–0.74)
ICU admission AUROC 0.62 (0.57–0.68)
PMEWS
Muller 2010 (236) External validation 607 patients admitted with 
influenza A or B
Hospital mortality AUROC 0.68 (0.61–0.74)
ICU admission AUROC 0.63 (0.57–0.69)
Pneumonia Severity Index
Muller 2010 (236) External validation 607 patients admitted with 
influenza A or B
Hospital mortality AUROC 0.78 (0.72-0.83)
ICU admission AUROC 0.67 (0.61–0.73)
SMART-COP
Muller 2010 (236) External validation 607 patients admitted with 
influenza A or B
Hospital mortality AUROC 0.69 (0.62–0.75)
ICU admission AUROC 0.73 (0.67–0.79)
SOFA
Adenji 2011 (238) External validation 62 inpatients with H1N1 ICU admission AUROC 0.77 (.65-.89)
IPPV AUROC 0.87 (.72-1)
STSS
Muller 2010 (236) External validation 607 patients admitted with 
influenza A or B
Hospital mortality AUROC 0.71 (0.66–0.77)
ICU admission AUROC 0.63 (0.57–0.69)
Adenji 2011 (238) External validation 62 inpatients with H1N1 ICU admission AUROC 0.88 (.78-.98)
IPPV AUROC 0.91 (.83-.99)
Pancreatitis
APACHE II
Meek 2000 (239) External validation 92 patients admitted with 
gallstone pancreatitis
>24h ICU care APACHE II>4 sensitivity 0.67 
specificity 0.74 PPV 0.29 NPV 
0.94
Gan 2003 (240) External validation
Retrospective review
53 HIV +ve patients admitted 
with pancreatitis
Mortality, ICU, local 
complications or surgery
Sensitivity 1, specificity 0.7, 
PPV 0.41, NPV 1
Halonen 2003 (241) External validation 60 patients admitted with 
“severe” pancreatitis
Inpatient mortality AUROC 0.817 (0.702-0.931)
Gurleyik 2005 (242) External validation 55 patients admitted with 
pancreatitis
Atlanta severity APACHE II >=7 
Sensitivity 0.615 
Specificity 0.857 
PPV 0.571 NPV 0.878
Taylor 2005 (243) External validation
Retrospective chart review
49 patients admitted with 
pancreatitis
Over 5/7 ICU AUROC 0.55
Papachristou 2006 (244) External validation 102 patients admitted with 
pancreatitis
ICU, necrosis or mortality AUROC 0.893
Yeung 2006 (245) External validation 101 patients admitted with 
pancreatitis
Atlanta severity AUROC 0.904
Ueda 2007 (246) External validation 137 patients admitted with 
pancreatitis
Bacteraemia or infected 
pancreatic necrosis
AUROC 0.73
Renal/hepatic/lung 
dysfunction
AUROC 0.88
Mortality AUROC 0.81
Garcea 2008 (247) External validation 181 patients admitted with 
pancreatitis
Mortality AUROC 0.875
Atlanta severity AUROC 0.861
APACHE-O
Papachristou 2006 (244) External validation 102 patients admitted with 
pancreatitis
ICU, necrosis or mortality AUROC 0.895
Yeung 2006 (245) External validation 101 patients admitted with 
pancreatitis
Atlanta severity AUROC 0.904
BISAP
Singh 2009 (248) External validation 397 patients admitted with 
pancreatitis
Hospital mortality AUROC 0.82
Early Warning Score
Garcea 2008 (247) External validation 181 patients admitted with 
pancreatitis
Mortality AUROC 0.827
Atlanta severity AUROC 0.853
Glasgow
Gan 2003 (240) External validation
Retrospective review
39 HIV +ve patients admitted 
with pancreatitis
Mortality, ICU, local 
complications or surgery
Sensitivity 0.67, specificity 
0.7, PPV 0.29, NPV 0.92
Taylor 2005 (243) External validation
Retrospective chart review
49 patients admitted with 
pancreatitis
Over 5/7 ICU AUROC 0.67
Ueda 2007 (246) External validation 137 patients admitted with 
pancreatitis
Bacteraemia or infected 
pancreatic necrosis
AUROC 0.73
Renal/hepatic/lung 
dysfunction
AUROC 0.74
Mortality AUROC 0.73
Glasgow (modified)
De Beaux 1995 (249) External validation 279 patients admitted to tertiary 
centre with pancreatitis
Mortality Score 0: 0/74, score 1 3/77, 
score 5 4/7, score 6 2/4.
Meek 2000 (239) External validation 92 patients admitted with 
gallstone pancreatitis
>24h ICU care Score >2 sensitivity 0.67 
specificity 0.85 PPV 0.4 NPV 
0.93
Imrie score
Meek 2000 (250) External validation 66 patients admitted with 
pancreatitis
Severe complications Imrie >2 sensitivity 0.86 
specificity 0.87 PPV 0.5 NPV 
0.98
Halonen 2003 (241) External validation 60 patients admitted with 
“severe” pancreatitis
Inpatient mortality AUROC 0.536 (0.364-0.708)
Garcea 2008 (247) External validation 181 patients admitted with 
pancreatitis
Mortality AUROC 0.794
Atlanta severity AUROC 0.747
MODS
Garcea 2008 (247) External validation 181 patients admitted with 
pancreatitis
Mortality AUROC 0.783
Atlanta severity AUROC 0.793
Ranson
Meek 2000 (250) External validation 66 patients admitted with 
pancreatitis
Severe complications Ranson >2 sensitivity 0.75 
specificity 0.67 PPV 0.29 NPV 
0.94
Gan 2003 (240) External validation
Retrospective review
31 HIV +ve patients admitted 
with pancreatitis
Mortality, ICU, local 
complications or surgery
Sensitivity 1, specificity 0.33, 
PPV 0.3, NPV 1
Halonen 2003 (241) External validation 60 patients admitted with 
“severe” pancreatitis
Inpatient mortality AUROC 0.655 (0.503-0.808)
Taylor 2005 (243) External validation
Retrospective chart review
49 patients admitted with 
pancreatitis
Over 5/7 ICU AUROC 0.54
Ueda 2007 (246) External validation 137 patients admitted with 
pancreatitis
Bacteraemia or infected 
pancreatic necrosis
AUROC 0.82
Renal/hepatic/lung 
dysfunction
AUROC 0.84
Mortality AUROC 0.83
Ranson (biliary)
Meek 2000 (239) External validation 92 patients admitted with 
gallstone pancreatitis
>24h ICU care Score >2 sensitivity 0.69 
specificity 0.67 PPV 0.31 NPV 
0.91
SAPS
van den Biezenbos 1998 
(251)
External validation
Secondary analysis of 
observational study
78 patients undergoing CT for 
pancreatitis
Mortality AUROC 0.747 (SE 0.085)
Pneumonia
A-DROP
Shindo 2008 (252) External validation 329 patients hospitalised with 
pneumonia
30-day mortality AUROC 0.846 (0.79-0.903)
APACHE II
Jeong 2011 (253) External validation 502 ED patients with pneumonia 30-day mortality AUROC 0.847 (0.804-890)
ATS
Angus 2002 (254) External validation 1339 patients admitted with 
pneumonia
30-day mortality AUROC 0.6 (0.54-0.65)
ICU admission AUROC 0.61 (0.57-0.65)
Buising 2006 (255) External validation 392 patients admitted via ED 
with pneumonia
Inpatient mortality AUROC 0.63
ICU admission AUROC 0.9
Kontou 2009 (256) External validation 158 patients hospitalised with 
pneumonia
ICU admission Sensitivity 0.9 (0.75-0.97), 
specificity 0.8 (0.73-0.86), 
PPV 0.53 (0.4-0.66), NPV 0.97 
(0.92-0.99)
Mortality Sensitivity 0.65 (0.43-0.82), 
specificity 0.71 (0.63-0.78), 
PPV 0.25 (0.15-0.38), NPV 
0.93 (0.87-0.97)
ATS (modified)
Valencia 2007 (257) External validation 457 patients admitted with PSI 
class V pneumonia
Inpatient mortality Sensitivity 0.75 specificity 0.8 
PPV 0.53 NPV 0.91
ICU admission Sensitivity 0.72 specificity 
0.77 PPV 0.44 NPV 0.91
Feldman 2009 (258) External validation 766 patients admitted with 
pneumonia
14-day mortality AUROC 0.7491
ATS 2007
Feldman 2009 (258) External validation 766 patients admitted with 
pneumonia
14-day mortality AUROC 0.7099
Kontou 2009 (256) External validation 158 patients hospitalised with 
pneumonia
ICU admission Sensitivity 0.9 (0.75-0.97), 
specificity 0.72 (0.64-0.80), 
PPV 0.44 (0.33-0.57), NPV 
0.97 (0.91-0.99)
Mortality Sensitivity 0.75 (0.53-0.89), 
specificity 0.65 (0.57-0.73), 
PPV 0.24 (0.15-0.36), NPV 
0.95 (0.88-0.98)
Phua 2009 (259) External validation 1242 patients admitted with 
pneumonia
Inpatient mortality AUROC 0.88 (0.86-0.91)
ICU admission AUROC 0.85 (0.81-0.88)
ATS 2007 (modified)
Kontou 2009 (256) External validation 158 patients hospitalised with 
pneumonia
ICU admission For 1+1 criteria;
Sensitivity 0.77 (0.62-0.89), 
specificity 0.77 (0.69-0.83), 
PPV 0.45 (0.33-0.59), NPV 
0.93 (0.87-0.97)
For 2+1 criteria:
Sensitivity 0.77 (0.62-0.89), 
specificity 0.84 (0.77-0.9), 
PPV 0.55 (0.4-0.68), NPV 0.94 
(0.88-0.97)
Mortality For 1+1 criteria:
Sensitivity 0.45 (0.26-0.66), 
specificity 0.68 (0.6-0.75), 
PPV 0.17 (0.09-0.29), NPV 0.9 
(0.82-0.94)
For 2+1 criteria:
Sensitivity 0.45 (0.26-0.66), 
specificity 0.75 (0.67-0.81), 
PPV 0.2 (0.11-0.35), NPV 0.9 
(0.84-0.95)
Man 2011 (260) External validation 767 ED patients with nursing-
home acquired pneumonia
30-day mortality or ICU 
admission
AUROC 0.627 (0.562-0.692)
BTS
Angus 2002 (254) External validation 1339 patients admitted with 30-day mortality AUROC 0.62 (0.57-0.69)
pneumonia ICU admission AUROC 0.58 (0.53-0.63)
BTS (modified)
Loh 2004 (261) External validation 108 patients admitted with 
pneumonia, including TB
Inpatient mortality Sensitivity 0.15, specificity 
0.93, PPV 0.71, NPV 0.52
CORB
Buising 2007 (262) Internal validation 330 patients presenting to ED 
with pneumonia
Mortality or ICU 
admission
AUROC 0.72 (0.63-0.76)
CRB
Bauer 2006 (263) External validation 1343 ED and primary care 
patients with pneumonia
30-day mortality AUROC 0.72 (0.654-0.787)
Buising 2007 (262) External validation 330 patients presenting to ED 
with pneumonia
Mortality or ICU 
admission
AUROC 0.74 (0.66-0.83)
CRB-65
Bauer 2006 (263) External validation 1343 ED and primary care 
patients with pneumonia
30-day mortality AUROC 0.785 (0.736-0.833)
Capelastegui 2006 (264) External validation 1776 ED patients with 
pneumonia
30-day mortality AUROC 0.864 (0.835-0.892)
Barlow 2007 (265) External validation
Secondary analysis quality 
improvement study
419 patients admitted with 
pneumonia
30-day mortality AUROC 0.73 (0.67-0.79)
Buising 2007 (262) External validation 330 patients presenting to ED 
with pneumonia
Mortality or ICU 
admission
AUROC 0.67 (0.61-0.73)
Man 2007 (266) External validation 1016 patients admitted with 
pneumonia
30-day mortality AUROC 0.694 (0.634-0.753)
ICU admission Score 0 3.9%, score 1-2 3.3%, 
score 3-4 9.5% p=0.01
Schaaf 2007 (267) External validation 105 patients hospitalised with 
pneumococcal pneumonia
Inpatient mortality AUROC 0.845 (0.739-0.951)
Chalmers 2008 (268) External validation 1007 patients hospitalised with 
pneumonia, excluding those with 
malignancy or 
immunosuppression
30-day mortality AUROC 0.74 (0.73-0.79)
IPPV or inotropes AUROC 0.77 (0.74-0.8)
Kruger 2008 (269) External validation 1671 in CAPNETZ cohort (primary 28-day mortality AUROC 0.79
Secondary registry analysis and secondary care)
Schuetz 2008 (270) External validation
Secondary analysis of RCT
373 ED patients with pneumonia, 
multiple exclusions
30-day mortality AUROC 0.66 (0.58-0.73)
Zuberi 2008 (271) External validation 137 patients admitted with 
pneumonia excluding nursing 
home residents
30-day mortality AUROC 0.84
Chalmers 2009 (272) External validation 1269 patients admitted with 
pneumonia
Complicated 
parapneumonic effusion 
or empyema
AUROC 0.52 (0.49-0.55)
Feldman 2009 (258) External validation 744 patients admitted with 
pneumonia
14-day mortality AUROC 0.7365
Menendez 2009 (273) External validation 453 patients admitted with 
pneumonia
30-day mortality AUROC 0.79 (0.72-0.87)
El-Solh 2010 (274) External validation 457 patients hospitalised with 
nursing-home acquired 
pneumonia
30-day mortality AUROC 0.605 (0.559-0.650)
ICU admission AUROC 0.62 (0.574-0.655)
CURB
Ewig 2004 (275) External validation 696 patients hospitalised with 
pneumonia
ICU admission AUROC 0.732 (0.676-0.787)
Aujesky 2005 (276) External validation 3181 ED patients with 
pneumonia
30-day mortality AUROC 0.73 (0.68-0.76)
Bauer 2006 (263) External validation 1343 ED and primary care 
patients with pneumonia
30-day mortality AUROC 0.793 (0.745-0.841)
Buising 2006 (255) External validation 392 patients admitted via ED 
with pneumonia
Inpatient mortality AUROC 0.74
ICU admission AUROC 0.7
Buising 2007 (262) External validation 330 patients presenting to ED 
with pneumonia
Mortality or ICU 
admission
AUROC 0.76 (0.71-0.82)
Valencia 2007 (257) External validation 457 patients admitted with PSI 
class V pneumonia
Inpatient mortality Sensitivity 0.78 specificity 
0.45 PPV 0.3 NPV 0.87
ICU admission Sensitivity 0.72 specificity 
0.42 PPV 0.24 NPV 0.86
Kontou 2009 (256) External validation 158 patients hospitalised with ICU admission Score >1 sensitivity 0.58 
pneumonia (0.41-0.74), specificity 0.79 
(0.71-0.85), PPV 0.4 (0.27-
0.55), NPV 0.89 (0.81-0.93)
Mortality Score >1 sensitivity 0.5 (0.3-
0.7), specificity 0.75 (0.67-
0.81), PPV 0.22 (0.13-0.36), 
NPV 0.91 (0.85-0.95)
El-Solh 2010 (274) External validation 457 patients hospitalised with 
nursing-home acquired 
pneumonia
30-day mortality AUROC 0.592 (0.543-0.638)
ICU admission AUROC 0.651 (0.605-0.695)
CURB-65
Lim 2003 (65) Combined derivation and 
validation
1068 patients admitted with 
pneumonia
30-day mortality Score 0/1 1.5%, score 2 9.2%, 
score >2 22%.
Aujesky 2005 (276) External validation 3181 ED patients with 
pneumonia
30-day mortality AUROC 0.76 (0.73-0.8)
Buising 2006 (255) External validation 392 patients admitted via ED 
with pneumonia
Inpatient mortality AUROC 0.74
ICU admission AUROC 0.61
Capelastegui 2006 (264) External validation 1776 ED patients with 
pneumonia
30-day mortality AUROC 0.87 (0.844-0.895)
España 2006 (277) External validation 1057 ED patients with 
pneumonia
Mortality, IPPV or septic 
shock
AUROC 0.78
719 ED patients with pneumonia AUROC 0.79
1121 ED patients with 
pneumonia
AUROC 0.71
Barlow 2007 (265) External validation
Secondary analysis quality 
improvement study
419 patients admitted with 
pneumonia
30-day mortality AUROC 0.78 (0.73-0.83)
Buising 2007 (262) External validation 330 patients presenting to ED 
with pneumonia
Mortality or ICU 
admission
AUROC 0.68 (0.6-0.76)
Man 2007 (266) External validation 1016 patients admitted with 
pneumonia
30-day mortality AUROC 0.733 (0.689-0.787)
ICU admission Score 0-1 2.3%, score 2 4.4%, 
score >2 6.5% p=0.02
Valencia 2007 (257) External validation 457 patients admitted with PSI 
class V pneumonia
Inpatient mortality Sensitivity 0.73 specificity 0.8 
PPV 0.53 NPV 0.85
ICU admission Sensitivity 0.6 specificity 0.44 
PPV 0.21 NPV 0.81
Ananda-Rajah 2008 
(278)
External validation 408 patients hospitalised with 
pneumonia
30-day mortality AUROC 0.69
ICU admission AUROC 0.63
Chalmers 2008 (268) External validation 1007 patients hospitalised with 
pneumonia, excluding those with 
malignancy or 
immunosuppression
30-day mortality AUROC 0.76 (0.74-0.79)
IPPV or inotropes AUROC 0.78 (0.75-0.81)
Charles 2008 (279) External validation 882 patients admitted with 
pneumonia
ETT, NIV or vasopressor AUROC 0.67
Schuetz 2008 (280) External validation 281 patients admitted with 
pneumonia
Mortality or intensive 
care admission
AUROC 0.66 (0.58-0.73)
Schuetz 2008 (270) External validation
Secondary analysis of RCT
373 ED patients with pneumonia, 
multiple exclusions
30-day mortality AUROC 0.69 (0.61-0.77)
Shindo 2008 (252) External validation 329 patients hospitalised with 
pneumonia
30-day mortality AUROC 0.835 (0.763-0.908)
Zuberi 2008 (271) External validation 137 patients admitted with 
pneumonia excluding nursing 
home residents
30-day mortality AUROC 0.86
Chalmers 2009 (281) External validation
Secondary analysis diagnostic 
study
314 ED patients with pneumonia 30-day mortality AUROC 0.79 (0.74-0.85)
IPPV or vasopressor use AUROC 0.77 (0.72-0.83)
Chalmers 2009 (272) External validation 1269 patients admitted with 
pneumonia
Complicated 
parapneumonic effusion 
or empyema
AUROC 0.54 (0.51-0.57)
Feldman 2009 (258) External validation 744 patients admitted with 
pneumonia
14-day mortality AUROC 0.7361
Huang 2009 (282) External validation 1653 ED patients with 
pneumonia
30-day mortality AUROC 0.78
Menendez 2009 (273) External validation 453 patients admitted with 30-day mortality AUROC 0.82 (0.76-0.89)
pneumonia
Parsonage 2009 (283) External validation 132 patients age 16-64 admitted 
with pneumonia
30-day mortality AUROC 0.93
92 patients age 65-74 admitted 
with pneumonia
AUROC 0.74
128 patients age 75-84 admitted 
with pneumonia
AUROC 0.74
76 patients age >84 admitted 
with pneumonia
AUROC 0.59
Phua 2009 (259) External validation 1242 patients admitted with 
pneumonia
Inpatient mortality AUROC 0.82 (0.78-0.85)
ICU admission AUROC 0.68 (0.63-0.72)
Renaud 2009 (69) External validation 6560 patients hospitalised with 
pneumonia
ICU admission in 1-3 days AUROC 0.69 (0.66-0.72)
Yandiola 2009 (284) External validation 671 patients hospitalised with 
pneumonia
ICU admission AUROC 0.61
Mechanical ventilation AUROC 0.61
Severe sepsis AUROC 0.66
Chen 2010 (285) External validation 348 ED patients age 18-64 with 
pneumonia
30-day mortality AUROC 0.8 (0.67-0.93)
438 ED patients age 65-84 with 
pneumonia
AUROC 0.73 (0.65-0.82)
201 ED patients age >84 with 
pneumonia
AUROC 0.6 (0.48-0.73)
El-Solh 2010 (274) External validation 457 patients hospitalised with 
nursing-home acquired 
pneumonia
30-day mortality AUROC 0.593 (0.543-0.638)
ICU admission AUROC 0.657 (0.611-0.7)
Schuetz 2010 (286) External validation 925 patients hospitalised with 
pneumonia
30-day mortality AUROC 0.74
Serious complication AUROC 0.66
Albrich 2011 (287) External validation 1359 patients hospitalised with 
pneumonia or LRTI
30-day mortality AUROC 0.73 (.68-.75)
30-day mortality, ICU 
admission or 
complication
AUROC 0.65 (.61-.69)
Jeong 2011 (253) External validation 502 ED patients with pneumonia 30-day mortality AUROC 0.764 (0.703-0.825)
Jones 2011 (288) External validation 2069 ED patients with 
pneumonia, multiple exclusions
30-day mortality AUROC 0.82
Man 2011 (260) External validation 767 ED patients with nursing-
home acquired pneumonia
30-day mortality or ICU 
admission
AUROC 0.702 (0.649-0.755)
Labarère 2012 (289) External validation 850 ED patients with pneumonia, 
excluding nursing home 
residents
30-day mortality AUROC 0.74 (0.67-0.82)
30-day ICU admission AUROC 0.65 (0.57-0.72)
3-day ICU admission AUROC 0.63 (0.55-0.71)
Park 2012 (290) External validation 126 patients hospitalised with 
pneumonia
28-day mortality AUROC 0.864
CURXO-80
Labarère 2012 (289) External validation 850 ED patients with pneumonia, 
excluding nursing home 
residents
30-day mortality AUROC 0.78 (0.72-0.84)
30-day ICU admission AUROC 0.74 (0.68-0.81)
3-day ICU admission AUROC 0.74 (0.67-0.8)
eCURB
Jones 2011 (288) Derivation 2069 ED patients with 
pneumonia, multiple exclusions
30-day mortality AUROC 0.86
External validation 1048 ED patients with 
pneumonia, multiple exclusions
AUROC 0.845
IDSA/ATS
Man 2011 (260) External validation 767 ED patients with nursing-
home acquired pneumonia
30-day mortality or ICU 
admission
AUROC 0.712 (0.654-0.770)
Labarère 2012 (289) External validation 850 ED patients with pneumonia, 
excluding nursing home 
residents
30-day mortality AUROC 0.75 (0.68-0.82)
30-day ICU admission AUROC 0.74 (0.67-0.81)
3-day ICU admission AUROC 0.72 (0.64-0.8)
Park 2012 (290) External validation 126 patients hospitalised with 
pneumonia
28-day mortality AUROC 0.844
Pitt bacteremia score
Feldman 2009 (258) External validation 766 patients admitted with 
pneumonia
14-day mortality AUROC 0.8397
Pneumonia severity score
Carusone 2007 (291) External validation
Control arm of RCT
353 nursing home residents with 
LRTI or pneumonia
30-day mortality Score 0 8%, score 1 8%, score 
2 10%, score 3 33%, score 4 
0%
Hospitalisation Score 0 19%, score 1 14%, 
score 2 45%, score 3 58%, 
score 4 100%
PSI
Flanders 1999 (292) External validation
Secondary analysis of quality 
improvement data
1024 patients admitted with 
pneumonia
Hospital mortality AUROC 0.847
Feagan 2000 (293) External validation 858 patients hospitalised with 
pneumonia
30-day mortality Class I-II 0, class III 3.3%, 
class IV-V 22.4%
ICU admission Class I-II 7.5%, class III 9.4%, 
class IV-V 17%
Dedier 2001 (294) External validation 1062 patients hospitalised with 
pneumonia
Hospital mortality class I 0, class II 1.6%, class III 
3.5%, class IV 3.6%, class V 
22.3% p<0.001
Angus 2002 (254) External validation 1339 patients admitted with 
pneumonia
30-day mortality AUROC 0.75 (0.71-0.78)
ICU admission AUROC 0.6 (0.56-0.65)
Mody 2002 (295) External validation 101 patients >60y admitted with 
pneumonia
30-day mortality Class 2 0, class 3 0.5%, class 4 
10.8%, class 5 25%
Ewig 2004 (275) External validation 696 patients hospitalised with 
pneumonia
ICU admission AUROC 0.607 (0.607-0.727)
Querol-Ribelles 2004 
(296)
External validation 302 ED patients with pneumonia 30-day mortality AUROC 0.91 (0.88-0.95)
Aujesky 2005 (276) External validation 3181 ED patients with 
pneumonia
30-day mortality AUROC 0.81 (0.78-0.84)
Buising 2006 (255) External validation 392 patients admitted via ED 
with pneumonia
Inpatient mortality AUROC 0.73
ICU admission AUROC 0.65
Capelastegui 2006 (264) External validation 1776 ED patients with 
pneumonia
30-day mortality AUROC 0.888 (0.864-0.912)
España 2006 (277) External validation 1057 ED patients with 
pneumonia
Mortality, IPPV or septic 
shock
AUROC 0.81
719 ED patients with pneumonia AUROC 0.79
1121 ED patients with 
pneumonia
AUROC 0.71
Migliorati 2006 (297) External validation 148 patients hospitalised with 
pneumonia
30-day mortality Class I-II 0, class III 6.2%, 
class IV 1.8%, class V 30.2%
ICU admission Class I-II 0, class III 6.2%, 
class IV 0, class V 13.2%
Sanders 2006 (298) External validation 284 immunocompromised 
patients admitted with 
pneumonia
Inpatient mortality AUROC 0.7 (0.6-0.79) overall; 
0.77 (0.52-1) low-risk (HIV, 
solid organ xplant); 0.6 (0.46-
0.74) high-risk (marrow 
xplant, haem malignancy, 
post-chemo)
Buising 2007 (262) External validation 330 patients presenting to ED 
with pneumonia
Mortality or ICU 
admission
AUROC 0.68 (0.62-0.75)
Etzion 2007 (299) External validation 591 patients hospitalised with 
pneumonia
30-day mortality AUROC 0.86 (0.8-0.92)
Man 2007 (266) External validation 1016 patients admitted with 
pneumonia
30-day mortality AUROC 0.736 (0.687-0.786)
ICU admission Group II-III 2.7%, group IV 
4.5%, group V 6.6 % p=0.063
Renaud 2007 (300) External validation 925 ED patients with pneumonia 28-day mortality AUROC 0.85 (0.81-0.88)
ICU admission Class I 4.3%, class II 7.6%, 
class III 6.5%, class IV 11.1%, 
class V 17.9%
853 ED patients with pneumonia 28-day mortality AUROC 0.89 (0.85-0.93)
ICU admission Class I 2.1%, class II 4.9%, 
class III 3.8%, class IV 1.4%, 
class V 7.1%
Ananda-Rajah 2008 
(278)
External validation 408 patients hospitalised with 
pneumonia
30-day mortality AUROC 0.72
ICU admission AUROC 0.58
Charles 2008 (279) External validation 882 patients admitted with 
pneumonia
ETT, NIV or vasopressor AUROC 0.69
Chen 2008 (301) External validation 250 patients hospitalised with Hospital mortality Class I-II 0, class III 2.9%, 
pneumonia class IV 7.8%, class V 25.3% 
p<0.001
Garau 2008 (302) External validation 3233 patients admitted with 
pneumonia
2-day mortality Class I: 0, II 0.2%, III 0.3%, IV 
1.3%, V 7.5%
ICU admission Class I: 2.5%, II 3.7%, III 3.9%, 
IV 5%, V 10.2%
Restrepo 2008 (303) External validation 730 patients hospitalised with 
pneumonia
30-day mortality Class I 2.7%, class II 2.6% 
class III 5.8%, class IV 8.6%, 
class V 27%
ICU admission Class I 9%, class II 7.7%, class 
III 14.4%, class IV 25%, class 
V 50%
Schuetz 2008 (280) External validation 281 patients admitted with 
pneumonia
Mortality or intensive 
care admission
AUROC 0.71 (0.65-0.78)
Schuetz 2008 (270) External validation
Secondary analysis of RCT
373 ED patients with pneumonia, 
multiple exclusions
30-day mortality AUROC 0.72 (0.65-0.78)
Chalmers 2009 (281) External validation
Secondary analysis diagnostic 
study
314 ED patients with pneumonia 30-day mortality AUROC 0.79 (0.73-0.84)
IPPV or vasopressor use AUROC 0.73 (0.67-0.78)
Chalmers 2009 (272) External validation 1269 patients admitted with 
pneumonia
Complicated 
parapneumonic effusion 
or empyema
AUROC 0.55 (0.52-0.58)
Feldman 2009 (258) External validation 742 patients admitted with 
pneumonia
14-day mortality AUROC 0.721
Huang 2009 (282) External validation 1653 ED patients with 
pneumonia
30-day mortality AUROC 0.83
Kontou 2009 (256) External validation 158 patients hospitalised with 
pneumonia
ICU admission PSI V: sensitivity 0.45 (0.29-
0.62), specificity 0.83 (0.76-
0.89), PPV 0.4 (0.26-0.56), 
NPV 0.9 (0.83-0.94)
PSI IV and V: 
Sensitivity 0.81 (0.64-0.91), 
specificity 0.5 (0.41-0.58), 
PPV 0.28 (0.2-0.38), NPV 0.91 
(0.82-0.96)
Mortality PSI V: sensitivity 0.5 (0.30-
0.7), specificity 0.82 (0.75-
0.87), PPV 0.29 (0.16-0.45), 
NPV 0.92 (0.86-0.96)
PSI IV and V: sensitivity 0.95 
(0.76-0.99), specificity 0.49 
(0.41-0.58), PPV 0.21 (0.14-
0.31), NPV 0.99 (0.92-0.99)
Menendez 2009 (273) External validation 453 patients admitted with 
pneumonia
30-day mortality AUROC 0.81 (0.75-0.87)
Pilotto 2009 (304) External validation 134 patients age >65 admitted 
with pneumonia
30-day mortality AUROC 0.71 (0.62-0.78)
Phua 2009 (259) External validation 1242 patients admitted with 
pneumonia
Inpatient mortality AUROC 0.86 (0.83-0.88)
ICU admission AUROC 0.75 (0.71-0.79)
Renaud 2009 (69) External validation 6560 patients hospitalised with 
pneumonia
ICU admission in 1-3 days AUROC 0.75 (0.73-0.78)
Yandiola 2009 (284) External validation 671 patients hospitalised with 
pneumonia
ICU admission AUROC 0.63
Mechanical ventilation AUROC 0.69
Severe sepsis AUROC 0.72
Chen 2010 (285) External validation 348 ED patients age 18-64 with 
pneumonia
30-day mortality AUROC 0.87 (0.77-0.97)
438 ED patients age 65-84 with 
pneumonia
AUROC 0.85 (0.8-0.9)
201 ED patients age >84 with 
pneumonia
AUROC 0.69 (0.6-0.79)
Schuetz 2010 (286) External validation 925 patients hospitalised with 
pneumonia
30-day mortality AUROC 0.84
Serious complication AUROC 0.69
Jeong 2011 (253) External validation 502 ED patients with pneumonia 30-day mortality AUROC 0.795 (0.742-0.848)
Man 2011 (260) External validation 767 ED patients with nursing- 30-day mortality or ICU AUROC 0.688 (0.633-0.744)
home acquired pneumonia admission
Labarère 2012 (289) External validation 850 ED patients with pneumonia, 
excluding nursing home 
residents
30-day mortality AUROC 0.82 (0.77-0.88)
30-day ICU admission AUROC 0.68 (0.61-0.75)
3-day ICU admission AUROC 0.66 (0.59-0.74)
Park 2012 (290) External validation 126 patients hospitalised with 
pneumonia
28-day mortality AUROC 0.875
REA-ICU
Renaud 2009 (69) Derivation 4593 patients hospitalised with 
pneumonia
ICU admission in 1-3 days AUROC 0.8 (0.77-0.83)
Internal validation 1967 patients hospitalised with 
pneumonia
AUROC 0.8 (0.76-0.84)
Labarère 2012 (289) External validation 850 ED patients with pneumonia, 
excluding nursing home 
residents
30-day mortality AUROC 0.74 (0.66-0.82)
30-day ICU admission AUROC 0.78 (0.72-0.84)
3-day ICU admission AUROC 0.76 (0.7-0.83)
SCAP
España 2006 (277) Derivation 1057 ED patients with 
pneumonia
Mortality, IPPV or septic 
shock
AUROC 0.83
Internal validation 719 ED patients with pneumonia AUROC 0.86
External validation 1121 ED patients with 
pneumonia
AUROC 0.72
Renaud 2009 (69) External validation 6560 patients hospitalised with 
pneumonia
ICU admission in 1-3 days AUROC 0.74 (0.71-0.76)
Yandiola 2009 (284) External validation 671 patients hospitalised with 
pneumonia
ICU admission AUROC 0.746
Mechanical ventilation AUROC 0.76
Severe sepsis AUROC 0.79
Man 2011 (260) External validation 767 ED patients with nursing-
home acquired pneumonia
30-day mortality or ICU 
admission
AUROC 0.650 (0.596-0.703)
SEWS
Barlow 2007 (265) External validation
Secondary analysis quality 
improvement study
419 patients admitted with 
pneumonia
30-day mortality AUROC 0.64 (0.57-0.7)
Chalmers 2009 (272) External validation 1269 patients admitted with Complicated AUROC 0.53 (0.50-0.56)
pneumonia parapneumonic effusion 
or empyema
SIRS
Barlow 2007 (265) External validation
Secondary analysis quality 
improvement study
419 patients admitted with 
pneumonia
30-day mortality AUROC 0.68 (0.61-0.75)
Schaaf 2007 (267) External validation 105 patients hospitalised with 
pneumococcal pneumonia
Inpatient mortality Non-SIRS 0%, SIRS 0%, 
severe/shock 30.6% 
(p<0.0001)
SMART-COP
Charles 2008 (279) Derivation 882 patients admitted with 
pneumonia
ETT, NIV or vasopressor AUROC 0.87
External validation 2067 patients admitted with 
pneumonia
AUROC 0.72 (0.68-0.77)
1307 patients admitted with 
pneumonia
AUROC 0.78 (0.72-0.83)
408 patients admitted with 
pneumonia
AUROC 0.81 (0.74-0.88)
608 patients admitted with 
pneumonia
AUROC 0.82 (0.77-0.86)
3074 patients admitted with 
pneumonia
AUROC 0.87 (0.83-0.91)
Labarère 2012 (289) External validation 850 ED patients with pneumonia, 
excluding nursing home 
residents
30-day mortality AUROC 0.71 (0.6-0.81)
30-day ICU admission AUROC 0.76 (0.79-0.83)
3-day ICU admission AUROC 0.75 (0.67-0.83)
SMRT-CO
Charles 2008 (279) Derivation
Secondary rule
882 patients admitted with 
pneumonia
ETT, NIV or vasopressor AUROC 0.8
External validation 2067 patients admitted with 
pneumonia
AUROC 0.69 (0.65-0.73)
1307 patients admitted with 
pneumonia
AUROC 0.74 (0.69-0.79)
408 patients admitted with 
pneumonia
AUROC 0.78 (0.7-0.85)
608 patients admitted with 
pneumonia
AUROC 0.76 (0.7-0.81)
3074 patients admitted with 
pneumonia
AUROC 0.8 (0.76-0.84)
SOAR
El-Solh 2010 (274) External validation 457 patients hospitalised with 
nursing-home acquired 
pneumonia
30-day mortality AUROC 0.765 (0.724-0.803)
ICU admission AUROC 0.734 (0.691-0.774)
ETT: endotracheal intubation; IPPV: intermittent positive pressure ventilation; NIV: non-invasive ventilation
Pulmonary embolism
Aujesky
Aujesky 2006 (305) Derivation 10354 patients with discharge 
diagnosis of PE
30-day mortality Sensitivity 0.99 (0.98-0.99) 
specificity 0.24 (0.23-0.25) 
PPV 0.12 (0.11-0.12) NPV 
0.99 (0.99-1)
Internal validation 5177 patients with discharge 
diagnosis of PE
Sensitivity 0.97 (0.95-0.98) 
specificity 0.23 (0.22-0.25) 
PPV 0.12 (0.11-0.13) NPV 
0.98 (0.98-0.99)
External validation
Secondary analysis of diagnostic 
study
221 patients undergoing CT for 
potential PE
Sensitivity 1 (0.54-1) 
specificity 0.35 (0.29-0.42) 
PPV 0.04 (0.02-0.09) NPV 1 
(0.95-1)
Palmieri 2008 (306) External validation 89 ED patients with non-massive 
PE
Hospital mortality Score <65 0, 65-85 0, 86-105 
11%, 106-25 23%, >125 22%
Haemodynamic 
instability
Score <65 0, 65-85 20%, 86-
105 56%, 106-125 39%, >125 
56%
PESI
Choi 2009 (307) External validation 90 patients with PE diagnosed by 
CT
30-day mortality Class I 0, class II 10.3%, class 
III 9.1%, class IV 0, class V 
50%.
Nordenholz 2011 (308) External validation
Retrospective review
168 patients with PE Mortality, respiratory 
failure, need for 
ventilation or 
thrombolysis
2.1% class I, 2.3% class II, 
15.6% class III, 8% class IV, 
15% class V
PESI (simplified)
Jimenez 2010 (71) Derivation
Prospective registry data
995 patients with symptomatic 
PE
30-day PE-specific 
mortality
AUROC 0.75 (0.69-0.8)
External validation
Prospective registry data
7106 patients with PE 30-day mortality NPV 98.9% (98.5-99.3)
Utrecht score
Agterof 2011 (309) Derivation 210 normotensive patients 
admitted with PE
10-day adverse events AUROC 0.82
Sepsis
APACHE II
Nguyen 2008 (310) External validation
Secondary analysis of RCT
246 patients meeting EGDT 
criteria
Hospital mortality AUROC 0.73 (0.67-0.8)
Chou 2010 (311) External validation 90 patients with Vibrio vulnificus 
infection
Hospital mortality AUROC 0.928 (0.854-0.972)
CURB-65
Howell 2007 (312) External validation 2132 ED patients with infection 28-day mortality AUROC 0.788 (0.744-0.833)
Crowe 2010 (313) External validation 216 ED patients receiving EGDT Hospital mortality AUROC 0.59 (0.51-0.67)
MEDS
Shapiro 2003 (74) Derivation 2070 ED patients having blood 
cultures taken
Hospital mortality AUROC 0.82 HL 0.21
Internal validation 1109 ED patients having blood 
cultures taken
AUROC 0.76 HL 0.39
Howell 2007 (312) External validation 2132 ED patients with infection 28-day mortality AUROC 0.849 (0.812-0.877)
Jones 2008 (314) External validation
Secondary analysis quality 
improvement study
143 patients with severe sepsis 
or septic shock
Hospital mortality AUROC 0.61 (0.5-0.72)
Lee 2008 (315) External validation 525 ED patients with SIRS 5-day mortality AUROC 0.89
5 to 30-day mortality AUROC 0.78
Nguyen 2008 (310) External validation
Secondary analysis of RCT
246 patients meeting EGDT 
criteria
Hospital mortality AUROC 0.6 (0.53-0.67)
Sankoff 2008 (316) External validation 385 ED patients with SIRS 28-day mortality AUROC 0.88 (0.83-0.92)
Vorwerk 2009 (317) External validation 307 ED patients with 2 SIRS 
criteria + infection
28-day mortality AUROC 0.82 (0.78-0.87)
Chou 2010 (311) External validation 90 patients with Vibrio vulnificus 
infection
Hospital mortality AUROC 0.830 (0.736-0.901)
Crowe 2010 (313) External validation 216 ED patients receiving EGDT Hospital mortality AUROC 0.74 (0.67-0.81)
Ghanem-Zoubi 2011 
(318)
External validation 1072 inpatients with sepsis 1-day mortality AUROC 0.79 (0.73-0.85)
5-day mortality AUROC 0.77 (0.73-0.81)
30-day mortality AUROC 0.73 (0.71-0.78)
Hermans 2012 (319) External validation 331 patients admitted via ED 28-day mortality AUROC 0.81 (.73-.88)
with sepsis
MEWS
Vorwerk 2009 (317) External validation 307 ED patients with 2 SIRS 
criteria + infection
28-day mortality AUROC 0.72 (0.67-0.77)
Ghanem-Zoubi 2011 
(318)
External validation 1072 inpatients with sepsis 1-day mortality AUROC 0.83 (0.77-0.88)
5-day mortality AUROC 0.73 (0.68-0.78)
30-day mortality AUROC 0.67 (0.63-0.71)
MPM0
Nguyen 2008 (310) External validation
Secondary analysis of RCT
246 patients meeting EGDT 
criteria
Hospital mortality AUROC 0.72 (0.65-0.79)
REMS
Howell 2007 (312) External validation 2132 ED patients with infection 28-day mortality AUROC 0.802 (0.752-0.852)
Crowe 2010 (313) External validation 216 ED patients receiving EGDT Hospital mortality AUROC 0.62 (0.54-0.69)
Ghanem-Zoubi 2011 
(318)
External validation 1072 inpatients with sepsis 1-day mortality AUROC 0.87 (0.83-0.92)
5-day mortality AUROC 0.8 (0.76-0.84)
30-day mortality AUROC 0.76 (0.72-0.79)
SAPS II
Kofoed 2008 (320) External validation 151 patients hospitalised with 2 
SIRS criteria + infection
30-day mortality AUROC 0.89 (0.8-0.98)
Nguyen 2008 (310) External validation
Secondary analysis of RCT
246 patients meeting EGDT 
criteria
Hospital mortality AUROC 0.71 (0.64-0.78)
Chen 2009 (321) External validation 298 patients hospitalised with 
pyogenic liver abscess
Hospital mortality AUROC 0.857 (0.812-0.895)
Sepsis algorithm
Thiel 2010 (322) Derivation 13785 hospitalised patients ICU admission in next 
24h
Sensitivity 56.9%, specificity 
93.7%
Temporal validation 13737 hospitalised patients Sensitivity 54.7, specificity 
93.4
Temporal validation 13937 hospitalised patients Sensitivity 55, specificity 93
Simple Clinical Score
Ghanem-Zoubi 2011 
(318)
External validation 1072 inpatients with sepsis 1-day mortality AUROC 0.85 (0.8-0.9)
5-day mortality AUROC 0.79 (0.76-0.83)
30-day mortality AUROC 0.77 (0.74-0.81)
SOFA
Kofoed 2008 (320) External validation 151 patients hospitalised with 2 
SIRS criteria + infection
30-day mortality AUROC 0.8 (0.65-0.94)
EGDT: early goal-directed therapy; SIRS: systemic inflammatory response syndrome
Surgical
APACHE II
Kulkarni 2007 (323) External validation 50 patients with peritonitis 
secondary to perforated hollow 
viscus (including from blunt 
trauma)
Hospital mortality AUROC 0.984
Ertan 2008 (324) External validation 102 patients undergoing 
emergency surgery for colorectal 
cancer
Hospital mortality AUROC 0.78
APACHE II (modified)
Mishra 2003 (325) External validation 140 patients with perforated 
peptic ulcer
Hospital mortality AUROC 0.84 +/- 0.06
APACHE III
Ertan 2008 (324) External validation 102 patients undergoing 
emergency surgery for colorectal 
cancer
Hospital mortality AUROC 0.773
Boey
Mishra 2003 (325) External validation 140 patients with perforated 
peptic ulcer
Hospital mortality AUROC 0.85 +/- 0.06
CR-POSSUM
Ertan 2008 (324) External validation 102 patients undergoing 
emergency surgery for colorectal 
cancer
Hospital mortality AUROC 0.718
Hacettepe
Mishra 2003 (325) External validation 140 patients with perforated 
peptic ulcer
Hospital mortality AUROC 0.72 +/- 0.08
Jabalpur
Mishra 2003 (325) Derivation 140 patients with perforated 
peptic ulcer
Hospital mortality AUROC 0.92 +/- 0.03
Mannheim Peritonitis Index
Mäkelä 2005 (326) External validation 172 patients undergoing surgery 
for perforated diverticular 
Mortality Age <70 score I 1% score II 
21% p=0.002
disease Age >70 score 1 2% score II 
50% p=0.001
Notash 2005 (327) External validation 80 patients undergoing surgery 
for peritonitis
Mortality AUROC 0.972
Biondo 2006 (328) External validation 156 patients undergoing surgery 
for distal colonic peritonitis
Hospital mortality AUROC 0.725 (0.648-0.794)
Mannheim (modified)
Mishra 2003 (325) External validation 140 patients with perforated 
peptic ulcer
Hospital mortality AUROC 0.85 +/- 0.06
MPM II
Ertan 2008 (324) External validation 102 patients undergoing 
emergency surgery for colorectal 
cancer
Hospital mortality AUROC 0.714
Peritonitis severity score
Biondo 2006 (328) External validation 156 patients undergoing surgery 
for distal colonic peritonitis
Hospital mortality AUROC 0.793 (0.721-0.854)
P-POSSUM
Poon 2005 (329) External validation 160 patients undergoing surgery 
for obstructing colorectal cancer
Mortality AUROC 0.75
SAPS II
Ertan 2008 (324) External validation 102 patients undergoing 
emergency surgery for colorectal 
cancer
Hospital mortality AUROC 0.83
Syncope
EGSYS
Del Rosso 2008 (330) Derivation 260 ED patients with syncope Cardiac cause found AUROC 0.904 (0.864-0.943)
Internal validation 256 ED patients with syncope AUROC 0.849 (0.778-0.921)
OESIL
Hing 2005 (331) External validation 100 ED patients with syncope Adverse cardiac outcome AUROC 0.73 (0.63-0.84)
Dipaola 2010 (332) External validation 492 ED patients with syncope 10-day mortality, major 
intervention or 
readmission
Sensitivity 0.88 (0.7-0.98), 
specificity 0.59 (0.55-0.64), 
PPV 0.11 (0.07-0.15), NPV 
0.99 (0.98-1)
Numeroso 2010 (333) External validation 200 patients with syncope on ED 
observation ward
Cardiogenic cause found OESIL >1 sensitivity 0.98, 
specificity 0.28, PPV 0.284, 
NPV 0.978 
San Francisco Syncope Rule
Quinn 2004 (83) Derivation 684 ED patients with syncope or 
near syncope
7-day serious outcome Sensitivity 0.96 (0.92-1), 
specificity 0.62 (0.58-0.66)
Quinn 2006 (334) External validation 791 ED patients with syncope or 
near syncope
30-day serious outcome Sensitivity 0.98 (0.89-1), 
specificity 0.56 (0.52-0.6)
Cosgriff 2007 (335) External validation 89 ED patients with syncope 7-day serious outcome Sensitivity 0.9 (0.6-0.98) 
specificity 0.57 (0.46-0.67) 
PPV 0.21 (0.11-0.35) NPV 
0.98 (0.89-0.99)
Sun 2007 (336) External validation 351 ED patients with syncope or 
near syncope
7-day serious outcome Sensitivity 0.89 (0.81-0.97) 
specificity 0.42 (0.37-0.48) 
PPV 0.22 (0.17-0.28) NPV 
0.95 (0.92-0.99)
Birnbaum 2008 (337) External validation 713 ED patients with syncope or 
near syncope
7-day serious outcome Sensitivity 0.74 (0.61-0.84) 
specificity 0.57 (0.53-0.61) 
PPV 0.14 (0.1-0.18) NPV 0.96 
(0.93-0.98)
Dipaola 2010 (332) External validation 492 ED patients with syncope 10-day mortality, major 
intervention or 
Sensitivity 0.81 (0.61-0.92), 
specificity 0.63 (0.58-0.67), 
readmission PPV 0.11 (0.06-0.15), NPV 
0.98 (0.97-1)
Transient ischaemic attack
ABCD
Bray 2007 (338) External validation 98 ED patients with TIA 7-day CVA incidence ABCD>4 sensitivity 1 (0.4-1) 
specificity 0.53 (0.43-0.63) 
PPV 0.08 (0.03-0.21) NPV 1 
(0.91-1)
Tsivgoulis 2007 (339) External validation 226 patients hospitalised with 
TIA
7-day CVA incidence ABCD>4 HR 8.74 (2.72-29.32)
30-day CVA incidence AUROC 0.78 (0.69-0.87)
Sciolla 2008 (340) External validation 274 ED patients with TIA 7-day CVA incidence AUROC 0.75 (0.63-0.88)
30-day CVA incidence AUROC 0.76 (0.66-0.86)
ABCD2
Johnstone 2007 (63) External validation 1069 ED patients with TIA 2-day CVA incidence AUROC 0.72 (0.6-0.84)
7-day CVA incidence AUROC 0.63 (0.57-0.69)
Ay 2009 (341) External validation 479 ED patients with TIA 7-day CVA incidence AUROC 0.66 (0.57-0.76)
Giles 2011 (342) External validation 3363 patients with TIA, tissue 
negative on MRI
7-day CVA incidence AUROC 0.73 (0.67-0.8)
1211 patients with TIA, tissue 
positive on MRI
AUROC 0.68 (0.63-0.73)
Stead 2011 (343) External validation 637 ED patients with TIA 7-day CVA incidence Low risk 1.1%, intermediate 
0.3%, high 2.7%
CVA: cerebrovascular accident; MRI: magnetic resonance imaging
Multi-diagnosis groups
APACHE II
Man 2007 (344) External validation 867 patients in ED resus area 14-day mortality AUROC 0.743 (0.705-0.798)
Cattermole 2009 (129) External validation 330 patients in ED resus area 30-day mortality AUROC 0.838 (0.793-0.876)
7-day mortality or ICU 
admission
AUROC 0.733 (0.681-0.780)
Emergency Severity Index
Platts-Mills 2010 (120) External validation 782 ED patients aged >65y Immediate life-saving 
intervention
ESI 1 sensitivity 42% (26%-
61%) specificity 99.1% (98.1-
99.5%)
HOTEL
Kellett 2008 (89) Derivation 6947 patients admitted to MAU Mortality in 15min-24h AUROC 0.865 (0.793-0.937)
Temporal validation 3343 patients admitted to MAU AUROC 0.854 (0.746-0.962)
MARS
Silke 2010 (345) Derivation 10712 patients admitted to MAU 5-day mortality AUROC 0.93 (0.92-0.94)
External validation 13182 patients admitted to MAU AUROC 0.92 (0.9-0.94)
MEWS
Kellett 2006 (92) External validation 3228 patients admitted to MAU 30-day mortality AUROC 0.649
Cattermole 2009 (129) External validation 330 patients in ED resus area 30-day mortality AUROC 0.754 (0.703-0.799)
7-day mortality or ICU 
admission
AUROC 0.761 (0.711-0.806)
PEDS
Cattermole 2009 (129) Secondary endpoint 330 patients in ED resus area 30-day mortality AUROC 0.898 (0.860-0.928)
Derivation 7-day mortality or ICU 
admission
AUROC 0.909 (0.872-0.938)
RAPS
Olsson 2003 (91) External validation 11751 patients at non-surgical 
Emergency Department
Hospital mortality AUROC 0.652 +/- 0.019
Goodacre 2006 (127) External validation
Secondary analysis quality data
2215 patients transported to ED 
by emergency ambulance
Hospital mortality AUROC 0.64 (0.59-0.69)
Man 2007 (344) External validation 867 patients in ED resus area 14-day mortality AUROC 0.654 (0.596-0.712)
REMS
Olsson 2003 (91) External validation 11751 patients at non-surgical 
Emergency Department
Hospital mortality AUROC 0.852 +/- 0.019
Goodacre 2006 (127) External validation
Secondary analysis quality data
2215 patients transported to ED 
by emergency ambulance
Hospital mortality AUROC 0.74 (0.7-0.78)
Man 2007 (344) External validation 867 patients in ED resus area 14-day mortality AUROC 0.723 (0.674-0.771)
Cattermole 2009 (129) External validation 330 patients in ED resus area 30-day mortality AUROC 0.771 (0.722-0.816)
7-day mortality or ICU 
admission
AUROC 0.696 (0.643-0.745)
RTS
Cattermole 2009 (129) External validation 330 patients in ED resus area 30-day mortality AUROC 0.766 (0.717-0.811)
7-day mortality or ICU 
admission
AUROC 0.748 (0.698-0.794)
SAPS II
Cosentini 2009 (346) External validation 211 patients admitted to MAU Hospital mortality AUROC 0.84 (0.77-0.91)
SEWS
Paterson 2006 (347) External validation
Secondary analysis of clinical 
audit
848 patients admitted to MAU or 
SAU
Hospital mortality Score 0-1 0.5%, 2-3 6%, 4-5 
15%, >5 20%
Simple Clinical Score
Kellett 2006 (92) Derivation 6736 patients admitted to MAU 30-day mortality AUROC 0.858 +/- 0.009
Internal validation 3228 patients admitted to MAU AUROC 0.856 +/- 0.013
Emmanuel 2010 (348) External validation 207 patients admitted to MAU Hospital mortality AUROC 0.94
Worthing
Duckitt 2007 (349) Derivation 3184 patients admitted to MAU Hospital mortality AUROC 0.74 (0.71-0.77)
Internal validation 1102 patients admitted to MAU AUROC 0.72 (0.66-0.79)
MAU: medical assessment unit; SAU: surgical assessment unit
Other
AF nomogram
Barrett 2011 (350) Derivation 832 ED patients with 
symptomatic AF
30-day mortality, 
cardiovascular event or 
return to ED
AUROC 0.67 (0.63-0.71)
APACHE II (modified)
Eizadi-Mood 2007 (351) External validation 131 patients hospitalised with 
organophosphate poisoning
Need for ET intubation AUROC 0.892 (0.826-0.940)
Mood 2011 (352) External validation 92 patients hospitalised with 
mixed drug overdose
Hospital mortality AUROC 0.81 (0.69-0.89)
Aronin
Aronin 1998 (353) Derivation 176 patients hospitalised with 
bacterial meningitis on LP
Hospital mortality AUROC 0.73 (0.62-0.81)
Internal validation 93 patients hospitalised with 
bacterial meningitis on LP
AUROC 0.81 (0.71-0.92)
Elbaz
Elbaz 2008 (354) Derivation 169 patients hospitalised with 
core temperature <35
Hospital mortality AUROC 0.81 (0.75-0.87)
Fournier’s Gangrene Severity Index
Corcoran 2008 (355) External validation 68 patients hospitalised with 
Fournier’s gangrene
Hospital mortality For cutoff 9 sensitivity 71.4% 
specificity 90%
GCS
Davies 2008 (356) External validation
Secondary analysis of RCT
990 patients hospitalised with 
organophosphate poisoning
Hospital mortality AUROC 0.84 (0.8-0.87)
Mood 2011 (352) External validation 92 patients hospitalised with 
mixed drug overdose
Hospital mortality AUROC 0.77 (.64-.86)
Get with the Guidelines Stroke Score
Smith 2010 (357) Derivation 164993 ED patients with 
ischaemic CVA
Hospital mortality AUROC 0.72
Internal validation 109995 ED patients with 
ischaemic CVA
AUROC 0.72
Get with the Guidelines Stroke Score with NIHSS
Smith 2010 (357) Derivation 164993 ED patients with 
ischaemic CVA
Hospital mortality AUROC 0.84
Internal validation 109995 ED patients with 
ischaemic CVA
AUROC 0.85
NIHSS
Fonarow 2012 (358) External validation 33102 patients hospitalised with 
ischaemic CVA
30-day mortality AUROC 0.82 (0.81-0.83)
Poison severity score
Davies 2008 (356) External validation
Secondary analysis of RCT
990 patients hospitalised with 
organophosphate poisoning
Hospital mortality AUROC 0.81 (0.77-0.85)
SOFA
Dutta 2008 (359) External validation 23 patients hospitalised with 
myxoedema coma
Hospital mortality AUROC 0.629 (0.38-0.878)
CVA: cerebrovascular accident; LP: lumbar puncture
Appendix 3 Variables in existing scoring systems
Age
Single cut-point
Mannheim Peritonitis 50
PSI Pneumonia 50
Modified Glasgow Pancreatitis 55
Ranson Pancreatitis 55
ABCD CVA/TIA 60
ABCD2 CVA/TIA 60
Altona Peritonitis 60
BISAP Asthma/COPD 60
BALI Pancreatitis 65
BAP-65 COPD 65
Bazzino ACS 65
CRB-65 Pneumonia 65
CURB-65 Pneumonia 65
Glasgow (Imrie) pancreatitis Pancreatitis 65
MEDS Sepsis 65
Modified TIMI ACS 65
OESIL Syncope 65
PMEWS Unselected 65
TIMI ACS 65
Sanchis ACS 67
Elbaz Hypothermia 70
Peritonitis severity score Peritonitis 70
Ranson (Biliary) Pancreatitis 70
Bordley 75
Hardman AAA 76
Modified Hardman AAA 76
Mayo ACS 80
REA-ICU Pneumonia 80
SCAP Pneumonia 80
Multiple cut-points
GRACE ACS 30, 40, 50, 60, 70, 80, 90
Hasdai ACS 30, 40, 50, 60, 70, 80, 90
Weisfelt Meningitis 30, 40, 50, 60, 70, 80
SAPS II Unselected 40, 60, 70, 75, 80
IHDI ACS 40, 70
REMS Unselected 45, 55, 65, 75
SAPS Unselected 45, 55, 65, 75
Kellett Unselected 50(m)/55(w), 75
PURSUIT ACS 50, 60, 70, 80
Freedom-from-event score ACS 40, 45, 50, 55, 60, 65, 
70, 75, 80, 85, 90
POSSUM Surgical 60, 70
PREDICT ACS 60, 70
RAAA-POSSUM AAA 60, 70
V-POSSUM AAA 60, 70
CR POSSUM Surgical 60, 70, 80
Rockall GI bleed 60, 80
Chang ACS 65, 75
PAMI ACS 65, 75
TIMI STEMI ACS 65, 75
Continuous variable
Coronary prognostic index 
(Norris)
ACS
EFFECT Heart failure
EMMACE ACS
Glasgow aneurysm score AAA
MINAP ACS
MPM II Unselected
Normand ACS
PESI PE
Selker ACS Truncated at 50 and 80
ADHERE logistic regression ACS x0.0288
Non-linear correlation
TIMI risk index ACS (Age/10)sq
AVPU consciousness level
Single cut-point
National asthma guidelines Asthma/COPD Not A
Kellett Unselected "Coma"
Worthing Unselected Not A
Multiple cut-points
Pitt Bacteremia score Sepsis AVPU
MEWS Unselected AVPU
PMEWS Unselected AVPU
SEWS Unselected AVPU
Diastolic blood pressure
Single cut-point
ABCD CVA/TIA 90
ABCD2 CVA/TIA 90
CRB-65 Pneumonia 60
CURB-65 Pneumonia 60
American Thoracic Society 
2001 Pneumonia 60
British Thoracic Society Pneumonia 60
CORB Pneumonia 60
CRB Pneumonia 60
CURB Pneumonia 60
Modified BTS Pneumonia 60
Multiple cut-points
Hasdai
ACS
20mmHg intervals 40-
200
Non-linear
Pitt Bacteremia score Sepsis Drop >20mmHg
Glasgow Coma Scale
Single cut-point
Edinburgh aneurysm score AAA 14
BISAP Pancreatitis 15
MPM II Unselected 5
Multiple cut-points
V-POSSUM AAA 9, 12, 15
Poison severity score Poisoning 9, 14
POSSUM Surgical 9, 12, 15
APACHE-O Unselected 8, 11, 14
PEDS Unselected 9, 13
RAPS Unselected 5, 8, 11, 14
REMS Unselected 5, 8, 11, 14
RTS Unselected 3, 4, 6, 9, 13
SAPS Unselected 4, 7, 10, 13
SAPS II Unselected 6, 9, 11, 14
SOFA Unselected 6, 10, 13, 15
Continuous variable
Weisfelt Meningitis
APACHE II Acute physiology Unselected
APACHE II Unselected
Mean arterial pressure
Single cut-point
Elbaz Hypothermia 90
SOFA Unselected 70
Multiple cut-points
CAPS Asthma/COPD 40, 50, 60, 70, 90, 100
APACHE II Acute physiology Unselected
49, 69, 109, 129, 159
APACHE II Unselected 49, 69, 109, 129, 159
REMS Unselected 50, 60, 110, 130, 160
RAPS Unselected 50, 60, 110, 130, 160
Non-linear correlation
Normand ACS Log
MODS Unselected 1/MAP
Oxygen saturation
Single cut-off
Pulmonary embolism 
severity index
PE
90 (No FiO2 analysis)
REA-ICU Pneumonia 90 (No FiO2 analysis)
CORB Pneumonia 90 (No FiO2 analysis)
MEDS Sepsis 90 (or requiring 
supplemental O2)
HOTEL Unselected 90 (No FiO2 analysis)
Multiple cut-offs
National asthma guidelines Asthma 92, 95 (No FiO2 analysis)
SMART-COP Pneumonia 93 (<50y), 90 (>50y) 
(Could use PaO2/FiO2)
Kellett Unselected 90, 95 (No FiO2 analysis)
PMEWS Unselected 90, 94, 96 (No 
FiO2analysis)
REMS Unselected 75, 85, 89 (No FiO2 
analysis)
SEWS Unselected 85, 90, 93 (No FiO2 
analysis)
Worthing Unselected 96, 94, 92 (Breathing 
room air)
Pulse rate
Single cut-point
BISAP Pancreatitis 90
SIRS Unselected 90
Normand ACS 100
Rockall GI bleed 100
Blatchford GI bleed 100
Strate GI bleed 100
TIMI STEMI ACS 100
Worthing Unselected 100
Modified Blatchford GI bleed 100
PAMI ACS 100
BAP-65 COPD 110
Pulmonary embolism 
severity index
PE
110
Pulmonary edema 
prognostic score
LVF
115
Weisfelt Meningitis 120
PSI Pneumonia 124
SMART-COP Pneumonia 125
SMRT-CO Pneumonia 125
REA-ICU Pneumonia 125
Multiple cut-points
Chang ACS 63, 85
Freedom-from-event score ACS 10bpm intervals 30-150
GRACE ACS 50, 70, 90, 110, 150, 200
PREDICT ACS 100, 120
Hasdai ACS 20bpm intervals 40-260
CAPS Asthma/COPD 80, 110, 130, 150, 170
National asthma guidelines Asthma 100, 120
Poison severity score Poisoning 40, 50, 140, 180
CR POSSUM Surgical 40, 100, 120
POSSUM Surgical 40, 50, 80, 100, 120
APACHE II Acute physiology Unselected 39, 54, 69, 109, 139, 179
APACHE II Unselected 39, 54, 69, 109, 139, 179
APACHE-O Unselected 39, 54, 69, 109, 139, 179
LODS Unselected 30, 140
MEWS Unselected 40, 50, 100, 110, 130
PMEWS Unselected 40, 50, 100, 110, 130
REMS Unselected 40, 55, 70, 110, 140, 180
RAPS Unselected 40, 55, 70, 110, 140, 180
SAPS Unselected 40, 55, 70, 110, 140, 180
SAPS II Unselected 40, 70, 120, 160
SEWS Unselected 30, 40, 50, 100, 110, 130
Continuous variable
TIMI risk index ACS
EMMACE ACS
MINAP ACS
ADHERE logistic regression LVF
MODS Unselected
MPM II Unselected
Non-linear correlation
Glasgow aneurysm score AAA "Shock"
Selker ACS Dependent on SBP
Kellett Unselected >SBP
Respiratory rate
Single cut-point
BISAP Pancreatitis 20
SIRS Unselected 20
MEDS Sepsis 20
PSI Pneumonia 30
REA-ICU Pneumonia 30
CRB-65 Pneumonia 30
CURB-65 Pneumonia 30
CORB Pneumonia 30
CRB Pneumonia 30
CURB Pneumonia 30
Le Conte LVF 30
Brigham LVF 30
British Thoracic Society Pneumonia 30
American Thoracic Society 
2007
Pneumonia
30
Modified BTS Pneumonia 30
SCAP Pneumonia 30
Multiple cut-points
SMART-COP Pneumonia 25 (<50), 30 (>50y)
SMRT-CO Pneumonia 25 (<50), 30 (>50y)
APACHE II Acute physiology Unselected 5, 9, 11, 24, 34, 49
APACHE II Unselected 5, 9, 11, 24, 34, 49
APACHE-O Unselected 5, 9, 11, 24, 34, 49
MEWS Unselected 9, 15, 21, 30
PMEWS Unselected 8, 18, 25, 30
RAPS Unselected 6, 10, 12, 25, 35, 50
REMS Unselected 6, 10, 12, 25, 35, 50
RTS Unselected 0, 1, 6, 10, 30
SAPS Unselected 6, 10, 12, 25, 35, 50
SEWS Unselected 8, 20, 30, 35
Worthing Unselected 20, 22
Continuous variable
Normand ACS Truncated <12
EFFECT LVF
Systolic blood pressure
Single cut-point
CRB-65 Pneumonia 90
CURB-65 Pneumonia 90
CORB Pneumonia 90
CRB Pneumonia 90
CURB Pneumonia 90
Edinburgh aneurysm score AAA 90
Brigham LVF 90
MEDS Sepsis 90 after fluids
PSI Pneumonia 90
San Francisco Syncope 90
SMART-COP Pneumonia 90
SMRT-CO Pneumonia 90
Peritonitis severity score Peritonitis 90
SCAP Pneumonia 90
Modified Hardman AAA 100
BLEED GI bleed 100
Bordley GI bleed 100
Rockall GI bleed 100
TIMI STEMI ACS 100
Pulmonary embolism 
severity index
PE
100
Worthing Unselected 100
HOTEL Unselected 100
Goldman ACS 110
Strate GI bleed 115
Pulmonary edema 
prognostic score
LVF
130
ABCD TIA 140
ABCD2 TIA 140
Mayo ACS 140
Multiple cut-points
V-POSSUM AAA 90, 100, 110, 130, 170
Chang ACS 120, 132
Freedom-from-event score ACS 100, 120, 140, 160, 180, 
200
GRACE ACS 80, 100, 120, 140, 160, 
200
Hasdai ACS 20mmHg intervals 80-
280
PREDICT ACS 60, 100
Blatchford GI bleed 90, 100
Modified Blatchford GI bleed 90, 100, 110
EFFECT LVF 90, 100, 120, 140, 160, 
180
Aronin Meningitis 90 or 40 drop
Poison severity score Poisoning 80, 100
American Thoracic Society 
2001
Pneumonia
90, shock
Modified ATS Pneumonia 90, shock
American Thoracic Society 
2007
Pneumonia
"hypotension", "shock"
Pitt Bacteremia score Sepsis 90 or drop 30
CR POSSUM Surgical 90, 100, 170
POSSUM Surgical 90, 100, 110, 130, 170
Kellett Unselected 70, 80, 100
LODS Unselected 40, 70, 90, 240, 270
MEWS Unselected 70, 80, 100, 200
PEDS Unselected 100, 140
PMEWS Unselected 70, 90, 100
RTS Unselected 0, 1, 50, 76, 90
SAPS Unselected 55, 80, 150, 190
SAPS II Unselected 70, 100, 200
SEWS Unselected 70, 80, 100, 200
Continuous variable
Coronary prognostic index 
(Norris)
ACS
Cont
EMMACE ACS Cont
MINAP ACS Cont
ADHERE logistic regression LVF Cont
Non-linear correlation
Glasgow aneurysm score AAA "Shock"
Selker ACS Continuous (truncated 
175) also squared
TIMI risk index ACS 1/SBP
Mannheim Peritonitis "Shock"
MPM II Unselected Continuous and squared
Temperature
Single cut-point
HOTEL Unselected 35
Worthing Unselected 35.3
American Thoracic Society 
2007
Pneumonia
36
SAPS II Unselected 39
Multiple cut-points
BISAP Pancreatitis 36, 38
PSI Pneumonia 35, 39.9
Pitt Bacteremia score Sepsis 35, 36, 39, 40
APACHE II Acute physiology Unselected 30, 32, 34, 36, 38.5, 39, 
41
APACHE II Unselected 30, 32, 34, 36, 38.5, 39, 
41
APACHE-O Unselected 30, 32, 34, 36, 38.5, 39, 
41
Kellett Unselected 35, 39
MEWS Unselected 35, 38.5
PMEWS Unselected 35, 36, 38, 39
REMS Unselected 30, 32, 34, 36, 38.5, 39, 
41
SAPS Unselected 30, 32, 34, 36, 38.5, 39, 
41
SEWS Unselected 34, 35, 36, 38, 39
SIRS Unselected 36, 38
Appendix 4: L’Abbé plots of risk for individual physiological variables
Each circle represents one study.
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Appendix 5: Odds ratios for individual physiological variables
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Appendix 6: Univariate analysis of continuous variables in the prediction of death at 7 days
Graphs present the proportion of patients dying, with 95% confidence intervals.
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Normal (70-100) 45 (3.5) 1289
High (>100) 6 (5.7) 105
Missing 16 (14.3) 112
Chi-sq p <0.001
Very low (<60) Low (60-69) Normal (70-100) High (>100) Missing
0
0.05
0.1
0.15
0.2
Dead Total
Temperature population quintiles
<36 42 (9.0) 469
36-36.3 19 (5.1) 373
36.4-36.8 22 (4.6) 477
36.9-37.3 15 (4.2) 358
>37.3 17 (4.5) 377
Missing 13 (4.2) 309
Chi-sq p 
0.012
<36 36-36.3 36.4-36.8 36.9-37.3 >37.3 Missing
0
0.02
0.04
0.06
0.08
0.1
0.12
Dead Total
Pulse pressure population quintiles
<40 35 (9.4) 373
40-52 25 (5.0) 505
53-64 14 (3.1) 456
65-80 16 (3.2) 498
>80 21 (5.0) 417
Missing 17 (14.9) 114
Chi-sq p <0.001
<40 40-52 53-64 65-80 >80 Missing
0
0.05
0.1
0.15
0.2
Dead Total
Pulse pressure value quintiles
<40 35 (9.4) 373
41-70 48 (4.1) 1174
71-109 22 (3.5) 637
110-140 5 (8.1) 62
>140 1 (33.3) 3
Missing 17 (14.9) 114
Chi-sq p <0.001
<40 41-70 71-109 110-140 >140 Missing
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
Dead Total
GCS population tertiles
<14 48 (24.2) 198
14 16 (5.5) 290
15 40 (2.6) 1564
Missing 24 (7.7) 311
Chi-sq p <0.001
<14 14 15 Missing
0
0.05
0.1
0.15
0.2
0.25
0.3
Dead Total
GCS a priori groups
3-5 13 (54.2) 24
6-8 7 (26.9) 26
9-12 26 (23.4) 111
13-14 18 (5.5) 327
15 40 (2.6) 1564
Missing 24 (7.7) 311
Chi-sq p <0.001
3-5 6-8 9-12 13-14 15 Missing
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
Dead Total
Oxygen saturations breathing air population quartiles
<95 33 (7.8) 421
95-6 10 (2.4) 424
97-8 6 (1.1) 551
99-100 8 (2.5) 326
Missing 71 (11.1) 641
Chi-sq p <0.001
<95 95-6 97-8 99-100 Missing
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
Dead Total
Oxygen saturations breathing air a priori groups
Very low (<90) 22 (16.8) 131
Low (90-3) 7 (4.0) 174
Normal (94-100) 28 (2.0) 1417
Missing 71 (11.1) 641
Chi-sq p <0.001
Very low (<90) Low (90-3) Normal (94-100) Missing
0
0.05
0.1
0.15
0.2
0.25
Dead Total
Oxygen saturations breathing supplemental oxygen 
population tertiles
<95 17 (15.2) 112
95-8 17 (7.7) 220
99-100 15 (6.9) 219
Missing 79 (4.4) 1812
Chi-sq p <0.001
<95 95-8 99-100 Missing
0
0.05
0.1
0.15
0.2
Dead Total
Age population quintiles
<50 4 (1) 435
50-69 17 (3.4) 504
70-78 27 (5.4) 498
79-85 30 (6.4) 466
>85 50 (10.9) 460
Chi-sq p <0.001
<50 50-69 70-78 79-85 >85
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
Dead Total
Age value quintiles
<35 1 (0.5) 188
36-50 4 (1.5) 269
51-65 11 (3.3) 329
66-80 39 (5.1) 772
>80 73 (9.1) 805
Chi-sq p <0.001
<35 36-50 51-65 66-80 >80
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
Appendix 7: 
Interactions between significant variables in predicting death in 7 days
Interaction term Wald Degrees of freedom p
Active malignancy by pulse 0.268 2 0.875
Active malignancy by respiratory rate 0.832 2 0.660
Active malignancy by SBP 5.479 3 0.140
Active malignancy by DBP 2.338 2 0.311
Active malignancy by SaO2 0.710 2 0.701
Active malignancy by respiratory 
disease
0.400 1 0.527
Age by pulse 3.200 6 0.783
Age by respiratory rate 8.305 6 0.217
Age by SBP 6.399 9 0.699
Age by DBP 5.860 6 0.439
Age by GCS 5.507 9 0.788
Age by SaO2 6.288 6 0.392
Age by pulse pressure 6.066 9 0.733
Age by respiratory disease 2.547 4 0.636
Pulse by respiratory rate 1.050 4 0.902
Pulse by SBP 9.920 6 0.128
Pulse by DBP 4.567 4 0.335
Pulse by GCS 6.665 6 0.353
Pulse by SaO2 6.598 4 0.159
Pulse by pulse pressure 1.815 6 0.936
Pulse by respiratory disease 0.753 2 0.686
Respiratory rate by SBP 8.490 6 0.204
Respiratory rate by DBP 4.960 4 0.291
Respiratory rate by GCS 3.066 6 0.801
Respiratory rate by SaO2 4.998 4 0.288
Respiratory rate by pulse pressure 8.751 6 0.188
Respiratory rate by respiratory disease 2.454 2 0.293
SBP by DBP 1.508 6 0.959
SBP by GCS 6.292 9 0.710
SBP by SaO2 4.613 6 0.594
SBP by pulse pressure 6.154 8 0.630
SBP by respiratory disease 4.917 3 0.178
DBP by GCS 2.019 6 0.918
DBP by SaO2 2.978 4 0.561
DBP by pulse pressure 9.131 6 0.166
DBP by respiratory disease 1.128 2 0.569
GCS by SaO2 5.845 6 0.441
GCS by pulse pressure 7.627 9 0.572
GCS by respiratory disease 4.408 3 0.221
SaO2 by pulse pressure 3.246 6 0.777
SaO2 by respiratory disease 0.363 2 0.834
Graphs below present proportion of deaths by interaction groups.
Active malignancy by age
B Sig. Exp(B)
Active malignancy present -5.808 <0.001 0.003
Age  .166  
Age 50-69 5.603 <0.00
1
271.246
Age 70-85 -0.686 0.036 0.504
Age >85 -0.810 0.006 0.445
Active malignancy by age  <0.001  
Active malignancy present by age 50-69 -14.575 <0.00
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0
Active malignancy present by age 70-85 -1.315 0.044 0.269
Active malignancy present by age >85 0.029 0.961 1.029
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Active malignancy by GCS
B Sig. Exp(B)
Active malignancy present -3.874 <0.001 0.021
GCS  <0.001  
GCS 3-5 9.230 <0.001 10201
GCS 6-12 1.731 <0.001 5.644
GCS 13-14 0.461 0.215 1.585
Active malignancy by GCS  <0.001  
Active malignancy present by GCS 3-5 -10.688 <0.001 0
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Active malignancy by temperature 
B Sig. Exp(B)
Active malignancy present 5.271 <0.001 194.706
Temperature <36 4.224 <0.001 68.328
Active malignancy present and temperature <36 6.917 <0.001 1009.38
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Active malignancy by pulse pressure
B Sig. Exp(B)
Active malignancy present -4.795 <0.001 0.008
Pulse pressure  <0.001  
Pulse pressure <40 0.995 0.001 2.705
Pulse pressure 40-53 2.752 <0.001 15.672
Pulse pressure >80 1.216 0.004 3.375
Active malignancy by pulse pressure  <0.001  
Active malignancy present by pulse pressure <40 0.236 0.703 1.267
Active malignancy present by pulse pressure 40-52 -4.854 <0.001 0.008
Active malignancy present by pulse pressure >80 -1.069 0.202 0.343
<40 40-52 53-80 >80
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Temperature by age
B Sig. Exp(B)
Temperature <36 2.569 <0.001 13.047
Age (ref <50) <0.001
50-69 -1.469 <0.001 0.230
70-85 -2.335 <0.001 0.097
>85 -0.990 <0.001 0.371
Temperature by age <0.001
Age 50-69 by temperature <36 -2.978 <0.001 0.051
Age 70-85 by temperature <36 -4.004 <0.001 0.018
Age >85 by temperature <36 -2.929 <0.001 0.053
<50 50-69 70-85 >85
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Pulse by temperature
B Sig. Exp(B)
Pulse <0.001
Pulse 80-105 0.334 0.009 1.396
Pulse >105 3.985 <0.001 53.808
Temperature <36 3.410 <0.001 30.255
Pulse by temperature <0.001
Pulse 80-105 by temperature <36 0.421 0.1 1.523
Pulse >105 by temperature <36 6.806 <0.001 903.281
<80 80-105 >105
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Respiratory rate by temperature
B Sig. Exp(B)
Temperature <36 3.174 <0.001 23.891
Respiratory rate (ref <19) <0.001
19-23 0.746 <0.001 2.108
>23 4.657 <0.001 105.311
Temperature by respiratory rate <0.001
Respiratory rate 19-23 by temperature <36 0.248 0.342 1.281
Respiratory rate >23 by temperature <36 5.586 <0.001 266.543
<19 19-23 >23
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SBP by temperature 
B Sig. Exp(B)
Temperature <36 2.211 <0.001 9.122
SBP (ref 140-60) <0.001
<110 -4.393 <0.001 0.012
110-139 -1.882 <0.001 0.152
>160 -3.031 <0.001 0.048
Temperature by SBP <0.001
SBP <110 by temperature <36 -2.950 0.007 0.052
SBP 110-139 by temperature <36 -1.562 <0.001 0.210
SBP >160 by temperature <36 -1.684 <0.001 0.186
<110 110-139 140-160 >160
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DBP by Temperature 
B Sig. Exp(B)
Temperature <36 2.990 <0.001 19.877
DBP (ref 65-90) <0.001
<65 1.306 <0.001 3.693
>90 4.229 <0.001 68.652
DBP by temperature <0.001
DBP <65 by temperature <36 0.090 0.727 1.095
DBP >90 by temperature <36 5.281 <0.001 196.587
<65 65-90 >90
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Temperature by GCS
B Sig. Exp(B)
Temperature <36 -1.459 0.010 0.232
GCS (ref 15) <0.001
3-5 9.569 <0.001 14315
6-12 2.554 <0.001 12.858
13-14 1.008 <0.001 2.739
GCS by temperature 0.002
3-5 by temperature <36 -8.358 <0.001 0
6-12 by temperature <36 0.035 0.942 1.036
13-14 by temperature <36 0.166 0.698 1.181
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SaO2 by temperature
B Sig. Exp(B)
Temperature <36 3.186 <0.001 24.2
SaO2 (ref low risk) <0.001
High risk 4.488 <0.001 88.928
Moderate risk 0.532 <0.001 1.703
Temperature by SaO2 <0.001
High risk by temperature <36 5.876 <0.001 356.496
Moderate risk by temperature <36 0.281 0.276 1.325
High Moderate Low
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
<36
>36
Pr
op
or
tio
n 
m
or
ta
lit
y
Temperature by pulse pressure
B Sig. Exp(B)
Temperature <36 2.191 <0.001 8.948
Pulse pressure <0.001
Pulse pressure <40 1.396 <0.001 4.037
Pulse pressure 40-52 1.009 <0.001 2.743
Pulse pressure >80 1.696 <0.001 5.453
Pulse pressure by respiratory disease <0.001
Pulse pressure <40 by temperature <36 0.702 0.020 2.017
Pulse pressure 40-52 by temperature <36 0.432 0.131 1.541
Pulse pressure >80 by temperature <36 1.440 <0.001 4.222
<40 40-52 53-80 >80
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Temperature by respiratory disease
B Sig. Exp(B)
Respiratory disease present 3.972 <0.001 53.107
Temperature <36 3.326 <0.001 27.824
Respiratory disease present and temperature <36 4.599 <0.001 99.382
Respiratory disease No respiratory disease
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Pulse pressure by respiratory disease
B Sig. Exp(B)
Respiratory disease present 3.608 <0.001 36.888
Pulse pressure  <0.001  
Pulse pressure <40 2.862 <0.001 17.491
Pulse pressure 40-52 1.419 <0.001 4.132
Pulse pressure >80 1.341 <0.001 3.824
Pulse pressure by respiratory disease  <0.001  
Pulse pressure <40 by respiratory disease present 3.447 <0.001 31.391
Pulse pressure 40-52 by respiratory disease present 1.408 0.002 4.088
Pulse pressure >80 by respiratory disease present 0.773 0.069 2.166
<40 40-52 53-80 >80
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Appendix 8: Patients with outcomes of interest in the derivation cohort
Patients sustaining inevitable death (n=15)
Reference Age/gender Description
271 91F Presented unresponsive, died day 0
767 86M Presented collapse, died day 6
1143 89F Presented unwell, died day 7
728 95F Presented with fall, died day 5
248 67M Presented difficulty breathing, died day 0
242 69M Presented heart failure, died day 1
752 81F Presented difficulty breathing, died day 1
945 75M Presented hypothermic, died day 6
409 73F Lung carcinoma, presented short of breath, died day 1
375 83F Presented respiratory failure, died day 7
1016 66M Presented collapse, died day 2
430 95F Presented short of breath, died day 0
508 94F Presented unwell, died day 0
568 79F Presented with possible cardiac arrest prehospital, died day 1
730 86M Presented unwell, died day 0
Patients sustaining preventable death (n=5)
Reference Age/gender Description
765 74M Presented unwell, CPAP, died day 1
490 84M Presented abdominal pain, died day 2
475 75M Presented short of breath, acute MI, died day 4
398 86M Presented unwell, pneumonia, died day 7
379 73F Presented short of breath, died day 2 from dissecting aneurysm 
not visible on CTPA day 1
Patients in whom death was prevented (n=79)
Reference Age/gender Description
232 57M Presented with potential abdominal problem, cardiac catheter 
day 0
233 84M Presented difficulty breathing, CPAP day 0
277 56M Presented difficulty breathing, appendicectomy day 1
303 20M Presented with potential pneumonia, chest drain day 0
305 58F Presented abdominal pain, appendicectomy day 1
316 36M Presented chest pain, thrombolysis day 0
327 73M Presented short of breath, CPAP day 0
346 56M Presented difficulty breathing, CPAP day 1
373 74F Presented difficulty breathing, CPAP day 0
493 74F Presented short of breath, BIPAP day 0
449 38F Presented unwell, ICU
534 46M Presented fitting, ICU
535 65M Presented chest pain, cardiac catheter
543 84M Presented vomiting blood, OGD with adrenaline injection
553 66F Presented exacerbation COPD, BiPAP day 0
591 41F Presented unwell, ICU day 2
623 36M Presented epigastric pain, appendicectomy day 1
628 70F Presented unwell, ICU day 0
486 57M Presented overdose, NAC
506 21F Presented overdose, NAC
338 94F Presented overdose, NAC
693 76F Presented chest pain, cardiac cath day 3
629 80M Presented chest pain, IV antibiotics sepsis
1070 69F Presented abdominal pain, transfusion for upper GI bleed
560 94F Presented collapse, cardioversion day 0
621 72M Presented with potential chest infection, IV antibiotics given for 
sepsis of unknown source
638 42F Presented chest/abdominal pain, CPAP day 1
749 76M Presented diabetic, IV antibiotics for sepsis
779 69F Presented fall, IV antibiotics and HDU day 4 for LRTI
257 89M Presented pyrexic, IV antibiotics urosepsis (died after day 7)
370 77M Presented fall, IV antibiotics urosepsis day 2
473 77M Presented short of breath, CPAP day 1
928 56M Presented short of breath, BiPAP day 0
695 68F Presented short of breath, BiPAP day 0
589 23F Presented pneumonia, IV antibiotics and fluids
548 48F Presented collapse, HDU IV antibiotics/antivirals for potential 
encephalitis
234 61M Presented collapse, IV antibiotics urosepsis
608 49F Presented asthma, IV MgSO4
351 85F Presented fast AF, IV antibiotics for sepsis of unknown source
551 39M Presented collapse, IV antibiotics HDU for DKA
530 73F Presented fall, 2L IVI for postural hypotension
935 63F Presented chest pain, cardiac catheter day 5
753 26F Presented unresponsive, naloxone
1066 68M Presented chest pain, thrombolysis day 0
737 89M Presented fall, IV antibiotics pneumonia
1109 39M Presented overdose, NAC
722 40F Presented asthma, IV MgSO4/aminophylline
794 74M Presented collapse, IV antibiotics sepsis of unknown source
1136 39F Presented overdose, NAC
538 79F Presented unwell, IV antibiotics sepsis day 2
396 75M Presented abdo pain, IV antibiotics sepsis of unknown source
549 73M Presented short of breath, cardiac catheter day 6
771 18M Presented hyperglycaemia, IVI/insulin DKA
633 76M Presented high temp, IV antibiotics urosepsis
1097 76F Presented difficulty breathing, BiPAP day 0
786 86M Presented CVA, intubated post-fit
1181 92F Presented unwell, IV antibiotics sepsis day 2
476 83F Presented unwell, IV antibiotics sepsis secondary to pneumonia
776 37M Presented fall, ICU day 0
696 23M Presented hyperglycaemic, HDU/IVI/insulin DKA
1152 42F Presented OD, flumazenil
667 69F Presented chest/abdo pain, IV antibiotics biliary sepsis
953 33F Presented collapse, neurosurgery for SAH day 2
1146 79M Presented social problems, IVI rhabdomyolysis
1129 90M Presented with potential MI, pacemaker day 4
700 30M Presented overdose, NAC
931 55M Presented chest pain, cardiac catheter day 1
763 55M Presented vomiting blood, OGD/adrenaline
710 75M Presented collapse, ICU day 0
660 42F Presented overdose of insulin, IV dextrose
679 40M Presented overdose, ICU day 0
1159 50F Presented overdose, NAC
922 31M Presented intoxicated, naloxone
1048 78F Presented with potential GI bleed, 4unit transfusion
949 82F Presented near faint, adenosine cardioversion
1094 72F Presented acutely short of breath, IV GTN/frusemide
947 71F Presented palpitations, metoprolol cardioversion
442 93F Presented short of breath, IV frusemide/nitrate/MgSO4
417 82M Presented abdominal pain, IV pamidronate for hypercalcaemia
Appendix 9: Univariate analysis of continuous variables in predicting potentially prevented and potentially preventable death at 7 days
Tables present numbers (percentages) with each outcome.
Each graph presents proportions of potentially prevented (green) and potentially prevented plus potentially preventable (red) deaths, with 
95% confidence intervals.
Pulse rate
By quintiles of population
Potentially preventable 
+ potentially prevented
Potentially 
prevented
Total
<71 6 (8) 6 (8) 76
71-82 15 (20) 13 (17) 76
83-95 16 (20) 15 (19) 80
96-110 11 (14) 10 (12) 81
>110 34 (44) 33 (43) 77
Missing 2 (25) 2 (25) 8
Total 84 (21) 79 (20) 398
Chi-sq p <0.001 <0.001
<71 71-82 83-95 96-110 >110 Missing
0
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0.3
0.4
0.5
0.6
Prevented/able
Prevented
By quintiles of value
Potentially preventable + 
potentially prevented
Potentially 
prevented
Total
<66 5 (10) 5 (10) 48
66-95 32 (17) 29 (16) 184
96-125 25 (21) 23 (19) 121
126-155 19 (59) 19 (59) 32
>155 1 (20) 1 (20) 5
Missing 2 (25) 2 (25) 8
Total 84 (21) 79 (20) 398
Chi-sq p <0.001 <0.001
<66 66-95 96-125 126-155 >155 Missing
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0.6
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Prevented
By groups a priori from DAVROS study
Potentially 
preventable+ 
potentially prevented
Potentially 
prevented
Total
Low (<60) 2 (12) 2 (12) 17
Normal (60-
100)
40 (17) 36 (15) 237
High (100-130) 29 (26) 28 (25) 112
Very high 
(>130)
11 (46) 11 (46) 24
Missing 2 (25) 2 (25) 8
Total 84 (21) 79 (20) 398
Chi-sq p 0.008 0.003
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High (100-130)
Very high (>130)
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Respiratory rate
By quintiles of population
Potentially preventable + 
potentially prevented
Potentially 
prevented
Total
<16 7 (12) 6 (10) 59
16-17 17 (21) 17 (21) 80
18 13 (17) 13 (17) 76
19-23 15 (25) 14 (23) 60
>23 25 (35) 22 (31) 72
Missing 7 (14) 7 (14) 51
Total 84 (21) 79 (20) 398
Chi-sq p 0.016 0.056
<16 16-17 18 19-23 >23 Missing
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By quintiles of value
Potentially preventable 
+ potentially prevented
Potentially 
prevented
Total
<15 6 (11) 5 (9) 56
15-23 46 (21) 45 (21) 219
24-32 15 (29) 14 (27) 51
33-40 9 (64) 7 (50) 14
>40 1 (14) 1 (14) 7
Missing 7 (14) 7 (14) 51
Total 84 (21) 79 (20) 398
Chi-sq p <0.001 0.009
<15 15-23 24-32 33-40 >40 Missing
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0.4
0.5
0.6
0.7
0.8
Prevented/able
Prevented
By groups a priori from DAVROS study
Potentially preventable + 
potentially prevented
Potentially 
prevented
Total
Low (<10) 0 0 1
Normal (10-
25)
58 (20) 56 (19) 297
High (>25) 19 (39) 16 (33) 49
Missing 7 (14) 7 (14) 51
Total 84 (21) 79 (20) 398
Chi-sq p 0.009 0.083
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Systolic blood pressure
By quintiles of population
Potentially preventable + 
potentially prevented
Potentia
lly 
prevent
ed
Total
<110 25 (32) 23 (29) 79
110-124 13 (18) 12 (16) 73
125-139 17 (20) 16 (19) 85
140-155 11 (15) 11 (15) 74
>155 15 (19) 14 (18) 77
Missing 3 (30) 3 (30) 10
Total 84 (21) 79 (20) 398
Chi-sq p 0.149 0.237
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By quintiles of value
Potentially preventable + 
potentially prevented
Potentially 
prevented
Total
<86 8 (42) 8 (42) 19
86-125 32 (23) 28 (20) 139
126-165 31 (17) 30 (16) 186
166-205 9 (23) 9 (23) 39
>205 1 (20) 1 (20) 5
Missing 3 (30) 3 (30) 10
Total 84 (21) 79 (20) 398
Chi-sq p 0.150 0.133
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By groups a priori from DAVROS study
Potentially 
preventable + 
potentially 
prevented
Potentially 
prevented
Total
Very low (<100) 15 (36) 14 (33) 42
Low (100-120) 22 (26) 20 (24) 84
Normal (120-180) 37 (15) 35 (14) 244
High (>180) 7 (39) 7 (39) 18
Missing 3 (30) 3 (30) 10
Total 84 (21) 79 (20) 398
Chi-sq p 0.003 0.005
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Diastolic blood pressure
By quintiles of population
Potentially preventable + 
potentially prevented
Potentiall
y 
prevented
Total
<65 18 (24) 15 (20) 76
65-9 16 (19) 15 (18) 85
70-75 9 (14) 9 (14) 63
76-86 19 (23) 19 (23) 81
>86 18 (22) 17 (21) 81
Missing 4 (33) 4 (33) 12
Total 84 (21) 79 (20) 398
Chi-sq p 0.588 0.611
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0.3
0.4
0.5
0.6
Prevented/able
Prevented
By quintiles of value
Potentially preventable 
+ potentially prevented
Potentially 
prevented
Total
<56 11 (32) 9 (26) 34
56-74 32 (17) 30 (16) 189
85-93 29 (23) 29 (23) 128
94-112 8 (25) 7 (22) 32
>112 0 0 3
Missing 4 (33) 4 (33) 12
Total 84 (21) 79 (20) 398
Chi-sq p 0.227 0.342
<56 56-74 85-93 94-112 >112 Missing
0
0.1
0.2
0.3
0.4
0.5
0.6
Prevented/able
Prevented
By groups a priori from DAVROS study
Potentially 
preventable + 
potentially prevented
Potentially 
prevented
Total
Very low (<60) 14 (33) 12 (28) 43
Low (60-69) 20 (17) 18 (15) 118
Normal (70-100) 40 (20) 39 (19) 205
High (>100) 6 (30) 6 (30) 20
Missing 4 (33) 4 (33) 12
Total 84 (21) 79 (20) 398
Chi-sq p 0.138 0.194
Very low (<60) Low (60-9) Normal (70-100) High (>100) Missing
0
0.1
0.2
0.3
0.4
0.5
0.6
Prevented/able
Prevented
Pulse pressure
By quintiles of population
Potentially preventable 
+ potentially prevented
Potentially 
prevented
Total
<40 21 (28) 21 (28) 76
40-50 26 (30) 24 (28) 86
51-62 7 (10) 6 (8) 72
63-76 10 (13) 8 (11) 75
>76 16 (21) 16 (21) 77
Missing 4 (33) 4 (33) 12
Total 84 (21) 79 (20) 398
Chi-sq p 0.005 0.003
<40 40-50 51-62 63-76 >76 Missing
0
0.1
0.2
0.3
0.4
0.5
0.6
Prevented/able
Prevented
By quintiles of value
Potentially preventable + 
potentially prevented
Potentially 
prevented
Total
<35 16 (36) 16 (36) 45
35-60 38 (22) 35 (20) 176
61-85 16 (14) 14 (12) 118
85-110 10 (24) 10 (24) 42
>110 0 0 5
Missing 4 (33) 4 (33) 12
Total 84 (21) 79 (20) 398
Chi-sq p 0.031 0.012
<35 35-60 61-85 85-110 >110 Missing
0
0.1
0.2
0.3
0.4
0.5
0.6
Prevented/able
Prevented
Temperature
By quintiles of population
Potentially preventable + 
potentially prevented
Potentially 
prevented
Total
<35.8 18 (26) 17 (25) 69
35.8-36.2 16 (23) 14 (20) 70
36.3-36.7 16 (23) 15 (21) 70
36.8-37.2 10 (15) 10 (15) 68
>37.2 18 (24) 17 (23) 75
Missing 6 (13) 6 (13) 46
Total 84 (21) 79 (20) 398
Chi-sq p 0.400 0.557
<35.8 35.8-36.2 36.3-36.7 36.8-37.2 >37.2 Missing
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
Prevented/able
Prevented
Glasgow Coma Scale
By quartiles of population
Potentially preventable + 
potentially prevented
Potentially 
prevented
Total
<13 13 (42) 11 (35) 31
13 2 (22) 2 (22) 9
14 8 (20) 8 (20) 40
15 49 (18) 48 (17) 275
Missing 12 (28) 10 (23) 43
Total 84 (21) 79 (20) 398
Chi-sq p 0.026 0.192
<13 13 14 15 Missing
0
0.1
0.2
0.3
0.4
0.5
0.6
Prevented/able
Prevented
Potentially preventable + 
potentially prevented
Potentially 
prevented
Total
3-5 2 (66) 1 (33) 3
6-8 4 (57) 4 (57) 7
9-12 7 (33) 6 (29) 21
13-14 10 (20) 10 (20) 49
15 49 (18)  48 (17) 275
Missing 12 (28) 10 (23) 43
Total 84 (21) 79 (20) 398
Chi-sq p 0.015 0.118
3-5 6-8 9-12 13-14 15 Missing
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
Prevented/able
Prevented
Oxygen saturations breathing air
By quartiles of population
Potentially preventable + 
potentially prevented
Potentially 
prevented
Total
<95 23 (32) 20 (27) 73
95-6 15 (22) 13 (19) 67
97-8 13 (16) 13 (16) 79
99-100 6 (9) 6 (9) 67
Missing 27 (24) 27 (24) 112
Total 84 (21) 79 (20) 398
Chi-sq p 0.015 0.05
<95 95-6 97-8 99-100 Missing
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
0.45
Prevented/able
Prevented
By groups a priori from DAVROS study
Potentially 
preventable + 
potentially 
Potentially 
prevented
Total
prevented
Very low (<90) 10 (32) 9 (29) 31
Low (90-3) 8 (33) 7 (29) 24
Normal (94-100) 39 (17) 36 (16) 231
Missing 27 (24) 27 (24) 112
Total 84 (21) 79 (20) 398
Chi-sq p 0.056 0.076
Very low (<90) Low (90-3) Normal (94-100) Missing
0
0.1
0.2
0.3
0.4
0.5
Prevented/able
Prevented
Oxygen saturations breathing supplemental oxygen
By tertiles of population
Potentially preventable + 
potentially prevented
Potentiall
y 
prevented
Total
<96 7 (32) 7 (32) 22
96-99 16 (25) 16 (25) 63
100 4 (19) 4 (19) 21
Missing 57 (20) 52 (18) 292
Total 84 (21) 79 (20) 398
Chi-sq p 0.439 0.264
<96 97-8 99-100 Missing
0
0.1
0.2
0.3
0.4
0.5
Prevented/able
Prevented
Age
By quintiles of population
Potentially preventable 
+ potentially prevented
Potentially 
prevented
Total
<45 22 (28) 22 (28) 78
 45-64 15 (19) 15 (19) 79
 65-75 21 (29) 18 (25) 72
 76-85 18 (19) 17 (18) 97
 >85 8 (11) 7 (10) 72
Total 84 (21) 79 (20) 398
Chi-sq p 0.039 0.047
<45 45-64 65-75 76-85 >85
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
0.45
Prevented/able
Prevented
By quintiles of value
Potentially preventable + 
potentially prevented
Potentially 
prevented
Total
<36 9 (26) 9 (26) 35
36-53 17 (24) 17 (24) 71
54-71 19 (21) 19 (21) 92
72-89 34 (21) 29 (18) 164
>89 5 (14) 5 (14) 36
Total 84 (21) 79 (20) 398
Chi-sq p 0.747 0.587
<36 36-53 54-71 72-89 >89
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
0.45
Prevented/able
Prevented
Appendix 10:
Interactions between significant variables in predicting potentially preventable 
and potentially prevented death
Interaction term Wald Degrees of freedom p
Pulse by respiratory rate 19.290 6 0.004
Pulse by SBP 19.200 6 0.004
Pulse by pulse pressure 9.008 4 0.061
Pulse by GCS 2.449 4 0.654
Pulse by SaO2 20.088 4 <0.001
Respiratory rate by SBP 12.699 9 0.177
Respiratory rate by pulse pressure 16.431 6 0.012
Respiratory rate by GCS 5.453 6 0.487
Respiratory rate by SaO2 14.071 6 0.029
SBP by pulse pressure 32.734 4 <0.001
SBP by GCS 2.424 6 0.877
SBP by SaO2 20.303 6 0.002
Pulse pressure by GCS 5.261 4 0.262
Pulse pressure by SaO2 17.221 4 0.002
GCS by SaO2 7.420 4 0.115
Graphs below present proportion of outcomes of interest by interaction groups.
Pulse by respiratory rate
B Sig. Exp(B)
Pulse (ref <71) <0.001
71-110 -0.467 0.197 0.627
>110 2.403 <0.00
1
11.060
Respiratory rate (ref <16) 0.001
16-18 -1.957 0.002 0.141
19-23 -1.017 0.181 0.362
>23 -1.005 0.147 0.366
Pulse by respiratory rate 0.004
71-110 and 16-18 0.122 0.891 1.130
71-110 and 19-23 -1.731 0.119 0.177
71-110 and >23 -1.189 0.251 0.304
>110 and 16-18 -5.801 0.003 0.003
>110 and 19-23 -6.683 0.001 0.001
>110 and >23 -7.001 <0.00
1
0.001
<71 71-110 >110
0
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Pulse by SBP
B Sig. Exp(B)
Pulse (ref <71) <0.001
71-110 -1.870 0.001 0.154
>110 -0.559 0.381 0.572
SBP (ref 121-180) <0.001
<100 1.442 0.001 4.230
100-120 0.752 0.060 2.122
>180 4.677 <0.00
1
107.470
Pulse by SBP 0.004
71-100 and <100 -0.830 0.461 0.436
71-100 and 100-120 -1.117 0.286 0.327
71-100 and >180 -10.620 <0.00
1
0
>110 and <100 -1.307 0.279 0.270
>110 and 100-120 -2.134 0.060 0.118
>110 and >180 -10.720 <0.00
1
0
<71 71-110 >110
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Pulse by SaO2
B Sig. Exp(B)
Pulse (ref <71) <0.001
71-110 -0.678 0.057 0.507
>110 2.121 <0.00
1
8.343
SaO2 (ref low risk) <0.001
High risk -0.324 0.554 0.723
Moderate risk -1.413 0.002 0.243
Pulse by SaO2 <0.001
71-100 and high risk -0.716 0.464 0.488
71-100 and moderate risk 1.222 0.128 3.393
>110 and high risk -5.193 <0.00
1
0.006
>110 and moderate risk -2.745 0.056 0.064
<71 71-110 >110
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Respiratory rate by pulse pressure
B Sig. Exp(B)
Respiratory rate (ref <16) <0.001
16-18 -0.632 0.065 0.532
19-23 0.805 0.073 2.237
>23 0.719 0.085 2.053
Pulse pressure (ref 51-75) 0.013
<51 0.272 0.345 1.313
>75 1.052 0.004 2.864
Respiratory rate by pulse pressure 0.012
16-18 and <51 1.412 0.057 4.106
16-18 and >75 0.010 0.992 1.010
19-23 and <51 -1.085 0.227 0.338
19-23 and >75 -0.414 0.737 0.661
>23 and <51 1.521 0.067 4.577
>23 and >75 0.483 0.660 1.621
<16 16-18 19-23 >23
0
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Respiratory rate by SaO2
B Sig. Exp(B)
Respiratory rate (ref <16) <0.001
16-18 -0.534 0.176 0.586
19-23 1.074 0.058 2.927
>23 1.127 0.045 3.085
SaO2 (ref low risk) <0.001
High risk -0.496 0.285 0.609
Moderate risk -1.349 <0.00
1
0.260
Respiratory rate by SaO2 0.029
16-18 and high risk 0.036 0.975 1.037
16-18 and moderate risk 0.506 0.560 1.658
19-23 and high risk -2.813 0.065 0.060
19-23 and moderate risk -3.028 0.034 0.048
>23 and high risk -2.685 0.068 0.068
>23 and moderate risk -2.487 0.085 0.083
<16 16-18 19-23 >23
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SBP by pulse pressure
B Sig. Exp(B)
SBP (ref 121-180) <0.001
<100 15.556 1 >1000
100-120 -12.779 0.999 >1000
>180 3.544 1 34.59
Pulse pressure (ref 51-75) 1
<51 11.992 1 >1000
>75 5.39 1 219.174
Pulse pressure by SBP <0.001
<100 and <51 -22.827 1 >1000
100-120 and <51 19.356 0.999 >1000
>180 and <51 47.714 1 >1000
>180 and >75 20.608 1 >1000
<100 100-120 120-180 >180
0
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SBP by SaO2
B Sig. Exp(B)
SBP (ref 121-180) <0.001
<100 1.384 0.001 3.990
100-120 0.556 0.147 1.744
>180 4.694 <0.00
1
109.311
SaO2 (ref low risk) 0.001
High risk 1.091 0.661 2.976
Moderate risk -0.667 0.604 0.513
SBP by SaO2 0.002
<100 and high risk -0.179 0.878 0.836
100-120 and high risk 0.531 0.624 1.7
>180 and high risk -0.406 0.967 0.666
<100 and moderate risk 0.433 0.701 1.541
100-120 and moderate risk 0.320 0.749 1.377
>180 and moderate risk -5.867 0.252 0.003
<100 100-120 120-180 >180
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Pulse pressure by SaO2
B Sig. Exp(B)
Pulse pressure (ref 51-75) <0.001
<51 0.835 0.003 2.306
>75 2.340 <0.00
1
10.384
SaO2 (ref low risk) <0.00
1
High risk 0.894 0.121 2.444
Moderate risk -0.963 0.006 0.382
Pulse pressure by SaO2 0.002
<51 and high risk 0.266 0.685 1.305
<51 and moderate risk 0.281 0.685 1.325
>75 and high risk 0.701 0.661 2.016
>75 and moderate risk -2.257 0.026 0.105
<51 51-75 >75
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Appendix 11
Interactions between significant variables in predicting potentially prevented 
death
Interaction term Wald Degrees of freedom p
Pulse by respiratory rate 16.646 6 0.011
Pulse by SBP 21.388 6 0.002
Pulse by pulse pressure 8.874 4 0.064
Pulse by SaO2 3.595 4 0.464
Respiratory rate by SBP 13.286 9 0.150
Respiratory rate by pulse pressure 14.386 6 0.026
Respiratory rate by SaO2 16.403 6 0.012
SBP by pulse pressure 36.601 4 <0.001
SBP by SaO2 22.282 6 0.001
Pulse pressure by SaO2 19.012 4 0.001
Graphs below present proportion of prevented deaths by interaction groups.
Pulse by respiratory rate
B Sig. Exp(B)
Pulse (ref <71) <0.001
71-110 -0.861 0.018 0.423
>110 1.689 0.006 5.413
Respiratory rate (ref <16) 0.003
16-18 -1.295 0.03 0.274
19-23 -0.220 0.769 0.803
>23 -0.397 0.556 0.672
Pulse by respiratory rate 0.011
71-110 and 16-18 0.061 0.941 1.063
71-110 and 19-23 -2.220 0.048 0.109
71-110 and >23 -1.818 0.079 0.162
>110 and 16-18 -3.600 0.049 0.027
>110 and 19-23 -4.746 0.010 0.009
>110 and >23 -5.062 0.004 0.006
<71 71-110 >110
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Pulse by SBP
B Sig. Exp(B)
Pulse (ref <71) <0.001
71-110 -2.119 <0.00
1
0.120
>110 -0.817 0.197 0.442
SBP (ref 120-180) <0.00
1
<100 1.364 0.002 3.911
100-120 0.726 0.070 2.068
>180 4.943 <0.00
1
140.137
Pulse by SBP 0.002
71-100 and <100 -0.709 0.529 0.492
71-100 and 100-120 -1.195 0.258 0.303
71-100 and >180 -11.174 <0.00
1
0
>110 and <100 -1.664 0.163 0.189
>110 and 120-180 -2.134 0.06 0.118
>110 and >180 -11.396 <0.00
1
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Respiratory rate by pulse pressure
B Sig. Exp(B)
Respiratory rate (ref <16) <0.001
16-18 -0.631 0.067 0.532
19-23 0.780 0.089 2.181
>23 0.601 0.155 1.824
Pulse pressure (ref 51-75) 0.002
<51 0.324 0.253 1.383
>75 1.286 <0.00
1
3.620
Respiratory rate by pulse pressure 0.026
16-18 and <51 1.211 0.102 3.357
16-18 and >75 -0.283 0.766 0.754
19-23 and <51 -1.013 0.255 0.363
19-23 and >75 -0.30 0.813 0.741
>23 and <51 1.130 0.170 3.095
>23 and >75 0.429 0.704 1.535
<51 51-75 >75
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Respiratory rate by SaO2
B Sig. Exp(B)
Respiratory rate (ref <16) <0.001
16-18 -0.511 0.197 0.6
19-23 1.100 0.063 3.003
>23 1.096 0.063 2.993
SaO2 (ref low risk) <0.001
High risk -0.710 0.134 0.492
Moderate risk -1.544 <0.00
1
0.213
Respiratory rate by SaO2 0.012
16-18 and high risk 0.012 0.992 1.012
16-18 and moderate risk 0.641 0.460 1.898
19-23 and high risk -3.259 0.041 0.038
19-23 and moderate risk -3.091 0.041 0.045
>23 and high risk -3.146 0.041 0.043
>23 and moderate risk -2.714 0.075 0.066
<16 16-18 19-23 >23
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SBP by pulse pressure
B Sig. Exp(B)
SBP (ref 121-180) <0.001
<100 -12.604 1 0
100-120 -12.722 0.999 0
>180 31.858 0.999 >1000
Pulse pressure (ref 51-75) 1
<51 43.796 0.999 >1000
>75 5.503 1 245.417
Pulse pressure by SBP <0.001
<100 and <51 19.428 1 >1000
100-120 and <51 19.074 0.999 >1000
>180 and <51 132.355 0.999 >1000
>180 and >75 20.458 1 >1000
<100 100-120 120-180 >180
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SBP by SaO2
B Sig. Exp(B)
SBP (ref 121-180) <0.001
<100 1.379 0.001 3.971
100-120 0.522 0.177 1.686
>180 5.017 <0.00
1
150.961
SaO2 (ref low risk) <0.001
High risk 0.980 0.743 2.663
Moderate risk -0.847 0.580 0.429
SBP by SaO2 0.001
<100 and high risk 0.035 0.976 1.036
100-120 and high risk 0.525 0.631 1.690
>180 and high risk -0.190 0.987 0.827
<100 and moderate risk 0.195 0.862 1.216
100-120 and moderate risk 0.219 0.827 1.245
>180 and moderate risk -6.240 0.306 0.002
<100 100-120 120-180 >180
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Pulse pressure by SaO2
B Sig. Exp(B)
Pulse pressure (ref 51-75) <0.001
<51 0.880 0.002 2.412
>75 2.552 <0.00
1
12.834
SaO2 (ref low risk) <0.001
High risk 0.838 0.168 2.313
Moderate risk -1.046 0.004 0.351
Pulse pressure by SaO2 0.001
<51 and high risk 0.360 0.633 1.433
<51 and moderate risk 0.325 0.641 1.384
>75 and high risk 1.093 0.520 2.982
>75 and moderate risk -2.239 0.031 0.107
<51 51-75 >75
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Appendix 12
Frequency distributions of other scores predicting death at 7 days in the validation 
cohort
Bispebjerg score
Hillerod score
Rapid Emergency Medicine Score (REMS)
Triage Early Warning Score (TEWS)
Vital Signs Score
ViEWS
NEWS
Appendix 13: Patients with outcomes of interest in the validation cohort
Patients sustaining inevitable death (n=2)
Ref number Age/gender Description
5613 65M Presented difficulty in breathing, died day 5
5590 94F Presented chest infection, died day 3
Patients sustaining potentially preventable death (n=1)
Ref number Age/gender Description
5177 92F Presented unwell, treated for UTI, discharged day 2, died day 4
Patients where death was prevented (n=35)
Ref number Age/gender Description
5231 39F Presented abdominal pain, appendicectomy day 3
5416 40M Presented difficulty breathing, SAH clipped day 2
5331 77F Presented difficulty breathing, IV antibiotics for sepsis
5512 78F Presented diabetic problem, IV antibiotics for urosepsis
5586 43F Presented with overdose, ICU
5320 86M Presented with faint, CPR day 1
5391 35M Presented collapse ?hypoglycaemia, IV dextrose for insulin OD
5517 42M Presented unwell, IV insulin for DKA
5217 91M Presented fall, IV fluids for rhabdomyolysis
5225 77F Presented difficulty breathing, NIV for exacerbation asthma
5504 84M Presented angina/chest pain, PCI day 7
5187 55M Presented severe breathing problems, BiPAP day 0
5214 78F Presented difficulty breathing, ICU IPPV day 0 for pneumonia
5213 67M Presented difficulty breathing, ICU vasopressors day 0 for sepsis
5142 66M Presented epigastric pain, PCI day 1
5552 67F Presented short of breath, IV antibiotics for urosepsis day 2
5427 70M Presented unwell, transfusion and IV fluids for GI bleed
5630 82M Presented chest infection, IV antibiotics for sepsis from LRTI
5506 84M Presented head injury, IV antibiotics for sepsis
5390 86M Presented unresponsive, IV antibiotics/anticonvulsants
5387 48F Presented ?fitting, ICU for status epilepticus
5406 80F Presented chest pain, PCI
5337 72M Presented hypothermia, ICU
5608 63F Presented asthma, IPPV for COPD day 0
5438 65F Presented pain in side, IV antibiotics pneumonia day 0
5488 93F Presented chest pain, IV antibiotics pneumonia day 1
5554 55F Presented abdominal pain/vomiting, IV antibiotics pneumonia
5307 87F Presented fall, IV antibiotics for urosepsis
5475 40M Presented difficulty breathing, HDU for CPAP for pneumonia day 0
5429 47M Presented overdose, endotracheal tube
5182 31M Presented abdominal pain, appendicectomy day 1
5526 35M Presented collapse, ETT and ICU day 0 for ?encephalitis
5181 25F Presented ?Addisonian/infection, IV steroids for Addisonian crisis
5334 56M Presented chest pain, chemical cardioversion of AF
5408 73M Presented ?obstruction, flatus tube for decompression sigmoid 
volvulus
Appendix 14
Frequency distributions of other scores predicting potentially preventable or 
potentially prevented death in 7 days
Bispbjerg
Hillerod
REMS
TEWS
Vital Signs score
ViEWS
NEWS
Appendix 15: Nominal group briefing document
Dear participant
Thank you for agreeing to help with my PhD studies.  I have developed a bedside 
score to try to predict which Emergency Department non-trauma patients will 
require life-saving intervention during their first week in hospital.  This phase of the 
project aims to develop a consensus of senior emergency physicians about the 
appropriate systematic responses to patients at different levels of risk.
Background
Why assess severity?
The general principle of healthcare provision in the UK reflects the “greatest 
happiness for the greatest number”(6).  Accurate assessment of illness severity has 
implications both for the individual patient and the health care system.  Patients 
admitted to critical care areas via non-critical care areas (such as standard wards) 
have higher rates of mortality than those admitted directly from the ED (9-11), with 
significant numbers of patients (23/122 (9) and 144/343 (11)) admitted to critical 
care more than 24 hours after their ED attendance.  NCEPOD has documented 
widespread failings in the identification of sick patients and their escalation to 
appropriately senior staff (14), and the National Early Warning Score has been 
launched by the Royal College of Physicians in response to the problem (15).
What is severity?
Severity of illness can be defined in a number of ways – risk of death in either the 
short or long term, magnitude of symptoms such as pain or nausea, effect on 
functional status and deviation from either clinical or laboratory “norms”.  I argue 
that patient acuity is not necessarily concurrent with illness severity.  I suggest that 
the point of an emergency care system is to provide prompt care to those patients 
likely to benefit in a time-sensitive manner from interventions.  These are not 
inherently the same patients who are at highest risk of death – some of these 
patients will progress to death irrespective of interventions. Nor are they the 
patients with the highest overall benefit from healthcare interventions – the young 
man with a testicular teratoma has massive potential for benefiting from treatment, 
but this will not be affected by whether he is seen within one hour or six hours in 
the Emergency Department.  A measure of patient acuity for the emergency 
department should therefore reflect patients whose outcome will be improved with 
prompt care and/or those whose outcome will worsen without this care.
Which patients should we identify?
Unfortunately within emergency care little evidence exists as to the time-sensitive 
nature of many interventions (16).  Although, as has been argued in the context of 
critical care outreach, it is intuitively appealing to define a deteriorating patient and 
respond rapidly (17), meta-analysis of tools to do this in an in-patient setting has 
failed to identify a benefit in terms of patient outcome (18-19). The introduction of 
a medical emergency team in one hospital was associated with a decrease in 
mortality amongst surgical patients but a sustained increase in mortality in medical 
patients, highlighting the non-congruence of risk of death with the potential to 
benefit from early medical intervention (20).  Recent commentary on clinical 
decision rules has drawn attention to the disconnect between the identification of 
patients at risk of a particular outcome and the potential of those patients to 
benefit from available interventions (21).  
What currently exists?
The Royal College of Physicians recently launched a National Early Warning Score 
developed by a multidisciplinary consensus panel.  This was in response to “the 
multiplicity of early warning systems used in different hospitals in the UK …causing 
a lack of consistency in detecting deterioration of patients’ conditions and calling 
for urgent medical help”. The NEWS is advocated, for the purposes of 
standardisation “during the initial prehospital and/or hospital assessment of a 
patient and throughout the patient’s hospital stay”, although the development 
group did not include emergency physicians or nurses as stakeholders and the 
group was unable to identify any relevant literature relating to Emergency 
Department patients (15). It uses a number of easily measurable physiological 
parameters to score a patient’s risk of deterioration and suggests clinical responses 
to each risk category as shown:
News score Clinical 
risk
Frequency of 
monitoring
Clinical response
0 Low Minimum 12 hrly Continue routine monitoring
Aggregate 1-4 Minimum 4-6 
hrly
Inform RN who must assess 
patient and decide if increased 
frequency of monitoring of 
escalation of clinical care 
required
Individual 
parameter 3
Medium Minimum 1 hrly RN to inform medical team 
urgently
Urgent assessment by clinician 
with core competencies in 
assessing acutely ill patients
Clinical care in environment with 
monitoring facilities
Aggregate 5-6
Aggregate 7 or 
more
High Continuous 
monitoring
RN to inform medical team 
immediately at SpR level
Emergency assessment by 
clinician with critical care 
competencies including 
advanced airway skills
Consider transfer to level 2 or 3 
care
The proposed score
This has been developed from a set of patients presenting at the Northern General 
Hospital, Sheffield, to identify patients at high risk of needing a life-saving 
intervention.  The score is:
Variable Points
Pulse
71-110 2
>110 10
Systolic BP
<100 4
100-120 1
>180 3
GCS
3-8 13
9-12 3
Why are we asking you to do this?
The score has been validated to demonstrate its ability to predict preventable 
mortality (ie to identify those patients likely to benefit in a time-sensitive way from 
emergency care).  We would like to use your expertise to explore how the score 
might be operationalised in a working ED, and what the resource implications of 
this might be.
Points for discussion
Below are 10 brief vignettes of information that would be available at the point of 
triage, with the proposed score calculated.  All of them relate to a 70 year old man 
who has presented with lightheadedness and “weakness”.  Please consider:
 Where in the ED should this patient be accommodated (resus, majors, waiting 
room etc). This may include streaming to primary care if you think appropriate.
 How often should this patient have observations repeated?
 Which staff should be informed about the patient (nurse in charge, doctor in 
charge, any nurse, any doctor, no specific need to inform anyone)?
 How soon should the patient be assessed by a doctor or nurse practitioner?
Case 1
P70, BP 130/72, GCS 15. Score 0.
Location in ED
Frequency of routine observations
Staff to be informed
Time to assessment
Case 2
P61, BP 120/65, GCS 15. Score 1.
Location in ED
Frequency of routine observations
Staff to be informed
Time to assessment
Case 3 
P84, BP 111/64, GCS 15. Score 3.
Location in ED
Frequency of routine observations
Staff to be informed
Time to assessment
Case 4 
P63, BP 93/69, GCS 14. Score 4.
Location in ED
Frequency of routine observations
Staff to be informed
Time to assessment
Case 5 
P102, BP 99/56, GCS 14. Score 6.
Location in ED
Frequency of routine observations
Staff to be informed
Time to assessment
Case 6
P35, BP 70/40, GCS 12. Score 7.
Location in ED
Frequency of routine observations
Staff to be informed
Time to assessment
Case 7 
P134, BP 149/80, GCS 15. Score 10.
Location in ED
Frequency of routine observations
Staff to be informed
Time to assessment
Case 8 
P123, BP 199/94, GCS 15. Score 13.
Location in ED
Frequency of routine observations
Staff to be informed
Time to assessment
Case 9 
P129, BP 82/57, GCS 12. Score 17.
Location in ED
Frequency of routine observations
Staff to be informed
Time to assessment
Case 10 
P114, BP 133/92, GCS 8. Score 23. 
Location in ED
Frequency of routine observations
Staff to be informed
Time to assessment
Appendix 16: Potential presentations of the score for clinical practice
1. Paper-based observation chart
2. Web-based triage form
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